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Abstract
Colorectal cancer in the commonest internal malignancy in western society today. At least a 
third of the incidence is likely to be due entirely or in part to inherited genetic factors. Over 
the last 15 years several genes have been described in which germline mutation leading to 
increased colorectal cancer risk may occur. The commonest are Hereditary Non-Polyposis 
Colorectal Cancer (HNPCC), which accounts for around 1-4% of colorectal cancer diagnosis 
without polyposis and is caused by mutations in mismatch repair genes and Familial 
Adenomatous Polyposis caused by mutations in the APC gene. In this thesis two related 
themes are addressed. Firstly I examine clinical, pathologic and molecular genetic 
information in kindreds recruited from family cancer clinics in order to investigate several 
relevant clinical problems relating to decisions regarding genetic testing and clustering of 
non-HNPCC families. Secondly, the group of individuals and families with multiple 
colorectal polyps without known genetic cause are investigated in several ways. A candidate 
gene analysis is undertaken looking for germline changes, an analysis of adenomas from such 
individuals for informative somatic changes is performed and I describe a new inherited 
syndrome of colorectal cancer and polyposis, MYH associated polyposis as well as the 
pathway of tumourigenesis in affected individuals.
I, Lara Lipton, confirm that the work presented in this thesis is my own. Where information has been derived 
from other sources, I confirm that this has been indicated in the thesis.
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Chapter 1 Introduction
1.1 Colorectal Cancer -  Hereditary Predisposition
Colorectal cancer (CRC) is the most common internal malignancy occurring in both men and 
women in Western society. Incidence is also rising steadily in Asian countries. Inherited and 
somatic genetic changes as well as environmental factors almost certainly contribute to its 
occurrence. Lifestyle factors and diseases common to our society such as obesity, lack of 
exercise, diets low in fruit and vegetables and diabetes all contribute to our high rate of CRC 
diagnosis.
Resources directed at the management of this major health problem, especially in regards to 
screening of susceptible persons, are rapidly increasing and one of the major challenges 
currently is to stratify our screening efforts, with intensive programs using colonoscopy 
directed towards those at highest risk who will benefit most. It has long been recognised that 
there are families showing a dominant predisposition to colorectal adenomas and/or cancers, 
but the identification of the genes and mutations responsible for such increase in familial risk 
is a much more recent phenomena (Peltokallio and Peltokallio 1966; Bussey 1982; Lynch 
and Lynch 1985; Lynch, Kimberling et al. 1986). Despite recent advances in the field many 
individuals and families with strong family histories of colorectal cancer with or without 
features of polyposis remain without genetic diagnosis. It is thought that about 30% of the 
total colorectal cancer burden can be accounted for by inherited genetic factors based on 
calculated relative risks in persons having one or more relatives affected with colon cancer. 
Relative risks increase when multiple relatives are affected or even one is affected at a very 
young age (Vasen, Griffioen et al. 1990; Fuchs, Giovannucci et al. 1994; Dunlop 1998; 
Winawer, Fletcher et al. 2003).
The overall aims of the following work include the categorisation and further analysis of 
patients and families who appear to have an increased predisposition to colorectal cancer 
and/or colorectal polyps and who do not possess pathogenic mutations in one of the 
previously described colorectal cancer predisposition genes. Identifying new genetic factors 
predisposing to colorectal cancer increases our ability to understand the following-
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• Knowledge of specific factors involved in carcinogenesis in both sporadic and 
inherited forms of cancer can provide targets for diagnostic tests, preventative 
strategies and novel treatment modalities.
• Identification of germline genetic predisposition by detection of specific gene 
mutations within a family member allows for the option of predictive testing among 
other family members. Mutation carriers within families can now be offered effective 
screening options to reduce the incidence and mortality of colorectal cancer (Jarvinen, 
Aamio et al. 2000).
• Genes found to play key roles in hereditary colorectal cancer syndromes are often 
found to contribute to the pathogenesis of sporadic colorectal carcinogenesis via 
somatic mutation leading to loss and epigenetic gene silencing of tumour suppressor 
genes or pathological activation of oncogenes.
1.2 Overview of Hereditary Colorectal Cancer Syndromes
Known inherited colorectal cancer predisposition syndromes can be usefully classified into 
those with and without large numbers (tens to thousands) of colorectal polyps or polyposis. 
The former can be further delineated by polyp histology. The non-polyposis colorectal cancer 
syndromes include Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and its variants 
Muir-Torre and Turcot’s syndromes. These are secondary to germline mutations in one of 
four mismatch repair (MMR) genes, MLH1, MSH2, MSH6 and hPMS2 with MLH1 and 
MSH2 being most commonly found to harbour mutations. Inflammatory syndromes of the 
colorectum, primarily Crohn’s disease and ulcerative colitis (UC) also predispose to cancer. 
Inheritance may play a part in a proportion of these cases.
Familial adenomatous polyposis (FAP), incorporating Gardner’s syndrome and some 
Turcot’s syndrome families, is characterised by in the presence of multiple adenomatous 
colorectal polyps, whereas in juvenile polyposis syndrome (JPS) and Peutz-Jeghers syndrome 
(PJS), the tumours are hamartomatous in nature. All are associated with an increased risk of 
developing colorectal cancer. Adenomas are dysplastic lesions with the proliferating 
epithelial tubules packed closely together in glands. Epithelial cells show disorganised, 
hyperchromatic nuclei, an increased nuclear to cytoplasmic ratio and an increased mitotic
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rate. Hamartoma are characterised by overgrowth of cells or tissues native to the area in 
which they normally occur. This typically involves the mesenchymal or stromal components, 
although the endodermal or ectodermal elements may be involved. Epithelial dysplasia may 
occur as hamartoma grow with invasive malignancy as a consequence. Hamartomatous 
polyps are also a feature of Cowden disease (CD) and Bannayan-Zonana Syndrome (BZS) 
(Hendriks, Verhallen et al. 2003; McGarrity, Wagner Baker et al. 2003; Merg and Howe 
2004). In these syndromes an increased risk of intestinal and other organ-specific 
malignancies is seen (Frayling, Bodmer et al. 1997). The hereditary mixed polyposis 
syndrome (HMPS) is phenotypically an overlap syndrome characterised by both 
adenomatous and hamartomatous polyps (Jaeger, Woodford-Richens et al. 2003). Intestinal 
polyps have also been described in Cronkhite-Canada syndrome and in tuberous sclerosis, 
but their clinical significance is less certain (Digoy, Tibayan et al. 2000; Jain, Nanda et al. 
2003; Nagata, Kijima et al. 2003; Yashiro, Kobayashi et al. 2004).
1.3 Colorectal Carcinogenesis and Genomic Instability
For the analysis of the molecular genetics of CRC I make several hypotheses. Firstly that 
cancer results via a multistep progression at both the molecular and the morphologic level. 
Secondly is that loss of stability of the genome is a key step in cancer formation. This may 
include chromosomal instability or defects in systems maintaining DNA sequence integrity. 
Thirdly that the genes affected in hereditary cancer syndromes frequently correspond to key 
genetic defects whose somatic occurrences drive the emergence of sporadic colon cancer. For 
example, one of the early events in the development of sporadic colorectal cancer is 
disruption in the WinglessfWnt signaling pathway component APC which is also implicated 
in the syndrome of FAP.
The evolution of normal epithelial cells to adenocarcinoma usually follows a predictable 
course of histological and genetic changes (Vogelstein, Fearon et al. 1988. The changes 
provide a growth advantage and lead to clonal expansion of altered cells. Subsequent waves 
of clonal expansion then occur as a consequence of progressive events that provide other 
growth advantages to the cell such as loss of cell contact inhibition and the ability to 
metastasise. The earliest identifiable lesion in colon cancer formation is the unicryptal 
adenoma (dysplastic changes occurring in a single colonic crypt). It appears that even these
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lesions can harbour mutations in KRAS and APC and may progress to cancer {Smith, 1993),
In addition to affecting cell biology, some genetic and epigenetic alterations result in loss of 
genomic stability, which contributes to the accumulation of mutations in tumour suppressor 
genes and oncogenes. Both the putative phenomena of chromosomal instability (CIN) and 
microsatellite instability (MSI) appear to occur early in tumourigenesis (Jacoby, Marshall et 
al. 1995; Ried, Knutzen et al. 1996) (Shih, Zhou et al. 2001; Nowak, Komarova et al. 2002). 
The underlying cause for CIN is still unknown, although recent studies have implicated 
mutations of APC as a possible cause. It has recently been shown that in cells with mutant 
APC, karyotypic abnormalities arise, specifically polyploidy, which suggests that APC may 
play a key role in chromosomal segregation and potentially in chromosomal instability, 
however, little evidence for APC’s role in karyotypic abnormality exists in vivo (Fodde, 
Kuipers et al. 2001; Fodde, Smits et al. 2001; Kaplan, Burds et al. 2001).
1.4 Familial Adenomatous Polyposis (FAP)
1.4.1 The Syndrome of Adenomatous Colonic Polyposis
Familial Adenomatous Polyposis (FAP) accounts for approximately 1% of all colorectal 
cancer cases seen in practice. It is has long been viewed as a distinctive syndrome, both in 
clinical presentation and genetic background (Bussey 1987). Classical FAP affects ~1 in 
10,000 individuals and is characterised by the presence of hundreds to thousands of 
adenomas in the colon and rectum (Bisgaard, Fenger et al. 1994; Bulow, Faurschou Nielsen 
et al. 1996). This leads to an almost 100% chance of malignant transformation in at least one 
of these polyps by the fifth decade. Polyps also develop in the upper gastrointestinal tract, 
especially the duodenum and these will progress to malignancy in approximately 10% of 
those so affected(Bulow, Aim et al. 1995; Sieber, Lamlum et al. 2002; Bulow, Bjork et al. 
2004). Fundic gland polyps also occur but there is no documented increased risk of gastric 
cancer in this condition. There is an increased risk of malignancy in other sites including the 
Ampulla of Vater (adenocarcinoma), the brain (glioblastoma), the thyroid gland (papillary 
carcinoma, especially in young women), and the liver (hepatoblastoma in young children) 
(Giardiello, Offerhaus et al. 1991; Lynch, Smyrk et al. 1993; Mori, Nagase et al. 1994; 
Hamilton, Liu et al. 1995; Cetta, Montalto et al. 1997; Soravia, Sugg et al. 1999; Hirschman,
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Pollock et al. 2005). Desmoid tumours are benign cancers of the connective tissues that can 
lead to life-threatening complications through their sheer size and impingement on vital 
structures (Gurbuz, Giardiello et al. 1994; Heiskanen and Jarvinen 1996; Pikaar, Nortier et al. 
2002). They occur in 5 to 10% of FAP patients, more commonly occurring in women. Other 
diagnostic features of FAP include retinal lesions, known as congenital hypertrophy of the 
retinal pigment epithelium (CHRPE), found in 60-90% of FAP patients, epidermis cysts, 
most notably on the scalp, osteomas (benign tumours of bone) and dental anomalies (e.g 
supernumerary and unerrupted teeth) in about one third of patients (Reck, Bunyan et al. 1997; 
Tourino, Conde-Freire et al. 2004; Bisgaard and Bulow 2006). Inheritance is autosomal 
dominant although 30% of cases do not have a family history of polyposis. In some of these 
persons a new APC mutation in the individual is causative and in others it is likely that 
separate genetic causes are responsible. This leads to a seemingly recessive phenotype within 
the family (Bisgaard, Fenger et al. 1994).
In undiagnosed cases of FAP, the leading cause of death is colorectal cancer. If diagnosed in 
childhood or early adulthood and managed appropriately, early death can still occur, 
principally from duodenal cancer and the effects of desmoid tumours (Galle, Juel et al. 1999). 
FAP shows variable clinical expression and severity between different families, some of 
which is explained by the location of the germline mutation within the gene (Nagase,
Miyoshi et al. 1992; Giardiello, Petersen et al. 1997; Crabtree, Tomlinson et al. 2002). 
Different families display different combinations of extracolonic features. Previously families 
with prominent extracolonic features, including sebaceous cysts, osteomas, desmoid tumours 
and dental abnormalities were classified as having Gardner’s Syndrome. This is now known 
to be a phenotypic variant of FAP (Leppert, Dobbs et al. 1987; Nakamura, Nishisho et al. 
1991; Nishisho, Nakamura et al. 1991; Nakamura, Nishisho et al. 1992; Giardiello, Petersen 
et al. 1997; Griffioen, Bus et al. 1998). Management of this condition will be discussed later.
1.4.2 The Adenomatous Polyposis Coli Tumour Suppressor Gene
The identification of an interstitial deletion on Chromosome 5q in a patient with Gardner’s 
syndrome combined with linkage analysis facilitated the positional cloning of the gene for 
FAP, Adenomatous Polyposis Coli (APC) in 1991 (Leppert, Dobbs et al. 1987; Groden, 
Thliveris et al. 1991; Kinzler, Nilbert et al. 1991; Kinzler, Nilbert et al. 1991; Nakamura, 
Nishisho et al. 1991; Nishisho, Nakamura et al. 1991). This gene has since been shown to
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play an integral role in the Wnt signalling pathway, especially in regard to the degradation of 
P-catenin within the cell cytoplasm (Rubinfeld, Albert et al. 1997) (Munemitsu, Albert et al. 
1995). The gene has 15 exons with exon 15 being a giant exon, and encodes a protein of up 
to 2861 amino acids (3 lOkDa). Germline mutations in APC have been found to be 
responsible for 70-90% of FAP cases and families. The APC protein occurs in multiple 
isoforms within cells, probably a result of alternative splicing at the mRNA level (Sulekova, 
Reina-Sanchez et al. 1995). The most common transcript lacks exon 10a and the protein 
contains 2843 amino acids. APC is thought to perform a number of intracellular functions 
and contains several amino acid motifs and domains, allowing it to dimerise and to interact 
with numerous other molecules having diverse functions with in the cell. B-catenin, GSK3p, 
axin, conductin, tubulin, EBI and hDLG are the major ones identified (Rubinfeld, Souza et al. 
1993; Su, Burrell et al. 1995; Deka, Kuhlmann et al. 1998; Sparks, Morin et al. 1998; Ikeda, 
Kishida et al. 2000; Spink, Polakis et al. 2000). Two motifs within the gene interact with p- 
catenin, a set of three x 15 amino acid repeats between residues 1020 and 1169 and a 
repeating sequence of seven x 20 amino acid repeats between residues 1262 and 2033 
(Rubinfeld, Souza et al. 1993; Rubinfeld, Albert et al. 1997). These motifs are highly 
conserved across species. Each 20 amino acid repeat contains a site mediating glycogen 
synthase kinase 3p (GSK3P), binding. Indispersed between the 20 amino acid repeat 
sequences are three SAMP (Ser-Ala-Met-Pro) repeats which are sites of axin binding. A 
region between 2200 and 2400 amino acids mediates microtubule binding and areas closer to 
the C-terminus (residues 2560-2843) interact with the microtubule associated protein EBI.
1.4.3 APC  Gene Functions
The major known function of APC within the Wnt/wingless pathway is a negative regulator 
of P-catenin (Hayashi, Rubinfeld et al. 1997; Hart, de los Santos et al. 1998; Chan, Wang et 
al. 2002). Upon binding of Wnt-1 to its transmembrane receptor frizzled, the disheveled 
protein is activated and inhibits the serine-threonine kinase GSK3p (Ikeda, Kishida et al. 
2000) (Rubinfeld, Albert et al. 1997). This represses p-catenin degradation and there is 
resulting accumulation of p-catenin, which can then translocate to the nucleus and interact 
with other transcription factors like T-cell factor (TFC) (Roura, Martinez et al. 2003; Hamada 
and Bienz 2004; Haraguchi, Nishida et al. 2004). TCF-4 is the predominant TCF family 
member expressed in colonic epithelium. Relevant targets upregulated by TCF-4 identified 
to date include cyclin Dl, c-myc, matrilysin, c-jun,fra-l, MDR-1 (multidrug resistance 1
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gene), GAS (gastrin gene), vascular endothelial growth factor and urokinase-type 
plasminogen activator receptor (Castrop, van Wichen et al. 1995; Korinek, Barker et al.
1997; He, Sparks et al. 1998; He, Chan et al. 1999; Roose and Clevers 1999; Clements, Lowy 
et al. 2003; Easwaran, Lee et al. 2003). Overexpression of Wnt targets cyclin D1 and c-myc, 
has been demonstrated in early adenomas from FAP patients (He, Sparks et al. 1998) (He, 
Sparks et al. 1998). APC is phosphorylated by GSK3p and complexes with the proteins axin 
and conductin. This complex mediates the ubiquination and degradation of P-catenin within 
the proteosome. The importance of APC-mediated p-catenin degradation is highlighted by 
the location of the mutation cluster region within the region of the APC gene encoding the 
20-aa repeats. Activating mutations of P-catenin in the GSK3p phosphorylation site required 
for its degradation results I the accumulation of P-catenin and have been documented in 
approximately 50% of colorectal tumours that do not contain APC mutations (Morin, Sparks 
et al. 1997)Experiments demonstrate that the nuclei of colon carcinoma cells not expressing 
APC contain stable p-catenin/Tcf4 complexes, which are constituently active, as measured by 
transcription of a TCF reporter gene (Korinek, Barker et al. 1998). In one experimental 
study, the introduction of APC removed P-catenin from TCF-4 and transcriptional activation 
ceased (Korinek, Barker et al. 1997). Evidence exists that APC is able to shuttle between 
nucleus and cytoplasm within the cell, possibly allowing it to compete with TCF-4 FOR P- 
catenin binding and remove p-catenin to the cytoplasm for degradation (Rosin-Arbesfeld, 
Townsley et al. 2000).
Other functions for APC include a role in cytoskeletal organisation. APC binds to the 
microtubule cytoskeleton via its basic domain and has a role in cell migration, division and 
polarity (Mimori-Kiyosue, Shiina et al. 2000; Mimori-Kiyosue, Shiina et al. 2000). The 
microtubule binding function of APC may also contribute to proper chromosome segregation 
during mitosis (Fodde, Kuipers et al. 2001; Kaplan, Burds et al. 2001). APC is also thought 
to play a pro-apoptotic role. Studies have shown that in SW480 cells which normally express 
truncated APC protein, delivery of full length APC promotes G1 cell cycle arrest and 
apoptosis (Groden, Joslyn et al. 1995).
1.4.4 Germline Mutations in the APC Gene
Germline mutations in the APC gene cause FAP, and somatic mutations occur in FAP 
tumours and sporadic colorectal tumours. Germline mutations throughout the APC gene
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differ in their penetrance, severity of polyposis and the expression of extra-colonic features 
(Bodmer 1999). About 95% of APC germ-line mutations are either nonsense (28%) or 
ffameshifts (67%) and hence the protein truncation test is generally adequate for their 
detection (Kinzler, Nilbert et al. 1991; Nagase, Miyoshi et al. 1992; Smith, Johnson et al. 
1993). Genotype-phenotype correlations exist with regard to the location of the germ-line 
mutation within the gene (Wallis, Morton et al. 1999). Generally, mutations in the central 
region of the gene (codons 1250-1464) give a profuse polyposis phenotype with thousands of 
intestinal polyps (Classical FAP). Two codons, 1061 and 1309 are mutational hotspots and 
account for approximately 11% and 17% of all germline mutations (Groden, Gelbert et al. 
1993). CHRPE is associated with germline mutations between codons 1395 and 1560 
(Wallis, Macdonald et al. 1994). A specific syndrome historically, Turcot’s syndrome, 
described as the occurrence within families of primary brain tumours (medulloblastoma) and 
colorectal adenomas, was shown in 1995 to be principally due to mutations in the APC gene 
(Lasser, DeVivo et al. 1994; Mori, Nagase et al. 1994; Hamilton, Liu et al. 1995; Rutz and 
Kikuchi 1995; Kunikata, Abe et al. 2000). These mutations, though all truncating, were 
heterogenous in type and location. A smaller number of phenotypically similar families 
whose primary brain tumours are glioblastoma multiforme have disease caused by various 
mutations in the known MMR genes (Leung, Chan et al. 1998; Chan, Yuen et al. 1999).
1.4.5 Germline APC  Mutations in Attenuated Adenomatous Polyposis Coli
The existence of an attenuated form of FAP had been suggested in 1990 by Leppert who 
showed linkage to 5q in a large family with an attenuated polyposis phenotype (Leppert, 
Dobbs et al. 1987). Families with attenuated adenomatous polyposis coli (AAPC) are 
characterised by the presence of one or more mutation carriers with multiple colorectal 
adenomas (<100) rather than profuse colorectal polyposis. Average age of diagnosis within 
families is later than that of classical FAP with cancer occurring, on average, 15 years later 
(Lamlum, Al Tassan et al. 2000; Sieber, Segditsas et al. 2006). Variable penetrance is seen as 
well as highly variable phenotype within families. Within a single AAPC kindred it is not 
uncommon to see mutation carriers with few polyps and others with a classic FAP 
phenotype. Overall extra-colonic features are less common but may occur in some mutation 
carriers. AAPC is associated with germline mutations occurring in the 5’ (codons 78-167) 
and 3’ (codons 1581 to 2843) regions of the APC gene and also in exon 9 (Spirio, Otterud et 
al. 1992; Spirio, Olschwang et al. 1993; van der Luijt, Meera Khan et al. 1996; Spirio, Green
15
et al. 1999) (Soravia, Berk et al. 1998). An attenuated phenotype has also been reported in 
some families with a complete deletion of one copy of the APC gene (Hodgson, Coonar et al. 
1993; Hodgson, Fagg et al. 1994). The latter is, however, likely to be a rare occurrence 
(Sieber, Lamlum et al. 2002). Some mutations associated with the AAPC phenotype lead to 
an unstable mRNA or protein. Other mutations in alternately spliced exons, such as those in 
exon 9, are spliced out of at least some mRNA species, resulting in a nearly full-length 
protein lacking the exon carrying the mutation (van der Luijt, Vasen et al. 1995; Young, 
Simms et al. 1998). It has been proposed that for tumours to occur in these patients both the 
wild type and the germline variant alleles need to undergo mutations or loss. Other genetic 
and environmental factors also influence clinical expression, as individuals with identical 
APC germline mutations are known to develop dissimilar phenotypes within and between 
families (Crabtree, Tomlinson et al. 2002) (Brensinger, Laken et al. 1998; Soravia, Berk et al. 
1998). Sibling pairs show a much higher correlation in disease severity and polyp number 
than do parent-child pairs or any other more distant relationship. Within AAPC families 
polyp numbers may be highly variable with some mutation carriers developing hundreds of 
polyps and others very few (van der Luijt, Meera Khan et al. 1996; Soravia, Berk et al.
1998).
AAPC or the multiple adenoma (MA) phenotype is due to detectable mutations in the APC 
gene in only a small proportion of cases (approximately 5%) (Lamlum, Al Tassan et al. 2000; 
Sieber, Lamlum et al. 2002).
1.4.6 Germline Missense Variants in APC
Two important missense variants in APC have been reported. The 11307K variant occurs in 
about 9% of Ashkenazi Jews and 2% of non-Ashkenazi Jews but is very rare outside this 
ethnic group with rates of 0 to 2% depending on ethnicity (Laken, Petersen et al. 1997; Guo, 
Lim et al. 2004; Kapitanovic, Cacev et al. 2004). It is present in around 10% to 12% of 
Ashkenazi jewish patients with colorectal cancer (Fidder, Figer et al. 2005; Rennert, Almog 
et al. 2005; Zauber, Sabbath-Solitare et al. 2005). Estimates of 10 to 28% risk of colorectal 
cancer exist for Ashkenazim with a family history of colorectal cancer and who carry the 
mutstion (Drucker, Shpilberg et al. 2000; Strul, Barenboim et al. 2003H). The relative risk of 
colorectal cancers in I1307K carriers may be around 1.5(Frayling, Beck et al. 1998; Gryfe, Di 
Nicola et al. 1998; Strul, Barenboim et al. 2003) (Rozen, Shomrat et al. 1999). Other studies
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have found no increase in CRC risk (Woodage, King et al. 1998). The question of colorectal 
screening for I1307K carriers remains open to debate. As colorectal cancer risk is only mildly 
elevated, the majority of centres do not advocate increased surveillance compared to the 
average population. Some centres in Israel suggest colonoscopy five to ten yearly for carriers 
(Rozen, Naiman et al. 2002).
The I1307K mutation leads, not to a truncated protein, but to the formation of an A8 tract 
(from the normal A3TA4) that is hypermutable and may undergo somatic slippage in colonic 
tissue to produce somatic frameshift mutations (Gryfe, Di Nicola et al. 1998). The 11307K 
allele frequently undergoes somatic mutation or is lost in tumour DNA suggesting that it does 
not directly participate in the tumourigenic process (Sieber, Lipton et al. 2003; Sieber, 
Heinimann et al. 2003). Studies of somatic APC mutations in cancers from I1307K patients 
commonly show a second mutation in the APC allele carrying I1307K . However as this 
missense mutation occurs near a site where other germline mutations cause very severe 
disease (for example truncating mutations at codon 1309), other functional effects of this 
mutation cannot be ruled out.
A further, missense variant E1317Q has been associated with the AAPC phenotype but has 
no clear effects on hypermutability (Frayling, Beck et al. 1998; Popat, Stone et al. 2000; 
Gismondi, Bonelli et al. 2002; Hahnloser, Petersen et al. 2003). It is present in around 0.5 to 
2% of the population and studies show little convincing evidence of a role in colorectal 
adenoma or cancer predisposition (Lamlum, Al Tassan et al. 2000; Gismondi, Bonelli et al. 
2002). El 317Q codes for a mutation in APC in the MCR that lies between the first and the 
second 20-amino acid p-catenin binding site. Limited evidence exists for an affect of this 
variant on APC function in respect to the degradation of p-catenin pathway. No special 
colorectal screening is currently recommended for carriers.
1.4.7 Somatic Mutations in APC
APC is a tumour suppressor gene, generally requiring the loss or mutation of both gene 
copies for tumour initiation. In the tumours occurring in germline A PC mutation carriers, the 
wild-type allele is generally disrupted by another mutation or, less frequently, lost. Most 
sporadic colorectal cancers also carry two inactivating APC mutations (Nakamura, Nishisho 
et al. 1992; Fodde 2002). In both familial and sporadic cases, somatic mutations are mainly
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confined to the 5’ half of the gene. The range is smaller than that for germline mutations 
generally, with over 80% of somatic mutations occurring between codons 1284 and 1580, the 
mutation cluster region (MCR) (Nakamura, Nishisho et al. 1992; Nagase and Nakamura 
1993; Miyaki, Konishi et al. 1994; Crabtree, Sieber et al. 2003). The MCR contains a set of 
20 aa repeats thought to be crucial for beta-catenin binding and degradation (Rubinfeld, 
Albert et al. 1997). Mutations at these positions suggest that loss or alteration of P-catenin 
binding is a crucial step towards tumour formation. These mutations are often accompanied 
by loss of the residual wild-type allele. Three somatic mutational hotspots occur at codons 
1309,1450 and 1554 accounting for approximately 75, 8% and 5% of somatic mutations 
respectively (Rowan, Lamlum et al. 2000). In APC most point mutations are C to T 
transitions, at CGA motifs -  generating the stop codon TGA (Nakamura, Nishisho et al. 
1992).
An association is now known to exist between the positions and types of the first and the 
second inactivating mutations in APC both FAP and sporadic tumours. Initial mutations 
around codon 1300 are associated with loss of wild type APC allele. In contrast, patients 
with germline mutations 3’ and 5’ to this generally show truncating ‘second hits’ in the 
mutation cluster region (Lamlum, Ilyas et al. 1999; Albuquerque, Breukel et al. 2002; 
Cheadle, Krawczak et al. 2002). Mutations in the different areas of the gene probably have 
different selective advantages to tumour growth with those in the MCR, around 1300 
providing the strongest impetus to tumour growth. Hence FAP patients with germline APC 
mutations around codon 1300 already possess the most strongly selected mutation and their 
adenomas lose the wild-type as a ‘second hit’ (Crabtree, Sieber et al. 2003). Patients with a 
germline mutation outside this region need to acquire a truncating mutation within the MCR 
to select for tumour growth. Sometimes the germline mutant in such patients is lost in the 
tumours of such patients in a ‘third hit’, resulting in the advantageous combination of one 
truncating mutation in the MCR and one lost allele (Spirio, Samowitz et al. 1998; Sieber, 
Segditsas et al. 2006).
1.4.8 The APC  Tumour Suppressor Gene and Tumourigenesis
There is probably no single reason why mutations in APC lead to tumour formation. It does 
not act as a simple tumour suppressor with a second hit causing complete loss of function as 
in Knudson’s hypothesis. The relation between the site and type of first, second and even
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third hits, the low frequency of allelic loss at APC and the attenuated phenotype that may 
result from mutations in exons one to four causing highly truncated protein suggest that such 
loss of function of APC may not make a cell as ‘cancer-prone’ as certain mutations leading to 
beta-catenin mediated cellular proliferation. Such mutations may give an optimal level of 
beta-catenin within the cell nucleus for progression to a cancer phenotype (Rubinfeld, Albert 
et al. 1997; Sieber, Heinimann et al. 2002; Crabtree, Sieber et al. 2003). Mutations giving a 
more stable truncated protein may also be selected. Like APC mutations, P-catenin 
mutations have an essential role in early colorectal tumour formation. The incidence of p- 
catenin mutations decreases from 2.5% in benign adenomas to 1.4% in invasive cancers 
suggesting that there is a level of excess p-catenin that does not favour progression from 
benign adenoma to cancer (Rubinfeld, Robbins et al. 1997; Samowitz, Powers et al. 1999).
In support of this, studies of P-catenin overexpression in colorectal adenomas show a gradient 
of staining from the base to the mouth of the crypt. Strong aberrant nuclear staining at the 
base gives way to normal membrane staining as the dysplastic cells move up the crypt 
(Brabletz, Herrmann et al. 2000; Preston, Wong et al. 2003) (Brabletz, Jung et al. 2001).
Mutations in APC cause loss of SAMP repeats and C-terminal functions. Truncation of the C 
terminus of APC will disrupt its interaction with EBI. Ebl belongs to a large family of 
highly conserved proteins which participate in chromosome segregation, spindle orientation 
and microtubule integrity (Berrueta, Kraeft et al. 1998; Timauer, Canman et al. 2002). APC 
is seen to localise to the kinetochore of dividing cells, truncating mutations may therefore 
result in disturbances of mitotic spindle stability and structural chromosomal abnormalities 
may follow. It is uncertain at what stage of tumour development, chromosomal instability 
caused by a truncated APC protein may come in to play relative to the effects of APC 
mutations on P-catenin build-up within cells.
1.5 Other Polyposis Syndromes Predisposing To Colorectal Cancer
1.5.1 Peutz-Jeghers Syndrome
The original descrition of Peutz-Jeghers Syndrome is credited to Peutz in 1921. This is an 
autosomal dominant inherited syndrome of specific hamartomatous polyps and characteristic 
mucocutaneous pigmentation. It occurs in approximately 1:200,000 live births .
Pigmentation is mostly (94%) around lips and buccal mucosa but can also occur in other
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areas. It begins to fade at puberty with only buccal pigmentation in adult life. Polyps are 
benign overgrowths of muscular tissue in the bowel wall, they range in size from millimetres 
to centimeters and are most common in the small bowel, also occurring in the colorectum and 
stomach. They are distinct from the polyps of Juvenile Polyposis without the cystic filled 
spaces common in the latter. Adenomatous change is uncommon but can occur (Hizawa, Iida 
et al. 1993; Bosnian 1999). Disease generally presents with benign complications of polyps, 
bleeding, obstruction and intussusception in the first three decades and with cancers in later 
life. Cancer risk includes a variety of sites. By 65 years of age there is a 39% risk of CRC, 
36% risk of pancreatic cancer, 29% risk of stomach cancer, 54% risk of breast cancer, 21% 
risk of ovarian cancer and lower (but still much above population) risks of small bowel, 
oesophagus, endometrial, malignant sex cord tumour, Sertoli cell tumour and lung cancers 
(Spigelman, Murday et al. 1989; Hizawa, Iida et al. 1993; Spigelman, Arese et al. 1995; 
Giardiello, Brensinger et al. 2000). Screening protocols are empiric and include 2 yearly 
colonoscopy and gastroscopy from late teens, 2 yearly mammography from 35 and annual, 
pelvic and testicular examinations and ultrasound of abdomen and pelvis, testes in males and 
ovaries in females (Spigelman and Phillips 1989; McGrath and Spigelman 2001; Dunlop 
2002). Women should begin yearly breast examination by a breast surgeon or general 
practitioner from age 25 (Altaha, Reed et al. 2003; Thull and Vogel 2004).
Disease causing mutations and deletions in the LKB1/STKII (19p 13) gene have been found in 
about half of affected families (Hemminki 1999; Wang, Churchman et al. 1999) (Wang, Ellis 
et al. 1999; Aretz, Stienen et al. 2005). This gene codes for a multifunctional serine-threonine 
kinase, important in second messenger signal transduction. Most documented mutations 
occur in the kinase domain of the gene (Scott, Crooks et al. 2002; Boudeau, Baas et al. 2003). 
Unlike other polyposis syndromes, inactivation of LKB1 occurs in epithelial tissues only 
(van der Weyden, Jonkers et al. 2002). This contrasts with the Juvenile Polyposis Syndrome, 
in which, inactivation of SMAD4 occurs in stromal tissues also. Both conditions result in the 
formation of hamartoma which consist primarily of stromal elements. Cancerous change, 
however, when it occurs involves epithelial cells.
1.5.2 Juvenile Polyposis Syndrome (JPS)
Juvenile polyps occur in 2% of children. They are hamatomatous polyps consisting of an 
overgrowth of lamina propria with mucin retention cysts. They have a smooth surface
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covered in exudate. Juvenile Polyposis Syndrome was first described in 1964 (McColl, 
Busxey et al. 1964). It is the most common of the hamartomatous syndromes and is inherited 
in an autosomal dominant manner with variable penetrance and with 20 to 50% of cases 
having a family history of juvenile polyposis (Desai, Neale et al. 1995). The diagnosis of JPS 
is made with the presence of three or more juvenile polyps in the GI tract, polyposis 
involving the entire gastrointestinal tract or any number of polyps in a proband with a known 
family history of juvenile polyposis (Giardiello, Hamilton et al. 1991). Polyps persist into 
adulthood and, unlike sporadic juvenile polyps, continue to develop. In addition to colorectal 
cancer, gastric, duodenal and pancreatic cancers have been reported in JPS (Cobum, Pricolo 
et al. 1995). At least one third of the affected families are found to have disease-causing 
mutations of the SMAD4 gene on chromosome 18q21, another 30% have mutations of the 
BMPR1A gene (Howe, Roth et al. 1998; Bevan, Woodford-Richens et al. 1999; Woodford- 
Richens, Rowan et al. 2001; Zhou, Woodford-Richens et al. 2001; Sayed, Ahmed et al. 2002; 
Howe, Sayed et al. 2004). In infancy, patients present with gastrointestinal bleeding, either 
acute or chronic, intussusception, rectal prolapse or protein losing enteropathy. In adulthood 
these patients will more commonly present with gastrointestinal blood loss and have tens to 
hundreds of polyps, with a distal colonic distribution. The lifetime risk of colon cancer is 
about 50% although quoted incidences vary markedly (Cobum, Pricolo et al. 1995; Desai, 
Neale et al. 1995) (Jass, Williams et al. 1988). A range of congenital defects has been 
described in association with the non-familial form of the disease. Colonoscopy and 
gastroscopy are recommended two to three yearly from the teenage years (Burt, Bishop et al. 
1990; Dunlop 2002; Half and Bresalier 2004).
1.5.2 Cronkhite-Canada Syndrome
Cronkhite-Canada syndrome is an acquired condition characterised by the rapid onset of 
generalised gastrointestinal juvenile polyposis (sessile polyps), cutaneous hyperpigmentation, 
hair loss, nail atrophy, hypogeusia, diarrhoea and weight loss (Johnson, Soergel et al. 1972; 
Jain, Nanda et al. 2003; Nagata, Kijima et al. 2003; Yashiro, Kobayashi et al. 2004). It is a 
rare sporadic condition (no familial cases described) with a 12% incidence of colorectal 
cancer and a course which may be acute and sometimes fatal or protracted. The cause 
remains elusive.
1.5.2 Cowden Syndrome
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Cowden syndrome was first described in 1963 ((Lloyd and Dennis 1963). It is an autosomal 
dominant condition with hamartomas and mucocutaneous features. It arises through 
germline mutations in the PTEN gene on chromosome 10q22 in 80% of patients meeting 
diagnostic criteria (Nelen, Padberg et al. 1996; Liaw, Marsh et al. 1997). Hamartomas 
involve the skin, intestine, breast and thyroid gland (Eng 2003). Gastrointestinal lesions are 
mostly juvenile polyps although other types occur. The most frequent skin lesions are facial 
trichilemmomas, with cafe-au-lait spots, vitiligo, squamous and basal cell carcinoma also 
occurring. Oral mucosal lesions, morphologically similar to the trichilemmomas occur in 
about 85% of patients. Two-thirds of patients develop goitre and there is a 10% risk of 
thyroid cancer (Eng 1999). Three quarters of affected females develop benign breast disease 
including fibrocystic disease and fibroadenomas. There is a 50% risk of breast cancer with 
frequent bilateral occurrence and median age of onset at 41 years (Ball, Arolker et al. 2001; 
Figer, Kaplan et al. 2002). Additional benign soft tissue and visceral tumours are observed 
along with developmental abnormalities such as hypoplastic mandible, prominent forehead 
and high-arched palate (Eng 2003). There is no documented increase in risk of 
gastrointestinal malignancy.
Related syndromes, Bannayan-Ruvalcaba-Riley syndrome and Lhermitte-Duclos syndrome 
are also believed to be due to mutation in the PTEN gene (Marsh, Dahia et al. 1997; Perez- 
Nunez, Lagares et al. 2004). The former is characterised by macrocephaly, lipomas and 
pigmented macules of the glans penis in addition to other features of Cowden’s syndrome, 
the latter by cerebellar gangliocytomatosis (Zigman, Lavine et al. 1997; Marsh, Kum et al. 
1999; Hendriks, Verhallen et al. 2003) (Ruvalcaba, Myhre et al. 1980; Gorlin, Cohen et al. 
1992).
1.5.3 The Hyperplastic Polyposis Syndrome
Hyperplastic polyposis is a rare syndrome usually defined as the presence of multiple 
hyperplastic polyps or the presence of large or proximal hyperplastic polyps. The WHO 
criteria for hyperplastic polyposis are as follows -
(i). At least five histologicaly diagnosed hyperplastic polyps proximal to the sigmoid colon, 
of which two are greater than 10mm in diameter, or
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(ii) Any number of hyperplastic polyps occurring proximal to the sigmoid colon in an 
individual who has a first degree relative with hyperplastic polyposis, or
(iii) Greater than 30 hyperplastic polyps but distributed throughout the colon.
Hyperplastic polyposis generally appears to occur in a sporadic manner although families 
with dominant inheritance have been reported in rare cases (Jeevaratnam, Cottier et al. 1996; 
Rashid, Houlihan et al. 2000; Lage, Cravo et al. 2004). These patients have an increased risk 
of colorectal cancer and a higher than normal incidence of CRC among family members 
(Place and Simmang 1999; Leggett, Devereaux et al. 2001; Hyman, Anderson et al. 2004; 
Lage, Cravo et al. 2004). This risk may be an over-estimate as many cases (at least 35%) are 
ascertained as the results of a CRC being diagnosed. No specific extracolonic features have 
been reported. Large hyperplastic polyps are more likely to be proximal. Hyperplastic polyps 
show overgrowth of the colonic epithelium with a ‘saw-tooth’ pattern in colonic crypts.
They grow out on stalks like adenomas but do not have nay features of epithelial dysplasia or 
tissue invasion. Serrated adenomas have a similar morphologic appearance but show 
dysplasia in epithelial cells. About 3% of polyps in patients with HPP are MSI-H. It has been 
postulated that hyperplastic polyps and serrated adenomas form the precursors to MSI-H 
sporadic cancer (lino, Jass et al. 1999; Jass, lino et al. 2000; Leggett, Devereaux et al. 2001). 
It is difficult to prove that this is actually the case. Several cases have been described in 
which cancer is seen arising form a hyperplastic polyp which does not show MSI in polyp or 
cancer but rather evidence of chromosomal instability or allelic losses (Hawkins, Gorman et 
al. 2000). Cancer arising in a hyperplastic polyp is not a common occurrence but does occur. 
Loss of MLH1 expression through hypermethylation has been seen in some hyperplastic 
polyps but this does not appear to be a common cause of sporadic or familial forms of 
hyperplastic polyposis. Another gene named HPP1 which is predicted to code for a 
transmembrane protein containing EGF-like domains has been found to be frequently 
inactivated by methylation in colorectal cancers and polyps including large hyperplastic 
polyps indicating a possible role in formation or progression of these lesions (Young, Biden 
et al. 2001). The cause of these syndromes remains obscure. Perhaps a more interesting 
question may be whether a syndrome exists in which hyperplastic and adenomatous polyps 
both occur and hyperplastic polyposis is at the extreme end of such presentations. If a 
germline predisposition is, in fact, responsible for hyperplastic polyposis, it is likely to be 
recessive in nature as the majority of affected individuals have no family history of polyposis 
although colorectal cancer may have occurred in the parents.
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1.5.6 The Hereditary Mixed Polyposis Syndrome or CRAC 1
Two large Ashkenazi families have been described in which susceptibility to colorectal 
cancers and adenomas, serrated adenomas, and juvenile polyps segregates in a dominant 
fashion (Whitelaw, Murday et al. 1997; Tomlinson, Rahman et al. 1999). Genome wide 
search revealed linkage for these families to a locus on chromosome 15ql3-ql4 (Jaeger, 
Woodford-Richens et al. 2003) (Jaeger, Woodford-Richens et al. 2003). 15ql3-ql4 has been 
termed colorectal adenoma and carcinoma 1 (CRAC1) or HMPS. All affected individuals 
share an identical haplotype in this region and penetrance appears high (18 out of 20 with the 
disease-related haplotype are affected). The specific haplotype in the families reported is 
most likely derived from a common founder. The minimal region covers a region of 10 cM 
and the disease-related haplotype has not been found in non-Ashkenazi patients or controls.
1.6 Hereditary Non-Polyposis Colorectal Cancer
1.6.2 The Hereditary Non-Polyposis Colorectal Cancer Syndrome (Lynch Syndrome)
The Hereditary Non-Polyposis Colorectal Cancer Syndrome (HNPCC) is an autosomal 
dominant condition which accounts for between 2 and 5% of bowel cancer in Western 
countries (Lynch, Lemon et al. 1997). The syndrome had been described long before the 
causative genes were identified and the diagnostic criteria known as the Amsterdam criteria 
had been formulated (Table 1.1). An early report by Warthin described several different 
families with dominant inheritance of a spectrum of HNPCC cancers and Lynch later 
continued following up some of these families (Vasen, Offerhaus et al. 1990). The members 
of affected families have no benign manifestations to help assign affection status, unlike 
FAP, and the most clearly distinguishing features are young age of colorectal cancer, a 
dominant pattern of inheritance, and a high frequency of certain other cancers in the family -  
endometrium, stomach, ovary, small intestine, urinary tract and biliary system (Aamio, 
Sankila et al. 1999; Lynch 1999). Another common event is the development of synchronous 
or metachronous cancers in individuals. Cancers are commonly in the proximal colon, 
although a proportion (around 20-30%) occur in descending colon or rectosigmoid (Lee, 
Petrelli et al. 2001). Compared to sporadic CRC, HNPCC cancers are more often poorly 
differentiated, mucinous or of signet cell type and show a pronounced lymphoid reaction
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(also known as a Crohn’s-like reaction) within cancers (Jass 2000; Jass 2004). The 
progression of precursor lesion or adenoma to carcinoma appears to be more rapid than in 
sporadic cancers although affected individuals do not develop a marked excess of adenomas. 
It is feared that interval cancers may occur if colonoscopy is not performed annually or 
biennially although data to substantiate this approach is difficult to obtain. It is unlikely that a 
randomized study will ever be performed. Several studies have suggested that, stage for 
stage, the survival of colorectal cancer patients with this syndrome may be superior to that of 
non-HNPCC colorectal cancer patients (Sankila, Aaltonen et al. 1996; Percesepe, Benatti et 
al. 1997; Aamio, Sankila et al. 1999; Tomoda, Baba et al. 1999). This may well be a function 
of MSI in the cancer DNA as this same survival benefit is seen for sporadic MSI-H cancers 
(Ribic, Sargent et al. 2003; Benatti, Gafa et al. 2005).
There have been several attempts to provide a sensitive and specific definition of the 
syndrome based on clinical features. In 1990 the Amsterdam criteria were established by the 
International Collaborative Group on HNPCC (ICG-HNPCC) as being minimum criteria for 
HNPCC in a family, especially in the context of entering such families in genetic trials 
(Vasen, Mecklin et al. 1991), These criteria state that to diagnose a family as having HNPCC 
there must be at least three members affected in two or more successive generations, with at 
least one affected by colorectal cancer younger than 50 years and one being a first degree 
relative of the other two. The Amsterdam criteria (Table 1.2) whilst still very specific for the 
presence of a pathogenic MMR gene mutation are overly restrictive, especially given small 
modem family sizes and the incidence of extracolonic cancers, particularly of the 
endometrium, in families carrying HNPCC mutations. Modified Amsterdam criteria were 
published in 1999 after discussions by the ICG-HNPCC in 1998 allowing the inclusion of 
certain HNPCC related cancers, endometrial, small bowel, ureter or renal pelvis (Table 1.3) 
(Vasen, Watson et al. 1999). Families without colorectal cancers such as those with 
endometrial cancers only could thus be classified as having HNPCC. A National Cancer 
Institute (NCI) workshop in 1997 reviewed molecular, genetic and histological data on 
HNPCC in order to increase the sensitivity of diagnostic criteria (Rodriguez-Bigas, Boland et 
al. 1997). They decided upon a set of clinicopathological criteria, which could help identify 
additional HNPCC patients and families -  the Bethesda criteria (Table 1.4). In 2004 a 
revision of these guidelines was published (Table 1.5) (Umar, Boland et al. 2004). The 
revised guidelines stress the importance of MSI-H tumour morphology and broaden the 
spectrum of HNPCC-associated tumours, including pancreas, brain, ovarian and biliary tract
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cancers as well as keratoacanthomas and sebaceous adenomas. Notably these guidelines are 
not designed or intended to be criteria for germline MMR gene analysis or HNPCC 
diagnosis, but for the performance of microsatellite instability testing and 
immunohistochemistry for mismatch repair protein expression. The sensitivity of the original 
Amsterdam criteria for mutation positive families is approximately 61% (specificity 67%) 
and the modified criteria 72% (Syngal, Fox et al. 2000). If the Bethesda criteria are used to 
guide mutation testing, sensitivity rises to 94% whilst specificity falls to 25%.
Once a history suggestive of HNPCC has been ascertained, further clues as to the mutation 
status of the family can be derived from looking for microsatellite instability (MSI) and loss 
of MMR protein expression within the tumour DNA (discussed later). In families with a 
consistent family history, microsatellite unstable (MSI-H) tumour DNA and loss of MMR 
protein expression in tumour, mutation analysis (including deletion studies) of the MMR 
genes in germline DNA will reveal pathogenic mutations in about 67% of cases (Chaves, 
Cruz et al. 2000; Loukola, Eklin et al. 2001; Terdiman, Gum et al. 2001). There remain a 
significant proportion of families who either fit all these criteria but do not have a germline 
mutation identified or who fulfill Amsterdam criteria without MSI in their tumours and in 
whom germline mutations are almost never identified. It is therefore likely that other genetic 
predispositions to colorectal cancer exist, causing tumour formation by differing genetic 
means.
Without or without the identification of a germline MMR mutation, families need to be 
counseled and risk management strategies put in place so as to reduce the morbidity and 
mortality from colorectal, endometrial and other cancers (Menko, Wijnen et al. 1996; Beck, 
Tomlinson et al. 1997; Lynch, Watson et al. 1999). Once a definite pathogenic germline 
mutation has been identified within a proband, predictive testing is possible for unaffected 
family members. Predictive testing is carried out after a programme of counseling, 
considering the consequences of both a positive and a negative test to each individual 
(Lerman, Hughes et al. 1999; Lynch, Watson et al. 1999). Persons testing positive for the 
family mutation are advised to have a screening colonoscopy every one to three years from 
the age of 25 or five years before the age of the youngest cancer occurrence in the family, 
whichever is earlier (Jarvinen, Aamio et al. 2000; Renkonen-Sinisalo, Aamio et al. 2000; 
Mecklin and Jarvinen 2005). Endometrial screening is currently advised for female mutation 
carriers although proof of efficacy is lacking (Vasen, Mecklin et al. 1993; Lynch and Lynch
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1995; Jarvinen, Aamio et al. 2000; Dove-Edwin, Boks et al. 2002). Non-carriers of the 
mutation are advised that their risk of colorectal and other HNPCC related cancers is 
equivalent to that of the general population from which they come. Mutation carriers found 
to have synchronous or metachronous cancers in the bowel are often advised to undergo total 
colectomy with or without rectal sparing. Female mutation carriers may be advised to have 
prophylactic hysterectomy and oophorectomy at the completion of child bearing (Sumoi, 
Hakala-Ala-Pietila et al. 1995; Lawes, SenGupta et al. 2002; Church and Simmang 2003;
Van Dalen, Church et al. 2003). Screening for other cancers in the HNPCC spectrum such as 
upper gastrointestinal, ureteric and biliary, has not yet been shown to have an affect on the 
incidence or mortality of these cancers (Renkonen-Sinisalo, Sipponen et al. 2002). It is 
reasonable to perform an initial gastroscopy and eradicate H. pylori if present as it is a WHO 
class 1 carcinogen. In families which seem predisposed to certain of these cancers, screening 
may be reasonable but evidence is lacking. Examples include urine cytology for ureteric 
transitional cell carcinoma and abdominal MRI for pancreatic cancer.
Muir-Torre syndrome (MTS) has historically been described as the coincidence of at least 
one sebaceous skin tumour or keratoacanthoma and one internal malignancy. About half of 
MTS patients have colorectal cancer. More recently MTS has been shown to be a subtype of 
HNPCC with germline mutations in genes overlapping with those characteristic of HNPCC 
seen in about 70% of such patients (Kruse and Ruzicka 2004; Ponti, Ponz de Leon et al.
2005; Ollila, Fitzpatrick et al. 2006). Skin and bowel tumours show MSI (Honchel, Hailing 
et al. 1994; Hailing, Honchel et al. 1995).
1.6.3 DNA Mismatch Repair Genes
The DNA mismatch repair (MMR) system spans over a billion years of evolution. It 
identifies and repairs, in a strand-specific manner, errors such as base/base mismatches and 
insertion/deletion mutations that result from the activity of DNA polymerase during 
replication. Runs of base repeats such as polyA tracts or dinucleotide repeats such as (CA)n 
(microsatellites) are prone to slippage during replication. The MMR system which involves 
many proteins binds to and excises the mismatched sequence, facilitating the re-synthesis of 
the correct DNA sequence. In species from bacteria to humans, DNA microsatellite 
instability due to unrepaired slippage of these mono and dinucleotide tracts, is a feature of 
genomes or cells that lack MMR activity (Loukola, Eklin et al. 2001). There are nine
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mammalian MMR genes comprising MLH1, hMLH3, PMS1&2 and MSH2-6 (Muller and 
Fishel 2002; Kunkel and Erie 2005). These are the homologs of the bacterial proteins MutL 
and MutS. They interact with each other to form dim£tr£, trimers and tetramers that mediate 
distinct functions involved in DNA mismatch repair. Their major function is to identify and 
repair single base mismatches and insertions or deletions of multiple base pairs which may 
form redundant ‘loops’ outside the double DNA strand. The hMSH proteins contact double 
stranded mammalian DNA scanning along the DNA for mismatches like a ‘sliding clamp’. 
When a base pair mismatch or insertion/deletion of bases is found, repair is initiated. The 
MSH proteins interact with a number of others including MLH, PMS and EXOl 
(Constantin, Dzantiev et al. 2005; Zhang, Yuan et al. 2005). The MSH2-MSH6 heterodimer 
is thought to primarily repair single base substitutions and 1 bp insertions and deletions while 
MSH2-MSH3 repairs l-4bp insertion or deletion mutations (Muller and Fishel 2002). MLH 
and PMS proteins interact with heterodimers of the MSH proteins to aid in catalyzing their 
different functions. MLH1-PMS2 is the primary complex that mediates the catalyst function 
for MSH2-MSH6 heterodimers. Although all nine MMR proteins can be seen to form 
dimmers in eukaryote cells, not all of these are of known function.
Loss of function within the mismatch repair system allows increasing numbers of mismatch 
and insertion and deletion mutations to occur, primarily in areas of the genome rich in 
repetitive DNA sequences. This mutator phenotype may be identified in tissue by instability 
in alleles with repetitive base sequences, so-called, microsatellite instability.
1.6.4 Germline MMR Gene Mutations
In the early 1990s, almost co-incidentally reports emerged regarding alterations in repetitive 
base sequences in a subset of colorectal cancer and linkage of Hereditary Non Polyposis 
Colorectal Cancer to a locus on chromosome two (Peltomaki, Aaltonen et al. 1993) (Ionov, 
Peinado et al. 1993). Several publications recognised that microsatellite instability was a 
feature of a subset of human colorectal cancers, often those in persons with a strong family 
cancer history (HNPCC)(Aaltonen, Peltomaki et al. 1993; Aaltonen, Peltomaki et al. 1994). 
At the same time Peltomaki et al performed linkage analysis in two large HNPCC kindreds 
and a putative locus was mapped to chromosome 2p (Peltomaki, Aaltonen et al. 1993). Fishel 
et al then reported the identification of the human homolog of the bacterial MutS protein, 
called MSH2 (Fishel, Lescoe et al. 1993; Fishel, Lescoe et al. 1994). This mapped to 
chromosome 2p22-21 and they suggested that mutations in MSH2 might be responsible for
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HNPCC. MSI had already been studied extensively in bacteria and yeasts and aided the use 
of positional cloning strategies to identify MSH2 on chromosome 2p and MLH1 on 
chromosome 3p (Fishel, Lescoe et al. 1993; Peltomaki, Aaltonen et al. 1993; Bronner, Baker 
et al. 1994) .A report was published almost simultaneously by Leach et at inwfuciithey 
reported sequencing the MSH2 gene and finding mutations in the germline and tumours of 
affected persons from HNPCC families (Leach, Nicolaides et al. 1993). Meanwhile a second 
HNPCC locus had been located using linkage analysis at 3p21-23 and tumors in the families 
involved found to be microsatellites unstable (Lindblom, Tannergard et al. 1993). The gene 
for the human homolog of MutL was found to be located at this locus and a pathogenic 
missense mutation found in one family by Bronner et al and almost simultaneously several 
more pathogenic mutations were identified in kindreds by Papadopoulis et al (Bronner, Baker 
et al. 1994) (Papadopoulos, Nicolaides et al. 1994). The first reports of PMS2 gerline 
mutations followed swiftly (Leach, Nicolaides et al. 1993; Peltomaki, Aaltonen et al. 1993; 
Nicolaides, Papadopoulos et al. 1994). In 1995 the human MSH6 gene was cloned and 
Miyaki et al discovered several germline mutations in Japanese HNPCC families 
(Drummond, Li et al. 1995; Miyaki, Konishi et al. 1997). Germline mutations in MLH3 and 
PMS1 have been postulated but their role in the causation of HNPCC remains uncertain 
(Lipkin, Wang et al. 2000; Wu, Berends et al. 2001). Tumours from persons in all such 
families were distinguished by microsatellite instability rather than by regions of allelic loss.
Germline mutations in MSH2 and MLH1 are widely distributed throughout both genes. The 
majorities are point mutations arising from single base-pair substitutions, deletions or 
insertions. In MSH2 this results primarily in frameshifts (60%) or premature truncations 
(23%), whereas frameshifts (40%) or missense mutations, some of which have unknown 
significance (31%) are observed in the MLH1 gene (Wijnen, Khan et al. 1996) (Peltomaki 
and de la Chapelle 1997). Simple assays to detect the functional consequences of these 
frequent missense mutations are not yet widely available and remain within the domain of 
research laboratories. Large genomic deletions and duplications in both hMSH2 and hMLHl 
also occur in the germline in a smaller percentage of HNPCC kindreds Wijnen (Wijnen, van 
der Klift et al. 1998; Charbonnier, Raux et al. 2000; Wang, Friedl et al. 2003). Alu-repetitive 
elements appear to be involved in the breakpoints of many deletions which may account for 
the mutations in up to 10% of HNPCC families (Wijnen, van der Klift et al. 1998). Several 
specific deletions have been shown to be founder mutations in families from Holland, France 
and the USA (Charbonnier, Raux et al. 2000; Wagner, Barrows et al. 2003). For example,
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three Finnish founder mutations in MLH1 may account for a slightly higher incidence of the 
disease in Finland (Aaltonen, Salovaara et al. 1998). The majority of mutations in the MMR 
genes can be detected with single stranded conformational polymorphism analysis (SSCP), 
denaturing gradient gel electrophoresis (DGGE), denaturing high performance liquid 
chromatography (DHPLC) and direct sequencing. Detection of large genomic deletions 
requires other methodology such as Southern bolt analysis, quantitative (real time) PCR and 
Multiplex Ligand-dependant Probe Amplification (MLPA).
1.6.5 Microsatellite Instability
The loss of MMR gene function leads to a defect in the repair of single base mismatches and 
of small deletions and insertions in tracts of DNA with repetitive base sequences. Over 
several generations of cell division, multiple different sized alleles in short repetitive DNA 
sequences will accumulate in a tumour which is deficient in MMR activity and this is called 
‘microsatellite instability’ (MSI) when it occurs at a microsatellite. Repetitive DNA 
sequences also occur within genes. Transforming growth factor p receptor type II (TGpRII), 
BAX, the insulin like growth factor receptor type II (IGFIIR), cell cycle regulated 
transcription factor E2F-4, TCF4, caspase 5 and even the MMR genes hMSH3 and MSH6 
contain such short repetitive sequences and can themselves be affected (Planck, Wenngren et 
al. 2000; Loukola, Eklin et al. 2001) (Yamashita, Arimura et al. 2000). MSI is seen in about 
90 to 95% of HNPCC cancers and is present at widespread microsatellite loci (Frayling 
1999). MSI is also present in 10-15% of sporadic colorectal cancers, therefore it is a sensitive 
but not specific marker for germline mutations of MMR genes (Herman, Umar et al. 1998). 
Sporadic adenomas very rarely exhibit MSI, therefore the finding of MSI in a dysplastic 
colorectal adenoma is a sensitive and specific marker for HNPCC (Loukola, Salovaara et al. 
1999; lino, Simms et al. 2000).
There has been and continues to be much debate regarding the definition of a microsatellite 
unstable cancer. Questions include which microsatellite should be used, how many of them 
need to be done, what percentage of these need to show MSI and if it matters whether or not 
a mononucleotide marker is unstable. There is also some disagreement as to how the actual 
test results should be interpreted for each microsatellite. In 1997 the International Workshop 
on MSI and RER Phenotypes in Cancer Detection and Familial Predisposition proposed a 
panel of five microsatellite markers to be used in MSI analysis. This reference panel is
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known as the Bethesda markers. It contains two mononucleotide repeats (BAT25 and 
BAT26) and three dinucleotide repeats (D2S123, D5S346 and D17S250) (Boland, Thibodeau 
et al. 1998). High level microsatellite instability (MSI-H) is said to be present in the tumour 
if two or more markers are unstable (40% <.of markers) and low level microsatellite 
instability (MSI-L) if only one is unstable (40%> of markers). Tumours with no unstable 
markers are said to be microsatellite stable (MSS). The MSS and MSI-L groups are often 
combined as a number of studies have shown no phenotypic differences between cancers and 
individuals with either pattern (Whitehall, Wynter et al. 2002). Also, there is an unknown 
baseline rate of instability in colorectal cancers such that if enough markers are done almost 
all will have at least one marker unstable (Halford, Sasieni et al. 2002; Laiho, Launonen et al. 
2002) (Tomlinson, Halford et al. 2002). It has been suggested that BAT-26 as a single 
marker is enough to determine MSI status when the aim is to determine whether an 
individual carries a germline MMR mutation (Samowitz, Slattery et al. 1999). BAT-26 is 
extremely reproducible, with a high level of agreement between observers (Cravo, Lage et al. 
1999). There are few germline polymorphisms, especially within the Caucasian population 
(0.7%), hence constitutional DNA is not required for comparison with tumour DNA, unlike 
all dinucleotide markers. The PCR reaction itself can be done with DNA derived from 
paraffin preserved archival tissue without the necessity of multiple repeats as is often the case 
for other markers in the Bethesda group. A study done by Loukola et al in a population of 
494 colorectal cancer patients tested for MSI using both BAT 26 and the Bethesda markers 
showed that 97% of MSI-H cancers were picked up using BAT-26 alone (Loukola, de la 
Chapelle et al. 1999).
1.6.5 Somatic Mutations in Microsatellite Unstable Tumours
MMR gene defects are presumed to lead to tumour development due to accumulations of 
widespread mutations in repetitive DNA sequences throughout the genome. Many of these 
microsatellites lie in non-coding regions and are probably functionally insignificant. Some 
however are found within exons of genes which may potentially contribute to carcinogenesis. 
The type II TGFp receptor gene was the first of this kind identified (Lu, Akiyama et al. 1995; 
Markowitz, Wang et al. 1995; Akiyama, Iwanaga et al. 1996; Percesepe, Kristo et al. 1998). 
TGFp is a potent inhibitor of colonic epithelial growth. Frameshift mutations common 
occurred in a short GT repeat sequence or a polyA tract as a result of insertions/deletions. As 
mentioned above, other mutational targets include the apoptosis regulator BAX, IGFR-II,
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E2F-4, TCF-4, caspase 5, CDX2, hMSH3 and MSH6 (Fujiwara, Stolker et al. 1998; Sakao, 
Noro et al. 1998; lino, Simms et al. 2000; Planck, Wenngren et al. 2000; Akiyama, Nagasaki 
et al. 2001). All of these genes, while frequently mutated in MSI-H tumours and never in 
MSS tumours, may play a role in the MMR/MSI pathway of tumourigenesis. Other genes 
with short repeat sequences but unlikely to be involved with tumour formation, the histones 
for example, do not show instability.
There is still debate regarding the frequency of mutations in APC, beta-catenin, K-ras, TP53, 
SMAD4 and DCC in MSI-H colon cancers (Table 1.6). Although initial reports suggested 
that mutations were present in only 21% of MSI-h tumours more recent studies show a high 
rate of P-catenin mutations in tumours with wild-type APC, indicating that over 60% of MSI- 
H tumours have mutations leading to disruption of the Wnt pathway (Mirabelli-Primdahl, 
Gryfe et al. 1999; Miyaki, Iijima et al. 1999; Shitoh, Furukawa et al. 2001; Johnson, Volikos 
et al. 2005), 1999}. Huang et al found a rate of 29 mutations in 52 MSI-H tumours compared 
with 47 mutations in 63 MSS tumours (Huang, Papadopoulos et al. 1996). Another group 
has found a very low incidence of biallelic inactivation of APC compared to MSS tumours 
and a total lack of truncating mutations in APC in tumours with TGFfiR-II mutations 
(Olschwang, Hamelin et al. 1997). It is likely that BRAF and K-ras mutations are mutually 
exclusive in colorectal cancers and that whilst Kras mutations are common in sporadic 
colorectal cancers and MSI-H cancers from persons with MMR gene mutations, BRAF 
mutations, specifically V600E are more common in sporadic MSI-H cancers (Rajagopalan, 
Bardelli et al. 2002; Oliveira, Westra et al. 2004; Rowan, Halford et al. 2005).
A study comparing 39 cancers form mutation positive HNPCC patients with 57 sporadic 
proximal colon cancers (30% of which were MSI-H) found a similar incident of K-ras 
mutations in codons 12 and 13 in both groups -  30% (Fujiwara, Stolker et al. 1998). G—>A 
in the second nucleic acid position of codon 13 represented 55% of mutations in HNPCC 
tumours whilst G—►A in the second nucleic acid position of codon 12 was over represented in 
the sporadic tumours. LOH at 18q and p53 gene product overexpression were inversely 
related to MSI. There was evidence for the mutational spectrum within cancers being 
dependant on the mechanism for MSI. BAX mutations were seen significantly more 
frequently in HNPCC related MSI-H cancers than sporadic MSI-H cancers and E2F-4 
mutations were more common in tumours of patients with germline mutations in MSH2 
(Moriyama, Sasamoto et al. 2002). Mutations in TP53 appear to be less frequent in MSI
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cancers than in MSS cancers. The mutation incidence in MSI colon cancers ranges between 
0 and 40% in different studies whereas the incidence in MSS cancers is between 31-67% 
(Konishi, Kikuchi-Yanoshita et al. 1996; Olschwang, Hamelin et al. 1997; Fujiwara, Stolker 
et al. 1998; Miyaki, Iijima et al. 1999),. The increase in BAX mutations may compensate for 
the low rate of TP53 mutations in MSI cancers. Some of these differences in these reports 
are likely to be accounted for by the use of different definitions by various groups of MSI -  
the number of markers required to be unstable and whether or not mononucleotide markers 
are included.
Another distinctive finding in MSI-H tumours of both sporadic and familial origin is their 
tendency to show a diploid chromosome complement as opposed to the majority of sporadic 
tumours, which show high levels of aneuploidy (Eshleman, Casey et al. 1998; Lindor, Jalal et 
al. 1998).
1.6.6 Immunohistochemistry for mismatch repair proteins
Mutation or promoter methylation of the MMR genes MLH1 and MSH2 is responsible for the 
majority of MSI-H tumours. Monoclonal antibodies against the protein products of both 
these genes as well as hMSH6 are commercially available (Kim, Piao et al. 1998). IHC of 
tumours can help to provide a guide as to whether a tumour has resulted from inactivation of 
a MMR gene and which gene this is likely to be (Kim, Piao et al. 1998) (Ichikawa, Lemon et 
al. 1999; Marcus, Madlensky et al. 1999). Lack of MLH1 protein may be due either to 
germline mutation or to somatic methylation of the promoter (Herman, Umar et al. 1998; 
Wheeler, Beck et al. 1999). Lack of MSH2 however is almost pathognomonic of germline 
MSH2 mutation. MSH2 and MSH6 staining are often lost together in germline MSH2 
carriers as dimerisation of the proteins occurs in vivo. A study which sought to correlate the 
results of IHC with those of MSI testing in a group of 114 tumours consecutively selected 
from several different sources found IHC for MMR proteins to be 92.3% sensitive and 100% 
specific in predicting MSI status (Terdiman, Gum et al. 2001). The observed predictive 
value of absence of expression of one of the MMR proteins was 100% and for the normal 
expression of both, 96.7%. Others have shown 100% correspondence between tumour MSI 
results and tumour IHC (Cawkwell, Gray et al. 1999; Dieumegard, Grandjouan et al. 2000). 
Several other groups have shown a much lower rate of concordance (Chaves, Cruz et al. 
2000; Ward, Meagher et al. 2001). There are several explanations for this. MSH6 mutations
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may account for some cases although MSH2 staining is occasionally lost along with MSH6 
in tumours from germline MSH6 mutants. Some missense variants of MLH1 and MSH2 may 
transcribe and translate a stable but non-functional protein, or low levels of stable protein. It 
is our own experience that decreased levels of staining as well as absence may occur in the 
tumours of germline mutants. Immunohistochemistry, although relatively cheap and simple 
involves some skill to perform and report in a reproducible manner and some centres may not 
have the proficiency of others. MLH1 antibodies in particular may give variable patchy 
staining (M Novelli, personal communication). On the other hand, IHC testing is more 
accessible for many service laboratories than MSI testing c^bid^involves the use of PCR-based 
techniques. IHC is now becoming widely used as confirmation of MSI status and to direct 
mutational testing.
1.6.7 Microsatellite Instability In Pre-Malignant Lesions
HNPCC patients form adenomas at a slightly but not strikingly increased rate compared to 
the general population. It is widely believed that adenomas in HNPCC patients are more 
likely to evolve into carcinomas and at a more rapid rate than sporadic colorectal adenomas 
(Jacoby, Marshall et al. 1995; Vasen, Nagengast et al. 1995; Vasen, Taal et al. 1995). 
Adenomas in HNPCC patients are more likely to occur at a young age, be large, have a 
tubulo-villous or villous histology and show severe dysplasia. MSI appears to be an early 
change in tumours in HNPCC patients, occurring in adenomas fairly frequently (57-80%) and 
being quite a specific indicator of MMR germline mutation status. A recent study by Kim et 
al showed that the variability of base numbers in polyA sequences was similar between 
adenomas and carcinomas in HNPCC, consistent with early loss of MMR activity (Kim, 
Salovaara et al. 2002). MSI is extremely uncommon in sporadic adenomas (0-3%) and given 
that 15% of sporadic tumours are MSI-H this points to a later onset of MSI in sporadic 
tumours. Conversely, the presence of MSI in an adenoma is strong evidence for the presence 
of a germline MMR mutation (Frayling 1999; Loukola, Salovaara et al. 1999). Evidence also 
exists for the occurrence of MSI in endometrial hyperplasia in female HNPCC patients (de 
Leeuw, Dierssen et al. 2000).
1.6.8 Microsatellite unstable sporadic tumours
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As previously stated, about 15% of sporadic colorectal cancers and approximately 3% of all 
sporadic colorectal adenomas show a MSI-H phenotype (Herman, Umar et al. 1998). This 
has repeatedly been shown to be due to the somatic hypermethylation of the 5’ CpG islands 
in the promoter region of MLH1 rather than any germline variant (Esteller, Levine et al.
1998; Fleisher, Esteller et al. 2000; Kuismanen, Holmberg et al. 2000; Lind, Thorstensen et 
al. 2004). Such epigenetic silencing has not been found in any other MMR gene despite the 
MSH2 gene also having a CpG island in its promoter region. It leads to a lack of MLH 1 
protein expression in these tumours on IHC (Young, Simms et al. 2001). Colorectal cancer 
cell lines with MSI can be shown to have similar hypermethylation which, when reversed, 
abrogates the MSI present in the cells and establishes re-expression of the ' M L|4 [ protein 
(Brieger, Trojan et al. 2002). Such methylation of MLH1 may also be a relatively common 
(46%) ‘second-hit’ to the wild-type allele for tumours occurring in MLH1 mutations carriers 
(Kuismanen, Holmberg et al. 2000). This is controversial with some groups finding almost 
no methylation in HNPCC tumours and LOH as the major second hit (Wheeler, Loukola et 
al. 2000). LOH or somatic mutations of MLH1 are detected in only a small minority of 
sporadic MSI-H cancers found to have MLH1 hypermethylation. Methylation of CpG sites 
upstream of MLH1 in normal colonic mucosa increases with age and it is postulated that 
tumour formation starts when a threshold decrease in MLH1 expression occurs. This is in 
keeping with the known occurrence of MSI-H sporadic cancers in an older population.
There is general agreement that MSI is a later phenomenon in the genesis of sporadic MSI-H 
CRC that in HNPCC related CRC. Hypermethylation of MLH1 also leads to MSI in gastric 
cancer, uterine cancer and atypical endometrial hyperplasia (Esteller, Catasus et al. 1999; 
Fleisher, Esteller et al. 1999; Fleisher, Esteller et al. 2000).
1.6.9 Germline Mutations in MSH6
MSH6 (MIM 600678) is one of the MMR genes less commonly mutated in the germline and 
the associated disease has some distinctive features in both molecular pathology and 
phenotype of affected families. The first family with a germline MSH6 mutation was 
described in the literature in 1997 (Miyaki, Konishi et al. 1997). The family did not meet the 
Amsterdam criteria for HNPCC. There was a high incidence of both endometrial and ovarian 
cancer and a relatively late onset of tumours with a colon cancer from one member being 
MSI-H. In another study, 25 germline MSH6 mutations were found in a group of 316 
probands of HNPCC-like families (Berends, Wu et al. 2002), Twelve had truncating
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mutations and a further 13 had missense mutations though to be pathogenic. 54% of 
endometrial and colorectal tumours from mutation carriers were MSS or MSI-L. 66% of 
tumours from carriers of truncating mutations and 18% with missense changes lacked MSH6 
protein immunostaining. Numbers of patients affected and their age at cancer diagnosis did 
not differ between those with truncating and missense mutations.
There are some common findings regarding MSH6 mutation carriers. Disease occurs at a 
later age on average and there appears to be a lower penetrance compared to MLH1/MSH2 
carriers. This is possibly due to the loss of MSH6 function causing only a partial MMR 
defect. There is risk of endometrial cancer development among female carriers of around 
70%, and colorectal tumours appear to have a left sided predominance (Wijnen, de Leeuw et 
al. 1999) (Berends, Wu et al. 2002),. Although the majority of cancers in persons with 
germline MSH6 mutations will show loss of MSH6 expression and high frequency MSI, some 
will not. Thus proceeding to germline MSH6 mutation testing may be reasonable in some 
HNPCC-like families with CRC and endometrial cancer and whose tumours are not MSI-H 
(Wagner, Hendriks et al. 2001; Hendriks, Wagner et al. 2004).
1.6.10 EXOl
The yeast homologue of EXOl has been shown to interact with MutS and strains deficient in 
EXOl have mutator phenotypes and dinucleotide repeat instability. The human protein 
product EXOl also interacts with MSH2 and is involved in the MMR process. In a first 
report, this gene was screened as a candidate in 33 probands from Amsterdam positive 
HNPCC families and in 225 probands from HNPCC-like families (Bethesda criteria) (Wu, 
Berends et al. 2001). Germline EXOl variants were found in 14 patients, one splice site and 
13 missense mutations. None of the 13 missense variants were present in 200 controls. Five 
missense variants were found in more than one patient. Seven of the fourteen patients had 
tumours which were MSS. In tumours of those with germline variants, 12 had loss of the 
variant allele and retention of the wild-type one.
A further study cast some doubt on the assertion that germline EXOl mutations have a 
pathogenic role. Jagmohan-Changur et al evaluated a series of 970 CRC patients and 1007 
controls from a number of countries for the EXOl variants found in the previous study plus 
any novel variants (Jagmohan-Changur, Poikonen et al. 2003). In an initial group of 20
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controls in which EXOl was fully sequenced, all but one of the previously described EXOl 
variants was present. The Pro640Ser variant still remained as a possible pathological 
mutation. Five of nine previously described mutations including the truncating variant 
IVS12-1 (G—*C) were detected in patients and controls with equal frequency. None of the 
missense variants occurred in a conserved amino acid. Functional studies have not been 
performed on any of the missense variants. They concluded that is was unlikely that 
germline variants in EXOl of themselves can cause an HNPCC phenotype in a family. It is 
still possible that EXOl has a role as a low penetrance allele causing predisposition to 
colorectal cancer.
1.6.11 Population-based Diagnosis of HNPCC
The lifetime risk of colorectal cancer in Western populations is approximately 1 in 20 to 25. 
Rates are lower but rapidly increasing in Asian and oriental societies. Causes of colorectal 
cancer include lifestyle factors including exercise, weight, diet, especially red meat intake 
and smoking as well as inherited genetic factors. For largely unknown reasons, a family 
history of colorectal cancer is a major risk factor and is present in 15 to 20% of those 
affected. Risk increases with decreasing age and increasing number of relatives affected. 
Germline mutations in the MMR genes are responsible for a small but significant proportion 
of colorectal cancer incidence, 2-5% in most populations. The number of kindreds who may 
potentially carry deleterious mutations may be underestimated given the limitations of 
modem small family size, early deaths due to non-cancer related causes and uncertain 
ascertainment of disease in prior generations. Therefore much effort has been directed 
towards the use of tumour samples from kindreds suspicious for HNPCC for MSI testing and 
immunostaining as predictors of germline mutation status. These tests are relatively simple 
and cheap compared with germline mutation analysis and can pin-point the gene involved, 
making mutation analysis of only one gene in germline DNA necessary.
Using clinical criteria alone for deciding upon mutation testing will exclude a significant 
proportion of families. Using the Amsterdam criteria alone a high number of HNPCC 
families will be missed. Winjen et al examined a series of 125 colorectal cancer families for 
germline MMR mutations. 49% of those meeting the Amsterdam criteria had a detectable 
pathological germline mutation compared with 8% of those who did not totally meet the 
criteria (Wijnen, Vasen et al. 1998). The original Amsterdam criteria has a sensitivity of
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about 60% with a specificity of 70%. Using the modified Amsterdam criteria (table 1) 
sensitivity rises almost 80% with a specificity of 62%. If all patients and families who meet 
Bethesda criteria are tested, sensitivity rises to 95% but specificity falls to 25% (Syngal, Fox 
et al. 2000). It would involve huge resources to perform germline mutation resting on all 
families included in the Bethesda criteria, but it does not seem unreasonable to use MSI 
testing and/or immunostaining for MMR proteins to narrow this group down to those who 
will go on to germline mutation testing. In practice this is increasingly being done (Ichikawa, 
Lemon et al. 1999; Vasen, Hendriks et al. 2004; Stormorken, Bowitz-Lothe et al. 2005).
In 1998, Aaltonen et al produced criteria for MSI testing of tumours (Aaltonen, Salovaara et 
al. 1998). After testing a series of 509 consecutive patients’ cancers for MSI and loss of 
MLH1 and MSH2 immunostaining and then performing mutation analysis in those with MSI- 
H tumours (and finding 10 germline mutations), it was felt that the same germline mutations 
would have been discovered if only a subset of tumours had been tested. If only all patients 
affected under 50 years, all patients with first degree relatives with colorectal or endometrial 
cancer and all patients with multiple primary cancers in the colorectum, endometrium or both 
had been tested for MSI, no patient found to have a germline mutation would have been 
missed. This would have involved testing 24% of patients presenting with colorectal cancer.
Aaltonen’s criteria were prospectively tested in a group of 535 CRC patients (Salovaara, 
Loukola et al. 2000). BAT-26 was used to determine MSI status in all cancers. Those who 
were MSI high went on to have mutation testing done. Had the above criteria been applied 
(patients affected under 50 years, all patients with first degree relatives with colorectal or 
endometrial cancer and all patients with multiple primary cancers in the colorectum, 
endometrium or both), 117 (22%) of patients would have undergone MSI testing and 17 of 
these would have been diagnosed with germline mutations. This would have missed one 
germline mutation in this population. All patients tested in both studies would also have been 
identified by the application of the Bethesda criteria, both original and revised.
In a similar prospective study, 257 unselected United State patients with CRC whose tumours 
were tested for MSI and loss of MLH1, MSH2, MSH6 protein products (Cunningham, Kim 
et al. 2001). Fifty-one (20%) tumours were MSI high. Of these 48 lacked MLH1 protein 
staining and 3 lacked both MSH2 and MSH6 immunostaining. All of these patients were 
examined for HNPCC mutations. Four MLH1 germline mutations were detected and three
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MSH2 mutations. Hypermethylation of the MLH1 gene promoter was seen in all cancers 
with absent MLH1 expression but no germline mutation. Overall 1.9% of the cohort tested 
had a germline mutation in a MMR gene.
A large study also in the United States by Samowitz et al examined 1066 CRC patients 
obtained retrospectively through Kaiser Permanente medical Care Program (Samowitz,
Curtin et al. 2001). Using BAT-26 and TGFpRII microsatellite markers, 14% (131/933) of 
tumours were classified as MSI-H. Germline sequencing was performed on 130 of these 
individuals revealing seven probable HNPCC mutations. Two of these seven had neither a 
family history of HNPCC-related cancer nor young age at diagnosis although the methods 
used to ascertain family history were not mentioned in the study. This correlated to an 
estimated 0.86% of cases of colorectal cancer occurring in HNPCC mutation carriers. A 
further 12 probands had missense changes of uncertain significance at least six of which were 
unlikely to be pathogenic.
In another recent study performed in Italy, Percesepe et al prospectively collected 336 cases 
of CRC and tested them for MSI Percesepe (Percesepe, Borghi et al. 2001). MSI-H cases 
were then stained for loss of MMR protein and MLH1 methylation studies were performed. 
8.3% (12) of the cancers showed high level MSI. Of this group, only one was shown to carry 
a germline mutation in MSH2 to give a population incidence of 0.3%. Seventy-one percent 
(20) of MSI-H carcinomas showed lack of expression of MLH 1 of which 14 had MLH1 
promoter methylation. No tumours showed loss of MSH2 staining. However in this entire 
cohort, apparently only 6 patients met the Amsterdam criteria (3 MSI-H and 3 MSS) and 
these were apparently, the only ones tested for germline MMR mutations.
Farrington et al studied a specific population of CRC probands diagnosed under age 30 
(Farrington, Lin-Goerke et al. 1998). Twenty eight percent were found to have pathologic 
MMR mutations. In this cohort the sensitivity and specificity for HNPCC of having a MSI-H 
tumour were 86% and 73% respectively with positive and negative predictive values of 63% 
and 90%. Interestingly, in this study only 21% of patients with germline mutations came 
from patients whose family met Amsterdam criteria. It is possible that some represented a 
new mutation event within the family.
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Other studies have shown that immunostaining alone is 90 to 95% sensitive for germline 
mutation status (Chaves, Cruz et al. 2000) (Dieumegard, Grandjouan et al. 2000; Terdiman, 
Gum et al. 2001). The specificity of MLH1 immunohistochemistry is low in the setting of 
general population screening as it is present in about 15% of sporadic MSI-H cancers with 
epigenetic silencing of MLH1.
Thus there exist a number of different models for screening populations for HNPCC. In 
populations where common founder mutations do not exist, mass mutation analysis is 
impractical. Genetic ‘pre-testing’ with MSI and immunohistochemical tests appears to be the 
most practical alternative. All groups agree on a Bethesda-like approach to who should be 
tested with IHC and MSI. Those diagnosed under age 50, those with multiple tumours, and 
those with significant family history especially those including endometrial and CRC are 
agreed upon. It seems practical to perform IHC at the time of cancer diagnosis for such 
persons. Lack of MLH 1 immunostaining may imply either MLH1 somatic methylation or 
germline MLH1 mutation. The probability of the Ufe'depends largely on pretest 
probabilities. The younger the affected person and the stronger the family history, the higher 
the chance of a mutation being found. If doubt exists and a second tumour is available within 
the family, testing it with IHC or MSI testing can clarify the issue. This is particularly helpful 
when no live affected family members exist and such testing is being done as an aid to 
screening recommendations for family members.
1.7 Colorectal Cancer Screening
1.7.1 Colorectal Cancer Screening For Persons At Average Risk
The benefits of any screening program depend on several factors; the incidence of the 
condition in the population being screened, the existence of a premalignant lesion or early 
lesion which can be detected and effectively treated, the sensitivity and specificity of the test, 
the morbidity and acceptability of the screening procedure. To a greater or lesser extent in 
any screening program, health economics will dictate how expensive the screening procedure 
and confirmative tests will be and what the costs per year of life saved by screening will be. 
Colorectal cancer presents one of the most compelling arguments for population screening 
strategies. It is common, a non-malignant precursor exists and colonoscopy is highly 
sensitive and specific and allows removal of the pre-malignant lesion at the time of the
40
procedure. Severe adverse complications are low and, at a population level, five to ten yearly 
or even once-off colonoscopy does not present a huge financial burden. Faecal occult blood 
testing (FOBT) leads to a 30% reduction in deaths from colorectal cancer (Mandel, Church et 
al. 1999; Ransohoff and Pignone 2001). It has a fairly high sensitivity for adenomas of 
significant malignant potential however false positive tests are fairly common. There are 
four major tools in use at the moment for colorectal cancer screening; FOBT, sigmoidoscopy, 
double contrast barium enema and colonoscopy. Many guidelines for the screening of 
average risk populations have been published but as yet no strategy exists on a national level 
in the UK (Rhodes 2000; Smith, Mettlin et al. 2000; Pignone and Levin 2002; Rex 2002; 
Smith, Cokkinides et al. 2002; Winawer, Fletcher et al. 2003; Pignone 2004; Winawer,
Faivre et al. 2005; Winawer 2005). There have been three major trials using guaiac-based 
FOBT as a screening measure to attempt to reduce mortality from CRC, from Minnesota 
USA, Denmark and the United Kingdom (Mandel, Bond et al. 1993; Hardcastle,
Chamberlain et al. 1996; Kronborg, Fenger et al. 1996; Mandel, Church et al. 1999). The 
Minnesota trial compared annual and biennial testing with no screening in a prospectively 
randomised group of 46,551 persons. Most FOBT test cards were rehydrated which 
increases sensitivity from 40% to 50-60% whilst reducing specificity from 96-98% to 90%, 
giving more false positive tests. (Church, Ederer et al. 1997; Lang and Ransohoff 1997; 
Ransohoff, Lang et al. 1997). Cumulative cancer mortality rates after 18 years of follow-up 
were 33% (Cl, 17-49%) lower among persons randomised to annual FOBT than those 
randomised to no screening. Biennial screening, which did not show a reduction in mortality 
at 13 years follow-up, produced a 21% (Cl, 3-38%) reduction in mortality rate at 18 years. 
The 18 year follow-up also showed a 20% (Cl, 10-30%) decrease in the incidence of CRC in 
the group screened annually compared to controls. The more recent trials from the United 
Kingdom and Denmark by Hardcastle et al and Kronborg et al used biennial testing only with 
guaiac-based testing cards and no rehydration of cards (Hardcastle, Chamberlain et al. 1996; 
Kronborg, Fenger et al. 1996). Reductions in CRC mortality of 15% (Cl, 1-26%) and 18% 
(Cl, 1-32%) were found in these two trials respectively. In the Minnesota trial, 28% of 
participants required colonoscopy for positive tests whilst in the two European trials, only 5% 
did so (Mandel, Bond et al. 1993; Hardcastle, Chamberlain et al. 1996; Kronborg, Fenger et 
al. 1996). This may be due to the increase in sensitivity with reduced specificity seen with 
FOBT card rehydration. In these three studies overall, FOBT detected 27-39% of patients 
who developed cancer in the screening group. This is an impressive results and the test itself 
is easy and cheap to perform and has no adverse effects. Nonetheless, there is a frequent
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requirement for colonoscopy, which can occasionally have adverse effects. The sensitivity of 
FOBT for detection of adenomas of low to moderate malignant potential is fairly low (<50%) 
and false reassurance may result from a negative test. It is noteworthy that semi-quantative 
FOBT based on immunochemistry can detect as little as lOOng of haemoglobin per ml of 
faeces. The tests can be ‘set’ to read positive at a given level of haemoglobin. Thus 
sensitivity can be adjusted up or down depending on the number of screening colonoscopies 
deemed acceptable within a screening program (Fraser, Matthew et al. 2006). There is 
agreement that whilst FOBT may be a suitable screening strategy for low risk populations it 
has little place as a sole modality in moderate to high risk ones.
Flexible sigmoidoscopy is currently being employed in two randomised trials, one in the UK 
using once only flexible sigmoidoscopy and one in the USA of five yearly sigmoidoscopy in 
conjunction with FOBT (Gohagan, Prorok et al. 2000; Atkin, Edwards et al. 2001; Atkin, 
Rogers et al. 2004). Two case-control studies one using rigid and one using flexible 
sigmoidoscopy have been published. Selby el al used data from the Kaiser Permanente 
Medical Care Programme (Selby, Friedman et al. 1992). They found that rigid 
sigmoidoscopy had been performed in 9% of persons who died of CRC occurring within 
20cm of the anus and in 24% of persons who did not die of such a cancer. The adjusted odds 
ration of 0.41 (Cl, 0.25 to 0.69) suggested that sigmoidoscopy screening reduced the risk for 
death by 59% for cancer within reach of the rigid sigmoidoscope. The risk reduction 
continued for 9 to 10 years after the test was performed. Thiis-Evensen et al performed a 
small randomized trial of flexible sigmoidoscopy in 800 persons (Thiis-Evensen, Hoff et al. 
2001). The relative risk reduction for diagnosis of colorectal cancer for screened persons was
0.2 (Cl, 0.03-0.95) and for mortality was 1.57 (Cl, 1.03-2.40) largely due to cardiovascular 
deaths. Sigmoidoscopy has a sensitivity for diagnosis of left sided colorectal cancers and 
polyps of around 70 to 80% with a false negative rate that is operator - dependent (Imperiale, 
Wagner et al. 2000; Lieberman, Weiss et al. 2000; Atkin, Rogers et al. 2004). Adverse 
effects are rare, bleeding in 3%, severe pain in 0.4% and bowel perforation in only two in 
49,501 sigmoidoscopies were reported in a recent study (Anderson, Pasha et al. 2000). 
Advantages of sigmoidoscopy include the lack of lengthy and uncomfortable bowel 
preparation and anesthesia and the ability of the operator to remove polyps during the 
procedure. The major drawback of such an approach is the failure to visualise the proximal 
portion of the bowel. The accuracy of sigmoidoscopy can be improved somewhat by the 
addition of FOBT (Berry, Clarke et al. 1997; Rasmussen, Kronborg et al. 1999).
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Double contrast barium enema has not been studied in randomised or case control studies as 
a screening procedure. Its sensitivity is 32% for polyps smaller than 0.4 cm, 53% for polyps
0.6 to 1.0 cm and 48% for polyps larger than 1cm (Winawer, Stewart et al. 2000). Adverse 
events are very rare. Discomfort is comparable to colonoscopy as is the length of the 
procedure.
The ability of colonoscopy to prevent CRC and mortality from CRC has not been 
prospectively measured in a screening trial in a population at average risk. Information from 
the National Polyp Study allows an estimation that 76% to 90% of CRC could be prevented 
by regular surveillance colonoscopy, based on comparisons with historic controls (Winawer, 
Zauber et al. 1993). However, all trial participants had polyps detected and removed at the 
time of entrance, limiting the applicability of this study to an average population. A case- 
control study found that patients with CRC were less likely to have had a previous 
colonoscopy. Odds ratios for disease incidence were 0.47 (Cl, 0.37-0.58) for colon cancer 
and 0.61 (Cl, 0.48-0.77) for rectal cancer. Colonoscopy is highly sensitive for large 
adenomas and cancers (>90%) and about 75% for smaller adenomas. This is operator 
dependant to some extent. Serious adverse events will occur in 0.3% of patients, most often 
bleeding or perforation, especially after polypectomy (Anderson, Pasha et al. 2000). It must 
be remembered that over a lifetime of regular screening, if the pre-test probability of cancer 
is small, the number of people harmed by screening could outway the number who benefit 
from it.
As the plethora of published guidelines and position statements attests, there is little 
consensus on the need for, method and timing of colorectal cancer screening in the average 
risk population. Many suggest starting screening at the age of 50 to 55 and recommend five 
yearly sigmoidoscopy or ten yearly colonoscopy with yearly FOBT.
1.7.2 Colorectal Cancer Screening For Persons At Above Average Risk
More (but only slightly more) agreement can be found in the arena of screening for 
moderate and high risk persons. Because in the familial syndromes described above, 
incidence is so high, false negative tests may be fatal, especially for HNPCC mutation 
carriers who may have rapid progression from adenoma to carcinoma; colonoscopy is the
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method of choice for screening the large bowel. In HNPCC the lifetime risk of colorectal 
cancer is 70 -  80%. A recently completed controlled 15 year trial of 3 yearly colonoscopic 
screening vs no screening in two cohorts of patients from HNPCC families showed a 
reduction in colorectal cancer incidence of 62% (Jarvinen, Aamio et al. 2000). In mutation 
positive subjects there was over 50% decrease CRC incidence in screened persons. None of 
the cancers detected in the screened group led to death compared with 9 in the control 
group. Overall, the death rate in mutation positive subjects was reduced by 66% in the 
screen cohort (p=0.05). The current recommendation for HNPCC mutation carriers is for 
yearly screening with colonoscopy starting at 25 years of age or five years before than the 
earliest age of diagnosis in the family, whichever is the younger age (Dunlop 2002; Halbert, 
Lynch et al. 2004). Prophylactic colectomy and ileorectal anastomosis are often considered 
in mutation carriers who present with a colon cancer. There is no randomised or controlled 
evidence for benefit of this practice at present. The risk of cancer in the retained rectum is 
3% every three years for the first 12 years so endoscopic surveillance of the rectum is 
necessary after colectomy. Screening for uterine cancer in female family member is widely 
performed but has unproven effectiveness (Dove-Edwin, Boks et al. 2002). Studies using 
newer methods of screening such as hysteroscopy with biopsy may show greater sensitivity 
and specificity. Screening for other HNPCC cancers such as stomach and transitional cell 
cancer of the urinary system is performed in some families in which these cancers occur. 
There is no proof for efficacy at present (Renkonen-Sinisalo, Sipponen et al. 2002).
The same frequency of colonoscopic screening may be necessary for families meeting the 
Amsterdam criteria but without MSI-H cancers or known HNPCC mutation. In a recent 
study by Lindor et al it has been suggested that colorectal cancer incidence is significantly 
lower and that there is no excess risk of extra-colonic cancers in families which meet 
Amsterdam criteria but whose tumours do not have a MMR-deficient phenotype (Lindor, 
Rabe et al. 2005). Screening for families with more moderate degrees of risk is somewhat 
empirical although there have recently been attempts to standardise this in Great Britain and 
in Australia (Dunlop 2002). For persons with two or more first degree relatives affected 
with CRC, not meeting the modified Amsterdam criteria, five yearly colonoscopy beginning 
at age 45 or ten years or earlier than the youngest cancer in the family (or a variant of this) 
is the normal recommendation. Other pedigrees such as two affected parents, one affected 
FDR< 40 or 45 and one first and one or more second degree relatives attract less overall 
agreement regarding screening. Microsatellite testing and immunostaining of tumours for
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loss of MMR proteins can be a helpful adjunct to deciding on screening intervals in some 
families, especially if germline mutation analysis is not possible.
Screening for patients with FAP is best done in specialist centres with expertise in the 
genetic and clinical aspects of the disease. In the majority of FAP families an APC or MYH 
mutation can be detected allowing non-carriers to avoid screening. At-risk individuals from 
families with classic FAP without known mutation require annual flexible sigmoidoscopy 
from the early teens until age 30 and then at three to five year intervals until age 60 if no 
polyps develop. Affected persons require colectomy in their teens to early twenties.
Options include total colectomy with ileorectal anastamosis and total proctocolectomy with 
ileostomy or with ileoanal pouch formation. This risk of cancer in the retained rectum is 
12-29% and the rectum must be examined yearly. Polyps can also form in the ileal pouch 
which must also be kept under review (van Duijvendijk, Vasen et al. 1999). FAP patients 
also require upper gastrointestinal surveillance although the efficacy of this approach is not 
supported by a high level of evidence. Two to three yearly oesophagogastroduodenoscopy 
(OGD) with a side viewing endoscope is used although this is increased to yearly in the case 
of Spigelman stage III to IV duodenal polyps. These polyps are extremely difficult to treat 
and still result in a mortality of five to 10% in FAP patients after colectomy (Bulow, Aim et 
al. 1995; Bulow, Bjork et al. 2004). It is highly important that registries be established to 
record the results of all screening colonoscopies in these familial conditions so that better 
prospective estimates can be made of frequency and types of polyps and tumours occurring 
in these populations. Interval cancers, prophylactic surgery and outcome of cancer 
treatment should be a part of this record.
1.8 Inflammatory bowel disease
Inflammatory conditions of the colorectum can also lead to an increased risk of carcinoma. 
Ulcerative colitis and Crohn’s disease are the two most common conditions in this category. 
This risk increases with duration of disease, early age of onset of disease and pancolitis. 
Ulcerative colitis associated cancers show several distinctive features when compared to 
sporadic colorectal cancer (Colliver, Crawford et al. 2006). They are predominantly left 
sided and often mucinous. They are frequently multiple, arising from flat rather than 
polypoid adenomas, possible because the sequence of dysplasia in the epithelium of the 
bowel is in the nature of a ‘field defect’ (Usaj, Tarabar et al. 2004). Precursor areas of flat
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dysplasia appear to be just as frequent on the right side of the colon, however, hinting at 
additional factors in the transition from dysplasia to neoplasia (Rutter, Saunders et al. 2004). 
Somatic APC mutations appear to be less common than in sporadic cancers and it has been 
suggested that TP53 mutations occur as a much earlier event, possibly as a means of escape 
from apoptotic stress due to continuing inflammation (Matsumoto, Yoshida et al. 2003; 
Rosman-Urbach, Niv et al. 2004). Although there is clearly an inherited component in both 
Crohn’s disease and UC, the genetics is complicated and probably confounded by 
environmental factors, which interact to mediate the immune and non-immune responses 
controlling inflammation. Many chromosomal regions have been described which contain 
putative susceptibility loci, some of which have been confirmed IBD1 (16P12-Q13), IBD2 
(12pl3.2-a24.1) IBD3 (the major histocompatibility complex on chromosome 6) and IBD4 
(14A11-12)) with others that await confirmation ; lp36, 3q, 4q, 5q, 7q, 14q and 19p (Cho 
2001; Lawrance, Fiocchi et al. 2001).
1.9 Familial Colorectal Cancer
Colorectal cancer is a common disease with a lifetime risk of developing of disease 1:20 to 
1:25 in western societies and a 1:50 lifetime risk of death. Thus it can appear to cluster in 
families by chance. Despite this, more familial clustering occurs than could be expected by 
chance and not all such families will fit the modified Amsterdam criteria. Much of the 10 to 
20% of colorectal cancer due to inherited factors is still unexplained. Even of families 
fulfilling the Amsterdam criteria, just over one half will have identified mutations in the 
MMR genes and up to a third will not display a MSI-H phenotype in their tumours. Good 
epidemiological evidence exists for the presence of other high and possible low penetrance 
predisposition factors. Winawer showed that in patients participating in the National Polyp 
Study the relative risk of colorectal cancer was 1.78 (95% Cl 1.18-2.67) in parents and 
siblings of persons found to have a polyp and that this increased to 2.59 (95% Cl 1.46-4.48) 
when the polyp was diagnosed at age <60 years (Winawer, Zauber et al. 1996). If one first 
degree relative had a polyp and another a colorectal cancer, RR was 3.25 (95% Cl 1.92- 
5.52). Fuchs et al found that in a very large cohort of men and women with data on family 
history of colorectal cancer and who were prospectively followed up for the occurrence of 
CRC that the RR for men with at least one FDR was 1.64 (95% Cl 1.04-2.58 and for women 
was 1.77 (95% Cl 1.32-2.37) (Fuchs, Giovannucci et al. 1994). This RR was markedly 
higher for members of the cohort with a FDR affected under 45 years (5.37) and approached
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one for those with one FDR affected at over 65 years of age. For persons with two or more 
affected FDR, RR was 2.75 (95% Cl 1.34 to 5.63). A case control study performed with 
over 2,500 unselected persons with colon cancer gave similar results for odds ratios (OR) for 
developing cancer (Slattery and Kerber 1994). Men with one FDR affected by colon cancer 
had an OR of 2.1 (95% Cl 1.65 -  2.69) and women had an OR of 2.57 (95% Cl 1.99 -  3.33). 
These ORs went up considerably if two or more relatives were affected or one relative was 
affected at under 45 yeas however there were only small numbers in these analyses.
Houlston et al found similar degrees of risk amongst their cohort with a lifetime risk of 
colorectal cancer of 1:6 for those with two affected FRD’s and 1:10 for those with one FDR 
affected under 45 years (Houlston, Murday et al. 1990). Some of these families were 
recruited through St Mark’s Hospital.
This work has been, first and foremost, aimed at explaining inherited aspects of colorectal 
cancer and its precursor the adenoma. The starting point has been the 2300 families 
comprising the Bobby Moore database at St Mark’s Hospital Family Cancer Clinic. These 
families have been seen at the clinic for advice and counseling on their family risk and need 
for colorectal cancer screening. Some families have undertaken discussions regarding 
specific gene testing and proceeded with such testing. Many individuals from these families 
have screening colonoscopies performed at St Mark’s Hospital. Other families have been 
recruited through the Clinical Genetics Unit at Guy’s Hospital. They are, as a group, very 
enthusiastic about research into the possible inherited causes of colorectal cancer.
When this work has initiated there were many families on the database who appeared to have 
an hereditary predisposition to colorectal cancer but in whom known genetic conditions had 
not been excluded. My first task was to perform microsatellite instability testing and 
immunohistochemistry on tumours from affected members of these families and then, where 
possible, to perform mutation analysis on germline DNA to uncover those families with true 
HNPCC. Whilst doing this it became apparent that there were a number of families who may 
well have harboured MMR gene mutations but in which there were no live affected members 
available for genetic testing. I set about developing an algorithm using all the clinical data 
from the family as well as pathological information and molecular data from the tumours to 
divide families into those which were truly HNPCC and likely to be mutation positive and 
those unlikely to have a mutation detected. Such an algorithm can help decide on screening
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for families who cannot undergo genetic testing and who may not fulfill the Amsterdam 
criteria.
On^the mutation positive HNPCC families had been fully described, the next task was to try 
to group the non-HNPCC families into groups for further studies. The clinical features of 
individuals and families and the molecular features of their tumours were analysed 
thoroughly before using a cluster analysis technique to partition the families into strata for 
further analysis.
One group of families appeared separate from the outset. These were families with multiple 
colorectal polyps and colorectal cancer. Many of these families had been examined for 
germline APC variants previously and were examined again as part of this study. A 
significant number did not have detectable APC mutations -  both families with autosomal 
dominant and recessive appearing pedigrees. A minority was found to have the CRAC1 
haplotype. We have used several approaches in the course of this work to elucidate the 
genetic basis of this patient group characterized by the presence of multiple colonic 
adenomas.
Initially a candidate gene approach was used and germline DNA in multiple adenoma 
families was screened for pathogenic variants in genes involved in pathways known to be 
important in colorectal carcinogenesis. These comprise a set of genes, which on the basis of 
their product’s activity should play a vital role in one of the known pathways disrupted in 
carcinogenesis. Many of these genes can be deduced from work in lower species and their 
human homologue then identified on the basis of sequence similarity. As new pathways 
involved in malignant change within cell emerge and increasing numbers of human genes are 
cloned, this list of genes changes and increases. Target genes for this kind of screening can 
also be deduced from those frequently found to be mutated in sporadic cancers.
Secondly linkage studies can be performed based on the assumption that high or moderate 
penetrance genes remain to be identified such as the CRAC1 locus on 15q. Large non- 
parametric linkage studies are currently also being performed with the additional aim of 
uncovering low penetrance alleles contributing to the familial clustering of colorectal cancer. 
Such studies are particularly difficult to perform as large numbers are needed, requiring 
blood collection on a huge scale. Ascertainment of affection status can be problematic when
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it relies on self-report from family members, and mutation of known germline predispositions 
must be excluded in each family.
During the course of the work we were able to verify that a new colorectal adenoma and 
cancer predisposition gene, MYH, does account for a number of these cancers and I was able 
to go on to describe the pathway of tumourigenesis in such tumours.
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Table 1.1 ICG Characteristics of HNPCC
1. Familial clustering of colorectal cancer and/or endometrial cancer
2. Associated cancers; cancer of the stomach, ovray, ureter/renal pelvis, brain, small
bowel, hepatobiliary tract and skin (sebaceous tumours)
3. Development of cancer at an early age
4. Development of multiple cancers
5. Features of colorectal cancer: (i) predilection for proximal colon (ii) improved 
survival (iii) multiple colorectal cancer (iv) increased proportion of mucinous 
tumours, poorly differentiated tumours, and tumours with marked host-lymphocytic 
infiltration and lymphoid aggregation at the tumour margin
6. Features of colorectal adenoma: (i) the numbers vary from one to a few (ii) 
increased proportion of adenomas with a villous growth pattern and (iii) a high 
degree of dysplasia (iv) probably rapid progression from adenoma to carcinoma
7. High frequency of microsatellite instability
8. Immunohistochemistry: loss of MLH1, MSH2 or MSH6 protein expression
9. Germline mutation in MMR genes (MSH2, MLH1, HSH6, PMS1, PMS2)
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Table 1.2 Classic ICG-HNPP Criteria (Amsterdam Criteria I)
• There should be at least three relatives with CRC; all the following criteria should be 
present:-
• One should be a first degree relative of the other two.
• At least two successive generations should be affected.
• At least one CRC should be diagnosed before age 50.
• Familial Adenomatous Polyposis should be excluded.
• Tumours should be verified by pathological examination.
Table 1.3 Revised ICG-HNPCC Criteria (Amsterdam criteria II)
There should be at least three relatives with an HNPCC-associated cancer (CRC, cancer of 
the endometrium, small bowel, ureter or renal pelvis)
One should be a first degree relative of the other two.
At least two successive generations should be affected.
At least one should be diagnosed before age 50.
Familial Adenomatous Polyposis should be excluded in the CRC case(s) if any.
Tumours should be verified by pathological examination.
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Table 1.4 Bethesda Guidelines for MSI testing of tumour.
1. Individuals with cancer in families that meet the Amsterdam Critera
2. Individuals with two HNPCC-associated cancers, including synchronous and 
metachronous CRC or associated extra-colonic cancers*
3. Individuals with CRC and a first degree relative with CRC and/or HNPCC-related 
extracolonic cancer and/or a colorectal adenoma diagnosed at age<40 years.
4. Individuals with colorectal cancer or endometrial cancer diagnosed at age <45 years.
5. Individuals with right-sided CRC with an undifferentiated pattern (solid/cribriform) 
on histopathology diagnosed at age <45 years.
6. Individuals with signet-ring-cell-type CRC diagnosed at aged <45.
7. Individuals with adenomas diagnosed at age <40 years.
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Table 1.5 Revised Bethesda Guidelines for MSI testing of tumour.
Tumours from individuals should be tested for MSI in the following situations
1. Colorectal cancer diagnosed in an individual who is less than 50 years of age.
2. Presence of synchronous, metachronous colorectal, or other HNPCC associated 
tumours*, regardless of age.
3. Colorectal cancer with MSI histologyA, diagnosed in a patient who is less than 60 
years of age.
4. Colorectal cancer diagnosed in one or more first degree relatives with an HNPCC 
related tumour, with one of the cancers being diagnosed under age 50 years.
5. Colorectal cancer diagnosed in two or more first- or second degree relatives with 
HNPCC-related tumours regardless of age.
• *HNPCC-related tumours include colorecta, endometrial, stomach, ovarian, pancreas, 
ureter and renal pelvis, biliary tract and brain (usually glioblastoma as seen in Turcot 
syndrome) tumours, sebaceous gland adenomas and keratoacanthomas in Muir-Torre 
Syndrome and carcinoma of the small bowel.
• APresence of tumour infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, 
mucinous/signet ring differentiation or medullary growth pattern.
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Table 1.6 Molecular genetic features of MSI-H tumours.
APC
(%)
B-Cat P53 (%) K-ras (%) SMAD4 or 
18q LOH
(%)
BAX TGF
RBII
Miyaki
(Miyaki, Iijima et 
al. 1999)
6/28
(21)
12/28
(43)
Sakao
(Sakao, Noro et al. 
1998)
11/19
(58)
Konishi
(Konishi, Kikuchi- 
Yanoshita et al. 
1996)
3/19
(16)
4/20
(20)
1/120 (5) 1/7 (14) 13/20
(65)
Fujiwara
(Fujiwara, Stolker 
et al. 1998)
2/55*
(3.6)
14/25
(27)
0/11 (0) 19/46
(41)
46/54
(81)
Huang
(Huang,
Papadopoulos et 
al. 1996)
28/52
(54)
Olschwang 
(Olschwang, 
Hamelin et al. 
1997)
1/9(11) 4/13
(31)
2/9 (22) 13/13
(100)
*P53 immunostaining only. Gene product overexpression in >50% nuclei.
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Chapter 2 Materials and Methods
2.1 DNA Extraction
2.1.1 DNA Extraction from Blood
DNA extraction from fresh or frozen blood was performed using either a DNA extraction kit 
(Nucleon), according to the manufacturer’s instructions, or using the ammonium acetate 
method set out as follows. The first steps of this method acted to break down the cell wall to 
allow access to the nucleus. Nine ml frozen blood samples were thawed and the blood 
transferred to a 50ml conical bottom Falcon tube (Greiner). Ice cold water was added to the 
tubes to give a final volume of 50mls, and then the tube inverted to mix and lyse the red 
blood cells. The tubes were then centrifuged at 2300rpm for 25 minutes at 4°C in a swing out 
rotor centrifuge (CR412 Jouan). The supernatant was discarded by inverting the tube gently, 
being careful not to disturb the pellet. The tube was inverted and placed on a clean paper 
towel to remove the last traces of supernatant. The pellet was then washed with 25 ml 0.1% 
NP-40 (Sigma) and centrifuged at 2300rpm for 20 minutes at 4°C. The wash was repeated if 
necessary. The supernatant was discarded and the tube inverted over a paper towel. To lyse 
the nuclei, 3ml nuclei lysis buffer was added to the pellets and the tube vortexed to re­
suspend the pellet completely. 200pl 10% SDS and 600pl proteinase K solution was then 
added to the tube to degrade any protein. The solutions were mixed by inversion and 
incubated at 60°C for 11/2-2 hours or overnight at 37°C. Following proteinase K digestion, 
lml of saturated ammonium acetate solution (148g NH4AC (BDH) in 50mls distilled water) 
was added and the tube vortexed vigorously for 15 seconds. The tube was left to stand at 
room temperature for 20 minutes, and then centrifuged at 2300rpm for 20mins at room 
temperature. The DNA was then in the supernatant and ready to be precipitated. The 
supernatant was transferred to a clean tube 50-ml falcon tube, and two volumes of ice-cold 
ethanol added. The contents were mixed by gentle inversion, and then the DNA was spooled 
out using either a fine glass rod or a fine plastic sterile loop. The spooled DNA was dipped 
into an eppendorf containing 70% ethanol (to wash the DNA and to remove any salts). The 
DNA was transferred to a labelled screw capped eppendorf, left to dry and then re-suspended 
in lml distilled water. To assess quantity and quality, an aliquot was diluted 1:50 and 
analysed by spectrophotometry at 260 and 280nm.
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2.1.2 DNA Extraction from Cell Lines
DNA was extracted from cell lines using a high salt method, avoiding the use of phenol. To 
pellet the cells, 50ml Falcon (Greiner) tubes were spun at lOOOrpm for 10 minutes. The 
supernatant was removed and the cells washed twice in phosphate buffered saline (PBS), 
before finally removing the supernatant. The cells (approximately 5x10 ) were re-suspended 
in 15mls SE buffer, and 50pl of lOmg/ml RNase A (Advanced Biotechnologies) added to the 
tube before incubation at 37°C for 1 hour to degrade any RNA. Proteinase K was then added 
to a final concentration of 200pg/ml and the tubes left overnight at 55°C to degrade the 
protein. 4.5mls of pre-warmed 5M NaCl was added to the tubes to give a final concentration 
of 1.5M NaCl. 20ml chloroform (Merck) was then mixed in by rotation for 30 minutes before 
centrifugation at 2000rpm for 10 minutes. The aqueous layer was transferred to a new tube 
and an equal volume of isopropanol (BDH) mixed in for 5 minutes to allow the DNA to 
precipitate. After spooling out the DNA, it was washed in 70% ethanol for a minimum of one 
hour to remove any remaining salt from the DNA. The DNA was then re-suspended in 
distilled water and subjected to spectrophotometry to assess quality and quantity.
2.1.3 DNA Extraction from Paraffin Embedded Tissue
Paraffin blocks were cut to give 10pm sections on non-coated slides. The slides were de­
waxed in xylene (BDH) for 10 minutes, followed by two washes of 10 minutes each in 100% 
ethanol (BDH). Using a haematoxylin and eosin stained slide as a guide for the area to be 
micro-dissected, the slides were scraped with a needle into an appropriate amount of 
digestion buffer (4.45ml dH20, 500pi lOx magnesium-free PCR buffer (Perkin-Elmer), 50pl 
20mg/ml Proteinase K (Merck)), depending on the size of the lesion. The tubes were 
vortexed and placed at 55°C for 1-3 days, with intermediate vortexing. The Proteinase K was 
de-activated by heating the tube to 95°C for 10 minutes and the tubes spun for 15 minutes at 
13000rpm in a microfuge. The supernatant containing the DNA was transferred to a fresh 
tube and ready to be used.
2.1.4 DNA Extraction from Fresh Frozen Tissue
DNA was extracted from fresh-frozen tissue using the QIAamp tissue kit (Qiagen) which is 
specified to allow up to 40pg of DNA to be extracted from 25mg of soft tissue. The
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manufacturer’s protocol was followed. Briefly, the tissue was cut into small pieces, lysed, 
precipitated with ethanol and added to a spin column to which the DNA bound. After several 
washes, the DNA was eluted from the column with distilled water.
2.1.5 DNA Extraction from Agarose Gels Using Geneclene® SPIN Kit
DNA was purified from agarose gels using the above kit. This system relies on a silica matrix 
that binds to single and double stranded DNA, from which the DNA is eluted at the end of 
the process in water. Manufacturer’s instructions were followed.
2.1.6 DNA Extraction from Clones
Isolation of DNA from PI artificial chromosomes (PACs) was achieved using the Plasmid 
Midi Kit (Qiagen), following the protocol designed for the isolation of BAC (Bacterial 
Artificial Chromosomes) DNA. Stabs were streaked onto agar containing 25pg/ml 
Ampicillin and grown overnight at 37°C. Single colonies were inoculated into starter cultures 
of 5ml LB medium containing 0.5 pi 25mg/ml Ampicillin and left to grow overnight with 
vigorous shaking (~250rpm). The manufacturer’s instructions for the kit were then followed.
2.2 The Polymerase Chain Reaction
The polymerase chain reaction (PCR) is used to amplify regions of target DNA, and can be 
used provided as least part of the target nucleotide sequence is known. Portions of the 
sequence which flank the desired target are used to design two synthetic DNA 
oligonucleotides, one complementary to each strand of the DNA double helix. These 
oligonucleotides serve as primers for in vitro DNA synthesis, which is catalysed by a 
thermostable DNA polymerase, with the primers determining the ends of the amplified DNA 
fragment. The Primer3 program was used to design primers (http://www- 
genome.wi.mit.edu/cgi-bin/primer/primer3 www.cgiV PCRs were usually performed in 
either 25pi or50pl volumes, although volumes could be scaled up and down as necessary. A 
typical 25pi PCR reaction would be:
2.5pl lOx Mg2+-free PCR buffer (Promega)
1.5pl Mg2+ (@ 25mM, giving final concentration of 1.5mM) (Promega)
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lpl dNTPs (deoxyribonucloside triphosphates @ 2.5mM, giving final concentration 
of 0.1 mM)(Pharmacia)
0.5pi Forward Primers (@ 20mM)
0.5pl Forward Primers (@ 20mM)
0.25 Taq DNA Polymerase (made in-house)
10-50ng DNA
Volume made up to 25pi with sterile dF^O 
The DNA was aliquoted separately into microtitre plates (Advanced Biotechnologies), and 
then the PCR master mix was made up with the remaining components, vortexed briefly and 
added to the plate containing the DNA. The plate was then sealed with a heat plate to prevent 
evaporation during thermocycling. Three main stages comprised the PCR - first denaturation 
into single stranded DNA, followed by annealing, allowing the primers to find and anneal to 
the target sequence, then extension of the primers along the target sequence. A typical PCR 
reaction consisted of an initial denaturation of 94°C for 5 minutes, then 30-35 cycles each of 
94°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds, then a final extension step of 
72°C for 10 minutes, usually performed on Tetrad PCR machines (MJResearch). The 
annealing temperature was optimised according to the Tm of the primers. When standard 
conditions failed to amplify the target DNA, a touchdown technique was employed, with the 
annealing temperature of 70°C decreasing by 0.5°C each cycle, for 19 cycles, then kept at 
52°C but increasing the length of the cycle by 1 second per cycle for 19 cycles.
2.3 Agarose Gel Electrophoresis
Agarose gel electrophoresis separates DNA molecules according to their size and was most 
frequently used for checking for the presence of PCR products. Agarose was prepared by 
boiling a mixture of agarose powder (Gibco BRL) in 1XTBE, at concentrations of 1-3% 
depending on the size of the DNA fragments. When cooled to approximately 50°C, ethidium 
bromide (lOmg/ml) (Pierce) was added and mixed in to a final concentration of 0.25pg/ml. 
The ethidium bromide intercalates with the DNA and fluoresced under ultraviolet light, 
allowing visualisation of the DNA fragments. Molten agarose was poured into a gel-casting 
tray with a comb in position and left to set. The comb was then removed; the gel was placed 
in a running tank and then covered with a running buffer of lxTBE. 5pi of DNA was 
combined with 2pl of tracking dye and loaded into each well. lOpl of 1Kb ladder was loaded 
in the final well to allow sizing of the fragments and the gel electrophoresed at 100-130V for
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10-30 minutes. Visualisation of the DNA was then performed by placing the gel on a UV 
transilluminator (260nm) and photographs taken using a UV products camera.
2.4 Purification of PCR Products
Prior to sequencing, PCR products were purified using the Qiaquick PCR purification spin 
columns or the Qiaquick 96-well format columns (Qiagen) according to the manufacturer’s 
instructions. The purification separated the target DNA from excess dNTPs and primers that 
may have interfered with subsequent downstream experiments. For example, if too much 
unbound primer were present in purified PCR products, the chances of primer-dimer 
formation increased. The sequencing reactions performed on such templates would mainly 
consist of primer sequences and not the PCR product.
2.5 Sequencing Protocols
2.5.1 Direct Sequencing of PCR Products
Sequencing of PCR products was performed using the Big Dye Terminator sequencing mix 
(Applied Biosystems) which incorporates base-specific fluorescent nucleotides, utilising the 
dideoxy chain-termination method (Sanger, 1981). This method is based upon the enzymatic 
incorporation of dideoxyribonucleoside triphosphates in which the deoxyribose 3’-OH 
normally present is missing. When these modified nucleotides are incorporated the addition 
of subsequent nucleotides is blocked, which leads to fluorescent DNA ‘ladders’ of differing 
lengths which can then be separated on polyacrylamide gels. Sequencing reactions were 
made as follows:
8 pi Big Dye Terminator mix (PE Applied Biosystems)
0.5pi primer (either forward or reverse, as used in the PCR)
6.5pi dH20
5 pi purified PCR product
Cycle-sequencing was performed in a PCR machine with an initial denaturation at 94°C for 4 
minutes, followed by 25 cycles of 94°C for 30 seconds, 50°C for 10 seconds and 60°C for 4 
minutes, with a final extension of 60°C for 7 minutes. The sequencing products were cleaned 
up to remove excess salts and big dyes using the Qiaquick columns as described in l.Q  and 
spun down in a vacuum centrifuge until dry. The products were then re-suspended in 3 pi of 
microSTOP loading buffer (Perkin-Elmer), denatured at 94°C for 4 minutes, and run on an
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ABI377 Sequencer (Applied Biosystems) on 5% Severn Super Sequencing mix (Severn) 
polyacrylamide gels.
2.5.2 Sequence Analysis
Sequences were analysed using Semi-adaptive base calling and Sequencing Analysis Version
2.1 (Applied Biosystems). Database searching using BLAST
(http://www.ncbi.nlm.nih.gov/BLASTA was performed to ensure the correct origin of the 
sequenced fragments. Alignment of sequences was performed using the Clustal V method 
based on a distance matrix (Higgins and Sharp, 1989) included in the MegAlign software 
module (DNASTAR). In addition, all sequences were examined by eye to look for 
heterozygous peaks that might not be detected by alignment tools.
2.6 Mutation Detection Techniques
2.6.1 Single Stranded Conformational Polymorphism Analysis
The rate of migration of single stranded DNA under non-denaturing conditions through a 
polyacrylamide gel is sensitive to secondary structure, and this structure in turn depends on 
the nucleotide sequence. If there are sequence differences between different strands of DNA, 
the secondary structure may be altered and this will be detected as a band of altered mobility 
on Single stranded conformational polymorphism (SSCP) analysis. SSCP was used to search 
for mutations such as point mutations (missense or nonsense), insertions and deletions in 
PCR products of up to 350 base pairs in length. Two main SSCP methods were employed -  
polyacrylamide gel electrophoresis (PAGE) combined with silver staining or capillary 
separation using an ABI3100 (Applied Biosystems).
2.6.1.1 SSCP Using Page and Silver Staining
PAGE was performed using either the Phast minigel system (Pharmacia) or using large self­
poured plates (Bio-rad Protean II SSCP system). For the Phast system, 2pl of the PCR 
product was combined with 2pl of SSCP loading buffer (98% formamide (Amersham) 
containing 0.05% bromophenol blue (Sigma) and 0.05% xylene cyanol (Sigma), and 
denatured at 95°C for 5 minutes. Larger fragments were run on pre-cast 12.5% gels for 130- 
150 volt-hours, and smaller fragments separated on pre-cast 20% gels for 140-150 volt hours, 
with the running temperature generally 10°C or 15°C. Silver-staining was used to detect the
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bands according to the manufacturer’s instructions. For the self-cast large gels, the following 
mix was prepared and poured between two clean plates assembled with spacers:
19.8mls dH20
8.2ml acrylamideibis 35% (39:1)
8ml 5XTBE
2ml Glycerol (BDH)
The gel mix was polymerised with 300pl 10% w/v ammonium persulphate (APS)(Sigma) 
and 50pl TEMED (NNN’N ’-tetramethylethylenediamine) (BDH). 5pi of PCR product was 
combined with 5pi SSCP loading buffer before being denatured and loaded on the set gels. 
To size the separated products, 5pl of 100 base pair ladder (Gibco) was combined with 5pl of 
SSCP loading buffer and loaded into the final well. The gels were then run at 150Mamps at 
room temperature for ~4 hours or overnight in the cold room (4°C). The gels were separated 
from the plates and then silver stained (shown in Solutions section). Any samples showing 
aberrant migration were re-amplified from the source DNA, purified using Qiaquick columns 
(Qiagen) and directly sequenced using the ABI Big Dye Terminator kit (Applied 
Biosystems).
2.6.1.2 SSCP Using the ABI 3100
The second technique for SSCP analysis utilised a capillary based method. PCR products 
were amplified with the forward and reverse primers fluorescently dye-labelled (FAM, TET 
or HEX). 5pl of diluted (1/50) PCR products were combined with 0.5pl internal size standard 
(Tamra 350, Applied Biosystems) and 11.5pl 310 loading buffer. The samples were 
denatured at 95°C for five minutes, plunged onto ice and then run on an ABI 3100 sequencer 
(Applied Biosystems), using 2% Genescan polymer containing glycerol (Applied 
Biosystems). SSCP was performed under two different temperature conditions (18°C and 
24°C), according to manufacturer’s instructions. Sequence changes within the fragments 
presented as a different pattern or altered size when compared to the size standard. Fragments 
showing both aberrant and normal migration were re-amplified using non-fluorescently 
labelled primers, purified using Qiaquick columns (Qiagen) and then sequenced in both 
forward and reverse orientations using the ABI Big Dye Terminator kit (Applied 
Biosystems). This 96-well format high throughput system allowed three fragments to be 
assessed simultaneously in the same well.
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2.6.2 Denaturing High Performance Liquid Chromatography Using the WAVE® 
System
Denaturing High Performance Liquid Chromatography (DHPLC) is a chromatographic 
mutation analysis method based on temperature-dependant separation of DNA containing 
mismatched base pairs from a pool of PCR amplified DNA fragments. Mutation detection by 
DHPLC relies on the formation and separation of double-stranded DNA fragments that 
contain mismatched bases known as heteroduplex DNA. Heteroduplex DNA is generated by 
denaturing and re-annealing a mixed population of reference or ‘wild-type’ sample and 
‘mutant’ DNA. The heteroduplex DNA fragments form as a result of base-pairing in the 
single-stranded, mutated DNA with a single-stranded ‘wild-type’ DNA. The two strands will 
not form hydrogen bonds at the mutation site because the base-pairs are mismatched, thus 
giving the heteroduplex different melting properties than the homoduplex. Using the 
WAVE® system, heteroduplexes can be resolved from homoduplexes. At a critical 
temperature (partially denaturing conditions), the mismatched bases in the heteroduplexes 
begin to separate, while the matched bases of the homoduplexes remain intact.
Heteroduplex fragments elute earlier in the gradient, specifically the heteroduplex DNA is 
detected by the presence of additional ‘peaks’ or ‘shoulders’ in the resulting chromatogram. 
When compared to a reference or ‘wild-type’ DNA amplicon, these additional peaks signal 
the presence of a mutation.
DHPLC was done using the 3500HT WAVE nucleic acid fragment analysis system 
(Transgenomic, Crewe, UK). The same primer set was used as for F-SSCP except that no 
fluorescent labelling was used for this technique. To enhance the formation of heteroduplexes 
prior to analysis, the PCR products were denatured at 94°C and re-annealed by cooling to 
50°C at a rate of 1°C per minute. DHPLC was carried out at the melting temperature 
predicted by Wavemaker (version 4.0) software (Transgenomic) with a 12% acetonitrile 
gradient over 2.5 minutes. Samples displaying aberrant dHPLC elution profiles were 
sequenced directly.
2.6.3 Protein Truncation Test
2.6.3.1 In-Vitro Translation of PCR Products
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The protein truncation test (PTT) detects nonsense mutations -  point mutations which result 
in a stop codon, or frameshifts which results in a downstream aberrant stop signal. PCR 
primers were designed with MYC, T7 RNA-polymerase binding site and RBS (ribosomal 
binding site) tags and an in-frame start codon on the forward primer. These latter tags 
enabled transcription and translation respectively. The tag added to the forward primers was 
as follows:
5’GGATCCTAATACGACTCACTATAGGAACAGACCACCATGGAACAAAAATTAAT
ATCGGAAGAGGATTTGAAT
PCRs were performed on cDNA using standard conditions to amplify the entire coding 
region with overlapping fragments, ensuring each fragment started in-frame. The products 
were then kept at -20°C until ready for use. To allow in v/Yro-coupled transcription and 
translation (IVTT), 15 pi of the tagged PCR products were combined with the following 
reagents which had been carefully mixed together:
8 pi Rabbit Reticulocyte Lysate 
0.66pl TnT buffer
0.34pl amino acids minus methionine 
0.34pl T7 polymerase 
0.66pl 35Smethionine 
0.33pl RNase inhibitor 
4.67pl dH20
The mix was then incubated for lor 2 hours at 30°C on a PCR machine, with the plate 
covered by 3MM paper to stop any isotope vapour escaping.
2.6.3.2 Electrophoresis of Translated Products
For the electrophoresis of the resulting ‘proteins’, two polyacrylamide gel mixes were 
required -  one to stack the proteins and one to resolve the proteins. Aberrant stops were 
detected as a truncated ‘protein’ band when subjected to PAGE. To prepare enough 12% 
resolving gel mix for two gels, 8ml acrylamide (30%, 37.5:1) (Severn Biotech) was mixed 
with 7ml distilled water and 5ml lower buffer mix. Two clean plates were assembled with a
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gasket acting as a spacer, and bulldog clips holding the assembly together. lOOpl of 20% w/v 
ammonium persulphate (APS) and 20pl of TEMED were added to the lower gel mix, swirled 
gently and then poured into the glass plate assembly. 500pl of water was added on top of the 
resolving gel to ensure a straight edge was obtained. Whilst the resolving gel polymerised, 
the 1.125% upper (stacking) gel mix was made by mixing 2.5ml acrylamide (30% 37.5:1) 
with 8.5ml distilled water and 2.5ml upper buffer. The water was poured away from the 
lower gel, and 500pl of the un-polymerised upper gel mix added in its place to allow good 
contact between the two gels. A 12-well sharks-tooth comb was added at an angle to allow 
the pouring of the upper gel. The upper gel mix was poured away from the lower gel, and 
20pi TEMED and lOOpl 20% APS added to the remaining upper mix before pouring it onto 
the lower gel. The comb was straightened and excess gel wiped away. 1.5-2 inches of PTT 
running buffer was added to the running tank. Once the gels had set (10-20 minutes), the 
clips and gasket and comb were carefully removed. The wells were rinsed and straightened 
using a syringe filled with running buffer. The two plates were clamped into the running tank 
and the reservoir filled with running buffer. lOjul of sample buffer (9pl bromophenol blue 
plus lpl 1M DTT) was added to each well, the plate was sealed and covered with 3MM to 
stop any vapour escaping and then denatured at 95 °C for 5 minutes. 15 pi of each sample was 
carefully loaded into wells 1-11, avoiding air bubbles, and then 7.5pl of multicoloured 
protein marker (NEN) was added to the final well for orientation. The gel was run at 60m 
amps for 1-1.5 hours or until the loading buffer was visible near the bottom of the gel.
2.6.3.3 Fixing, Drying and Exposure of the Gel
Following electrophoresis, the running buffer was carefully disposed of in the hood and the 
plate assemblies were placed on paper towels to ensure that no isotope was left on the 
surface. The plates were separated using forceps and the gels placed into fixing solution until 
the bromophenol blue in the sample buffer had turned green. In the meantime, the gel dryer 
was warmed to 80°C with a piece of 3MM paper in. The gels were then transferred onto a 
piece of 3MM on the bench added to the 3MM in the dryer. The gels were dried under 
vacuum fori hour and then taped into an X-ray cassette. In the dark room, Kodak film was 
laid over the gels and left overnight before developing in an automatic developer.
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2.7 Sterile Lymphocyte Separations
Separations were performed so that the lymphocytes could be established as permanent cell 
lines by Epstein - Barr virus transformation. 25ml blood was collected in Falcon tubes 
containing 25ml sodium citrate medium. The contents of the Falcon were poured into a 
250ml flask, and the tube rinsed with 4ml filtered RPMI which had been brought to room 
temperature. Approximately 25 sterile glass beads (BDH) and 0.6ml 1M CaCkCBDH) were 
added to the flask and defibrination started immediately for 15 minutes at 250rpm on a 
gyratory shaker. 20ml RPMI was added to the flask and the defibrinated blood divided into 
two tubes, layering carefully over 15ml lymphoprep (Robbins Scientific). The tubes were 
spun at 1800 rpm for 20 minutes in a centrifuge with a swing out centrifuge rotor, with the 
speed carefully brought up and down. The interface was then transferred to a new Falcon and 
spun at 2300rpm for 10 minutes. The pellet was washed in 20ml RPMI then re-spun at 
2300rpm for 10 minutes. The pellets were re-suspended in 2ml freeze mix, divided into two 
labelled cryotubes (Coming) and placed at -80°C overnight. The lymphocytes were then 
stored in liquid nitrogen until ready for transformation.
2.8 Tissue Culture
2.8.1 Feeding Cell Lines
Once the lymphocytes had been transformed and returned as a growing culture, the cells 
would either need feeding or spinning down for DNA/RNA/protein extraction as described 
above. The cells were examined under a microscope to determine the viability and density. If 
the cells were to be left to continue to grow but were confluent, an equal volume of growth 
medium was added to the flask and left at 37°C overnight in 10% CO2. The cells were then 
re-examined and either left to grow or spun down for required protocol.
2.8.2 Freezing Down Cells To Replace Stocks
To ensure the cell lines remain a permanent resource, an aliquot of the growing cultures was 
always frozen down. 50ml of the growing culture was spun at 2000rpm for 5 minutes, the 
supernatant removed and the tube inverted to dry. The pellet was then fully re-suspended in 
2ml freeze mix, and aliquoted into sterile cryotubes labelled with the cell line name, date,
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volume spun down and initials. The tubes were frozen at -70°C overnight then stored in 
liquid nitrogen.
2.9 Comparative Genomic Hybridisation
Comparative genomic hybridisation (CGH) is a useful tool for performing a genome wide 
scan of chromosomal loss and gains in a tumour (Kallioniemi et al., 1992). A mixture of 
DNA from malignant and normal cells are differentially labelled with red or green 
fluorochromes and then hybridised onto metaphase spreads. Images of 5-10 metaphases are 
captured and quantification of the fluorescence ratios performed using a digital image 
analysis system. The relative ratios of red and green are then compared. Regions of genetic 
material which have been lost during tumour progression will show as red, and regions which 
have been gained will show as green. The thresholds of detection for CGH are regions greater 
than 10Mb for loss of genetic material, and gains of 2Mb or more if the region is amplified 
five times.
2.9.1 Nick Translation and Precipitation Of Probe
One pg of tumour DNA or test DNA was labelled with FITC-12-dUTP (Vysis) or Texas 
Red-5-dUTP (Vysis) respectively. This was achieved by mixing the DNA, lpl of the 
relevant fluorochrome, 5 pi dNTPs, lOpl DNA polymerase I/DNase mix, and lpl DNA 
polymerase I and distilled water to make a total volume of 50pl. The mix was incubated at 
15°C for 2 hours, and then left on ice while 5pl was run on a 1% agarose gel. Probe 
fragments forming a smear ranging in size between 500 and 2000 base pairs were the best 
length for smooth hybridisations. The reactions were stopped by adding 5pi of 0.5M EDTA 
and could be stored at -20°C until ready for use. The tumour and test DNAs were then 
combined in an Eppendorf tube and mixed with 50pl of human Cot-1 DNA, 0.1 volume 3M 
sodium acetate, and 2 volumes cold absolute ethanol. The DNA was precipitated on dry ice 
for 30 minutes or overnight at -20°C. After spinning at 15000rpm, the supernatant was 
carefully removed and the pellet left to air dry. The pellet was then re-suspended in lOpl of 
hybridisation mix and denatured at 75°C for 5 minutes. The DNA was left to pre-anneal at 
37°C for 30 minutes to 1 hour whilst the slides were prepared for hybridisation.
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2.9.2 DOP-PCR Labeling Of Tumour DNA for CGH
Degenerate oligonucleotide primed polymerase chain reaction (DOP-PCR) labelling of 
tumour DNA was performed when there was not sufficient or good quality DNA to nick 
translate, usually when the DNA was extracted from paraffin embedded tissue. The PCR- 
labeling used a degenerate primer (sequence 5’ ccgactcgagnnnnnnatgtgg 3’) and had two 
stages, initial low stringency cycles, where the specific bases at the 3' end of the 
oligonucleotide theoretically primed every 4 kb along the template DNA, and then an 
increased number of cycles with high stringency, whereby the oligonucleotide ‘tailed’ DNA 
from the initial cycles was amplified. Further DOP-PCR, with differential fluorescent 
nucleotides incorporated into the PCR reaction was then performed to label the tumour and 
normal DNA with their respective fluorochromes. Labeled DNA was then precipitated and 
hybridised to metaphase spreads, using the same protocols as those for nick-translated DNA. 
The first round DOP-PCR reactions were set up as follows;
2.5nl 10 X Mg2* free PCR buffer
2.5pl dNTPs (@ 2 mM, giving final concentration of 200pm)
0.5pl DOP 6MW primer (at 100pm giving concentration of 2.0p M)
4pl Mg2+ (@25mM giving concentration of 4mM)
0.5pl Taq polymerase 
15 pi tumour or normal DNA 
Volume made up to 25pl with dFLO 
The DOP-PCR conditions were as follows: 1 cycle of 9 mins @ 94°C, 8 cycles of (1 min @ 
94°C, 1.5 mins @ 30°C, 3 mins @ 72°C) then 25 cycles of (1 min @ 94°C. 1 min @ 62°C,
1.5 min @ 72°C) followed by a final extension of 8 mins at 72°C.
The second round labeling DOP-PCR experiments were set up as follows;
5nl 10 X Mg2+ free PCR buffer
5pl labeling dNTPs (2 mM each of dATP, dCTP and dGTP, 0.5mM dTTP, giving 
final concentration of 200pm)
0.5pl DOP 6MW primer (at 100pm giving concentration of 2.0p M)
8pl Mg2+ (@25mM giving concentration of 4mM) 
lpl Taq polymerase
lOpl of first round DOP-PCR tumour or normal DNA
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Volume made up to 50pl with dtfeO 
The labeling DOP-PCR conditions were as follows: 1 cycle of 4 mins @ 94°C, then 25 
cycles of (1 min @ 94°C. 1 min @ 62°C, 1.5 min @ 72°C) followed by a final extension of 8 
mins at 72°C.
2.9.3 Denaturing the Slide and Hybridisation
Each batch of slides, whether commercial (Vysis) or made in-house, had a pre-determined 
optimal denaturing time. Prior to denaturing, slides were examined under the microscope to 
ensure they were suitable for hybridisation, with many, distinct metaphases free of cytoplasm 
being ideal. The slides were then denatured on a hotplate at 73°C with denaturation solution 
under a 22 mm X 50 mm cover slip. The cover slip was then flicked off and the slides placed 
in ice cold 70% ethanol for three minutes, and then dehydrated through an ethanol series for 
three minutes each. The slides were air dried and then ready for use. For the hybridisation, 
the slides were placed on a hotplate at 37°C and lOpl of a denatured probe added to each half 
of the slide. Each probe was covered with a 22 X 22mm cover slip, sealed with rubber 
cement and sealed in a moist chamber for 48-72 hours at 37°C.
2.9.4 Post-Hybridisation Washing Of the Slides
Following hybridisation, the cover slip was removed from the slides and the slides subjected 
to 3 X 5 minute washes in 50% formamide/2XSSC at 42°C, then 3X 5  minutes in 2XSSC, 
again at 42°C. The slides were then subjected to a 5 minute wash at room temperature in 
SSCT, whilst shaking gently, before dehydrating through an ethanol series (70%, 95%, and 
100%) and being left to air dry. The slides were then mounted in DAPI (approximately 20pl 
under a 22 X 50mm coverslip), and either stored in a cardboard folder at 4 °C or captured 
immediately.
2.9.5 Image Acquisition and Analysis
5-10 metaphases per experiment were captured using an epifluorescence microscope 
(Applied Imaging) equipped with a triple-color epifluorescence filter set (selective for the 
fluorochromes DAPI, FITC, and rhodamine) in combination with a cooled CCD camera 
(Quantix Photometrix). Images were captured using Quips software (Vysis). The metaphases
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were karyotyped using the digitally inverted DAPI image which gave a G-banded pattern. 
After karyotyping the relative intensities of the red and green signals were analysed and an 
average obtained for multiple metaphases. CGH experiments were considered successful if 
enough fluorochrome had been incorporated to give smooth intense color that was not 
granular in appearance.
2.10 Immunohistochemistry
2.10.1 Slide Preparation
Five micrometre sections were placed on slides. Slides were dewaxed in a xylene to water 
series. Racked slides were immersed in xylene for 5 minutes then 100% ethanol for three 
minutes, 90% ethanol for three minutes, and 70% ethanol for three minutes. Endogenous 
peroxide activity was then blocked with 2% H2O2 by immersion for 20-30 minutes.
2.10.2 Exposing Antigen and Applying Primary Antibody
Citrate buffer was heated to boiling in a pressure cooker and slides were placed in the 
pressure cooker on full pressure for four minutes. Slides were allowed to cool in the citrate 
buffer then rinsed in PBS pH 7.45. PBS was then tipped off and the nonspecific 
immunoglobulins blocked with normal serum at a dilution of one in 5 for 30 minutes.
For polyclonal antibodies (such as MSH2) 15pl goat serum is diluted in 985pi PBS.
For monoclonal antibodies (such as MLH1) 15pl horse serum is diluted in 985pi PBS. 
Primary antibody (75pl of diluted mixture) is then added at a concentration of 1/100 (MSH2, 
MLH1, MSH6, beta-catenin and SMAD4) or 1/1000 (P53) and the slides incubated at 4°C 
for 24 hours.
2.10.3 Applying Secondary Antibody and Counterstaining
Sections were rinsed in PBS for five minutes. They were then incubated in biotinylated 
secondary antibody at a dilution of 1/200 for 30 minutes.
For polyclonal antibodies: 15pl goat serum + 5pl Anti-rabbit + 980pl PBS per lmL.
For monoclonal antibodies: 15pl horse serum + 5pl Anti-mouse + 980pl PBS per lmL.
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Next the slides were incubated in Streptavidin-Peroxidase C l88 (Dako E354) 1/300 for 30 
minutes then washed twice in PBS for five minutes. Peroxidase substrate (DAB) was then 
applied for two minutes watching progress carefully to avoid overstaining. Slides were then 
washed in water and counterstained in Haematoxylin for two minutes. Finally slides were 
dehydrated through a series of ethanol 70%, 90%, 100% and xylene and then mounted in 
DPX mountant.
2.11 Flow Cytometry
Flow cytometry is used to measure the DNA content of cells amongst many other 
applications. This can allow estimation of the degree of polyploidy or aneuploidy of a 
population of cells. It can also give information about the cell cycle. The DNA-binding 
fluorochrome propidium iodide was used for all analysis in this project.
All cells in the G1 phase will take up the same amount of dye and will fluoresce in a single 
channel however there will be minor conformational variations in the DNA leading to 
different amounts of dye being taken up. This is quantitated by using the coefficient of 
variation of the G1 peak. The lower the co-efficient of variation, the better changes such as 
aneuploidy can be assessed. The DNA content is being inferred by the amount of 
fluorochrome binding and the scatter pattern of light as cells pass through the reading laser. 
Larger cells cause greater scatter of light and this can be quantitated.
2.11.1 Isolating Nuclei from Paraffin Embedded Tissue
40pM sections were cut from paraffin embedded archival tissue. These were placed between 
layers of 3MM Whatman paper and placed in a small histopathology cassette. These were 
dewaxed in xylene for one to 12 hours if many samples were being processed. The samples 
were then re-hydrated through an alcohol series 95%, 70% and 50%. The 95% ethanol was 
changed once to remove all traces of xylene. The tissue was left in each solution for 20 to 30 
minutes. Cassettes were then rinsed in ddFLO for 15-20 minutes twice. The re-hydrated 
tissue section was removed from the cassette and transferred to a 1.5ml eppendorf tube. One 
ml of 0.4% pepsin solution at 37°C was added and the tissue allowed to digest for 30 
minutes. Digestion was stopped by adding 0.2% glycine in 2xPBS. The nuclei were then 
spun down and washed with PBS twice.
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2.11.2 FACS Analysis
Cells were resuspended in lOOul RNase (Sigma; lOOug/ml) and 400ul propidium iodide
(Sigma; 50ug/ml) and incubated at room temperature for 30 minutes. Samples were analysed
using a FACS Calibur (Becton Dickinson, San Jose, Ca) with gates being set on forward and
side scatter to exclude debris and PI signal area and
width to exclude cell doublets. Propidium iodide fluorescence was
collected above 670nm and samples were analysed using CellQuest software
(BD).
2.12 Cloning of PCR Products
2.12.1 Ligation of PCR Products into Cloning Vectors
PCR was performed using 100 ng of template DNA. This was run on 2% LMP agarose gel at 
60V for 90 minutes. The resulting band was then cut out over ultraviolet light and the DNA 
purified. PCR products were cloned directly into the pGEM® Easy vector using the pGEM®' 
T Easy Vector System (Promega) following the manufacturers instructions.
2.12.2 E.coli Transformation
A 14ml FALCON® tube (Becton Dickinson) was chilled on ice for each transformation. 50- 
lOOpl of competent cells (Stratagene) was added. Two microlitres of p-mercaptoethanol were 
added and the mixture left on ice for ten minutes. Two microlitres of each ligation mix was 
added to a tube of cells which was then incubated on ice for 30 minutes. Cells were heat 
shocked at 42°C for 30 seconds then returned to the ice bath. 0.9ml of preheated 42°C NZY* 
broth was added and the tubes incubated at 37°C for one hour with shaking at 225-250 rpm. 
lOOpl of each sample was plated on an agar plate containing 0.2mM IPTG (Isopropylthio-p- 
D-galactoside) and X-gal (5-Bromo-4-chloro-3-indolyl-P-D-galactoside) 0.3mg/ml and 
incubated overnight at 37°C.
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2.12.3 Generation of Single Stranded DNA and Purification of Plasmid DNA
Each clone/colony to be analyses was picked of the plate and inoculated into 5ml of Luria 
broth containing Ampicillin (Sigma) at 50pg/ml. The cultures were incubated overnight at 
37°C with shaking at 300rpm. The following morning the cells were pelleted by spinning at 
13000rpm for 1 minute. Preparation of the DNA is performed as follows using a QIAprep® 
Miniprep kit (Quiagen). Bacterial cells containing plasmid then were lysed under alkaline 
conditions and the lysate neutralized and purified by passing through a filter before 
adsorption on a silica-gel membrane in the presence of a high salt concentration. 
Endonucleases and salts were removed by washing in kit buffers and DNA eluted in water.
1.5pi of each DNA was then used in a sequencing reaction for the region of interest and run 
on the ABI 377 or ABI 3100 using standard protocols.
2.13 Solutions and Media For Molecular Techniques 
1M CaCl?
14.7g of Calcium Chloride (BDH) made up to 100ml with dH20 
Cell lysis buffer
lml buffer (2x bromophenol blue, with SDS+sucrose)
800pl dH20
200pl 1M DTT (makes 0.1M DTT)
Citrate Buffer
10L ddH20 
20g Citrate acid 
8g NaOH pellets 
Adjust to pH 6.0 
DAB
5mg DAB (Sigma D5637)
10ml PBS 
20pl H20 2
100
Denaturing solution:(for 2 gels)
262.93g sodium chloride
60g sodium hydroxide pellets (BDH) - made up to 3L with dtfeO.
3100 dilution and running buffer
12.5ml 20xTBE 
25ml glycerol (BDH)
Made up to 250ml with dH20 and stored at 4°C.
lOOXDenhardt’s solution
lOg ficoll 400 (Pharmacia) 
lOg polyvinlypyrrolidine (BDH) 
lOg bovine serum albumin (Sigma)
Made up to 500ml with dH20, stored at -20°C.
0.5M Ethvlenediamine tetraacetate (EDTA)
93g EDTA (BDH)
lOg sodium hydroxide pellets (BDH)
400ml dH20
pH adjusted to 8.0, made up to 500ml with dH20 and autoclaved. 
Ethidium bromide (lOmg/mD
O.lg of ethidium bromide (Pierce) dissolved in 10ml dH20. Stored in dark.
Fixing solution :10% ethanol/5% acetic acid
lOOmls 100% ethanol (BDH)
50mls acetic acid (BDH)
850mls dH20
Freeze mix (90%FCS/10%DMSQ)
9ml foetal calf serum (GibcoBRL)) 
lml Dimethyl sulphoxide (BDH)
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5% stock Genescan polymer
7.14ml GS polymer (Applied Biosystems)
2.86ml 3100 dilution buffer
2%  Genescan polymer
2ml 5% stock GS polymer 
3ml 3100 dilution buffer 
Growth Medium 10% FCS/RPMI 
180mls RPMI (one bottle)
20mls FCS (one vial)
2% BbO?
600mL Methanol 
36mL 30% H202
High stringency wash (0.2XSSC/0.1%SDS)
lOmls 20XSSC
lOmls 20% SDS - up to 1L with dH20
Hybridisation solution (500ml)
211.25mls dH20
150mls 20XSSC
lOOmls 50% Dextran Sulphate
12.5mls 10% SDS
25mls 100X Denhardts solution
1.25mls lOmg/ml Salmon Sperm DNA (Amersham)
310 Loading buffer
1 lOOpl deionized formamide (Amersham)
50pl 0.3N (0.6g/50ml) sodium hydroxide
Low stringency wash (2XSSC/0.1% SDS)
lOOmls 20XSSC
lOmls 20% SDS - up to 1L with dH20
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Lower buffer mix (pH 8.8)
90.75g Tris (1.5M)
20ml 10%SDS (0.4%)
made up to 500ml with dH20 and pH adjusted to 8.8 with HCL.
Luria Broth (LB)
lOg sodium chloride 
5g bacto yeast extract 
lOg bacto-trytone 
900ml dH20
pH adjusted to 7.0 with sodium hydroxide, made up to 1L with with dH20, and autoclaved. 
LB agar plates
LB medium prepared as above, and 15g/Litre bacto-agar added before autoclaving.
Nuclei lysis buffer(50mB
lOmM Tris (500pl 1M)
400mM NaCl (4mls 5M)
2mM EDTA (200pl 0.5M) (BDH)
45.3mls dH20
Neutralising solution:(for 2 gels)
262.93g sodium chloride (Sigma)
181.5g Trizma base (Sigma) - made up to 3L with dH20.
PBS
lOdL ddH20 
80g NaCl 
2g KC1
11.5gNa2HP04 
2g KH2P04 
Adjust to pH 7.5
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Pepsin solution:(For FACS analysis)
0.4% pepsin in 0.1M HC1 pH 1.8 -(pre-warm 200ml 0.1M HC1, add 0.8g pepsin JUST 
before use).
Prehvbridisation solution: (500ml)
311.25mls dH20
150mls 20XSSC
12.5mls 10% SDS
25mls 100X Denhardts solution
1.25mls lOmg/ml Salmon Sperm DNA (Amersham)
Proteinase K buffer (stored at 4°C1
2mM Na-EDTA (200pl 0.5M solution)
1% SDS (5ml 10%SDS)
44.8mls dH20
Proteinase K solution
2mg Proteinase K (Merck) in 1ml EDTA/SDS buffer.
PTT running buffer
3g Tris (Sigma)
14.4g glycine (BDH)
10ml 10% SDS, made up to 1L with distilled water 
3% w/v skimmed milk powder
12g skimmed milk powder (Premier Brands) in 400mls PBS 
5% w/v skimmed milk powder
20g skimmed milk powder (Premier Brands) in 400mls PBS 
SE buffer
75mM NaCl (7.5mls 5M)
25mM EDTA pH 8.0 (2.5mls 0.5M)
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1% SDS (50mls 10%)
made up to 500ml with dH20 and sterilised through 0.2 p pore filter.
Silver Staining solutions/protocol
2 x 3  minutes in fixing solution: 10% Ethanol(100ml/L), 0.5% acetic acid (5ml/L) 
1x15 minutes in staining solution: 0.1% (lg/L) silver nitrate (AgNCU) (Sigma) 
2x 1  minute in dH20
1 x 20 minute in developing solution: 1.5% (9.374g/L)sodium hydroxide (BDH), 
0.1% (lml/L)Formaldehyde (BDH), prepared immediately before use.
1x10 minutes in stop solution:0.75% (7.5g/L) sodium carbonate (NA3CO4) (BDH). 
Gentle agitation required with all solutions.
3M Sodium acetate
61.52g sodium acetate (BDH)
200ml dH20
pH adjusted to 6.0, made up to 250ml with dH20, and autoclaved.
5M sodium chloride fNaCl)
73.lg sodium chloride (BDH)
made up to 250ml with dH20 and autoclaved.
Sodium dodecvl sulphate (SDS)
10% w/v volume SDS (BDH) in sterile dH20.
5xTBE
54g Tris base (Sigma)
27.5g Boric acid (BDH)
20ml 0.5M EDTApH 8.0
Made up to 1 litre with dH20 and autoclaved.
Transfer buffer(20XSSQ
88.23g Tri-sodium citrate (BDH)
175.32g sodium chloride (Sigma)- made up to 1L with dH20 (final pH7-8).
1M Tris
60.55g Tris base (Sigma)
400ml distilled water, pH adjusted to 8.0, then made up to 500ml dH20 and autoclaved. 
Upper buffer mix (pH 6.8)
30.25g Tris (0.5M)
20ml 10%SDS (0.4%)
Made up to 500ml with dH20, pH adjusted to 6.8 with HCL.
2.11 solutions for cytogenetic techniques 
Denaturing solution for slides
70% formamide (700pl)
2XSSC (lOOpl 20XSSC)
200pl dH20 
Detection reagents
For Biotin labelled probes -  avidin-FITC (Vector labs) diluted 1/500 with SSCT 
For digoxygenin labelled probes -  anti-Dig-Rhodamine (Boehringer Mannheim) diluted 
1/100 in SSCT.
Ethanol series for dehydration
70% - 700ml absolute ethanol and 300ml dH20 
95% - 950ml absolute ethanol plus 50ml dH20 
100% - absolute ethanol 
2XSSC (10% v/v 20XSSC)
50ml 20XSSC 
450ml dH20 
SSCT
4X SSC (100ml 20XSSC)
0.05% Tween-20 (250pl)
pH 7.0, made up to 500ml with dH20
SSCTM
5% skimmed milk powder (25g) 
made up to 500ml with SSCT
106
2.14 Abbreviations
aa -  amino acid
AAPC -  Attenuated adenomatous polyposis coli.
A - adenine
APC - adenomatous polyposis coli
BER - base excision repair
BMPR1A - bone morphogenic protein receptor 1A
bp -base pairs
CD - Cowden disease
CGH - comparative genomic hybridisation
CRAC1 -colorectal cancer haplotype 1
CRC -  colorectal cancer
cDNA -  copy DNA
C - cytosine
dH20 -  distilled water
DNA - deoxyribonucleic acid
FAP - familial adenomatous polyposis
FDR -  first degree relative
GI - gastrointestinal
G - guanine
HMPS -  hereditary mixed polyposis syndrome
hMLHl or MLH1 -  Human Mut L homologue 1.
hMSH2 or MSH2 -  Human Mut S homologue 2.
hMSH6 or MSH6 -  Human Mut S homologue 6.
hMLH3 or MLH3 -  Human Mut L homologue 3
hMTHor MTH1 -  Human Mut T homologue.
hMYH or MYH -  human Mut Y homologue
HNPCC -  Hereditary non-polypsis colorectal cancer
HPP -  hyperplastic polyp.
JPS -juvenile polyposis syndrome
k-ras -  Kirsten Ras
Kb -  kilo base pairs
LOH -  loss of heterozygosity
MA
MAP
Mb
MMR
MSI
MSI-H
MSI-L
MSS
nt
OGGI
8-oxoG
PCR
PJS
PTT
RNA
SA
SSCP
TA
T
TVA
U
-  multiple adenoma (phenotype)
-  MYH associated polyposis.
-  mega base pairs
-  mismatch repair.
-  microsatellite instability
-  High level microsatellite instability
-  Low level microsatellite instability
-  Microsatellite stable
- nucleotides
-  Human Mut M homologue
- 8-oxo-7,8-dihydro2’deoxyguanosine
-  polymerase chain reaction
- Peutz-Jeghers Syndrome
-  protein truncation test
- ribonucleic acid
- serrated adenoma
-  single stranded conformational polymorphism
-  tubular adenoma
-  thiamine.
-  tubulovillous adenoma
- uracil
All genes have been italicised throughout, whereas protein and phenotypic symbols 
shown in plain text.
Chapter 3 Candidate Gene Analysis in Multiple Adenoma Patients
3.1 Introduction
Patients with a multiple colorectal adenoma phenotype develop from 3 to 100+ colorectal 
adenomas throughout their lifetime. These may be synchronous or metachronous. The 
condition can appear to be sporadic/recessive or dominant within families. There appears to 
be no significant increase in extra-colonic manifestations or other cancers aside from those 
families found to have APC  mutations. About 5% of multiple adenoma cases are due to 
mutations in the extreme 3’ and 5’ ends of the APC gene with some AAPC mutations also 
having been found in exon 9 (Spirio, Olschwang et al. 1993; Lamlum, A1 Tassan et al. 2000). 
The phenotype in these families tends to vary widely from person to person. It is possible for 
persons with APC mutations generally associated with AAPC to develop a florid polyposis 
phenotype. A small proportion of such cases may also be due to HNPCC although the 
incidence of adenoma formation does not seem to be much higher than normal in MMR gene 
mutation carriers. The majority of patients who present in this manner have no detectable 
germline mutations. A candidate gene screen has therefore been undertaken in a group of 
multiple adenoma patients in an attempt to explain the germline predisposition in more of 
these patients. Candidate genes were selected o the basis of their integral role in pathways 
already known to be involved with colorectal carcinogenesis in both hereditary and sporadic 
forms.
The APC gene, known to be involved in both sporadic and familial adenoma formation is an 
integral part of the Wnt signaling pathway (Vogelstein, Fearon et al. 1988; Lamlum, 
Papadopoulou et al. 2000; Rowan, Lamlum et al. 2000). As described in chapter 1, the APC 
protein interacts with GSK3p, axin and conduction to form a complex which mediates 
proteosomal degradation of cytosolic beta-catenin, preventing its translocation to the nucleus 
and activation of a variety of transcription response elements. APC2, an APC homologue 
located on chromosome 19p 13.3 has also been shown to interact with beta-catenin binding 
domains, armadillo repeats and regulatory domains but lacks the COOH terminus domain 
which mediates microtubule binding. Human APC2 is a 2301 aa protein which is expressed 
in many different tissues including colon, central nervous system, breast and ovary. There is 
frequent LOH involving 19p in ovarian and breast cancers (Osbome and Leech 1994; Jarrett, 
Blancato et al. 2001). In SW480 cell lines lacking functional APC protein, transfection with
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the APC2 gene inhibited beta-catenin mediated TCF signaling (van Es, Kirkpatrick et al.
1999).
Somatic mutations of conductin have been found in about a quarter of microsatellite-unstable 
cancers (Liu, Dong et al. 2000). All mutations were frameshifts in mononucleotide repeats 
and involved the disheveled and axin (DIX) domain, although bi-allelic mutations were not 
demonstrated. Conductin levels and mRNA levels have also been shown to be increased in 
human cancers and cancer cell lines with disrupted Wnt signaling and increased nuclear 
levels of beta-catenin. There is also an increase in levels in APC deficient Min mice. Beta- 
catenin stabilisation appeared to precede conductin up-regulation. Conductin may therefore 
be a target of the Wnt pathway, up-regulated in a negative feedback loop to control Wnt 
signaling activity.
The TGFp signaling pathway through a cascade of SMAD proteins leading to effects within 
the cell nucleus is also known to be disrupted in germline by mutations in SMAD4 on 
chromosome 18^21.1 giving rise to the Juvenile Polyposis syndrome (JPS) in about 30-50% 
of families (Howe, Roth et al. 1998; Woodford-Richens, Rowan et al. 2001). LOH at 18q is 
frequent (about 70%) in sporadic colorectal cancers and SMAD4 mutations have been found 
in 16% of colon cancers (Thiagalingam, Lengauer et al. 1996; Riggins, Kinzler et al. 1997; 
Zhou, Buckhaults et al. 1998). The SN4A4-/+ mouse develops gastric and intestinal juvenile 
polyps and gastric cancer after several months (although not colon cancer) (Xu, Brodie et al.
2000). It acts as a tumour suppressor gene both in sporadic colorectal and pancreatic cancer 
and in polyps and cancer . from JPS patients. The polyps observed 
in JPS and the invasive cancers in the SMAD4+/- mouse show allelic loss, supporting the 
notion that bi-allelic inactivation of SMAD4 is needed for colon cancer formation 
(Woodford-Richens, Williamson et al. 2000). TGFp-II is also frequently mutated in MSH-H 
tumours both familial and sporadic indicating a role in tumourigenesis or progression (Lu, 
Kawabata et al. 1998; Roth, Johansson et al. 2000). The TGFp superfamily includes the 
BMP’S (Bone Morphogenetic Proteins). Germline mutations in BMPR1A have recently also 
been shown to cause about 38% of cases of JPS without SMAD4 mutations (Zhou, 
Woodford-Richens et al. 2001; Sayed, Ahmed et al. 2002; Howe, Sayed et al. 2004). The 
mutations were predominantly nonsense leading to a truncated protein and loss of the wild- 
type allele was seen in these tumours. As with the TGFp receptor, the best understood post-
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BMP receptor pathway is the SMAD pathway including SMAD4 (Kawabata, Inoue et al. 
1998).
Although none of the patient group tested was known to have developed juvenile polyps, 
these genes remain good candidates given their role in the development of colorectal cancer 
in both sporadic and hereditary forms. Some patients with juvenile polyposis syndrome -  
caused by germline SMAD4/DPC4 or ALK3/BMPR1A mutations -  also develop adenomas, 
although all cases described so far have had a personal or family history of juvenile polyps in 
addition to their adenomas.
Both beta-catenin and axin 1 had been screened for in the germline of a similar set of patients 
so the candidate genes screened were GSK3J3, Conductin, APC2, SMAD4 and BMPR1A.
3.2 Methods
Screening of Conductin/Axin2, APC2, GSK3J3 and MSI testing were undertaken equally by 
Dr Oliver Sieber and I.
3.2.1 Selection of Probands
Probands were affected persons from 95 different families recruited through the Cancer 
Research UK Family Cancer Clinic at St Marks Hospital London and the Guys Hospital 
Clinical Genetics Department London. Forty-one were undergoing regular colonoscopy at St 
Mark’s Hospital. All patients gave consent to the use of their DNA in a research context.
The clinical features of the initial cohort of 47 are included in Table 3.1. Probands had 
developed between 5 and 115 adenomatous polyps in their lifetimes (synchronous or 
metachronous). Although 25% of patients had developed hyperplastic as well as 
adenomatous polyps, no patient had predominantly hyperplastic polyps. The majority (83%) 
had other family members affected with multiple adenomas and/or cancer. The relatively 
low incidence of cancer in this group reflects this as most had their first screening 
colonoscopy as a result of family history and from then on received regular screening 
colonoscopy, reducing the risk of colorectal cancer development. In all patients pathogenic 
germline mutations in APC were excluded using SSCP, DGGE and PTT. The majority did 
not undergo testing for large deletions and APC as a previous study had shown no such
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mutations in a cohort of 100 multiple adenoma patients (Sieber, Lamlum et al. 2002),. All 
had MYH mutations excluded using SSCP and, some cases sequencing. Where cancer tissue 
was available (26 cases), microsatellite instability was excluded using the microsatellite 
markers BAT 26, TGFpRII and D5S346. As multiple colorectal adenomas are not a feature 
of HNPCC it was thought highly unlikely that MMR gene mutations could account for 
disease in the other 11 cancer cases.
3.2.2 Screening APC2
Primer pairs to amplify overlapping fragments were designed for the coding regions 
including exon-intron boundaries of APC2 (exon one to codon 1388 in exon 14-including the 
“twenty amino acid repeat’ region) (Table 3.3). Fluorescent SSCP (F-SSCP) was performed 
on PCR products. Fragments showing aberrant migration were re-amplified, and then 
sequenced in both forward and reverse orientations. The protein truncation test (PTT) was 
used for the remainder of exon 14 (see chapter 2 for method).
3.2.3 Screening GSK3fi
Primer pairs to amplify overlapping fragments including intron/exon boundaries were used to 
amplify the 9 exons of GSK3f$ and F-SSCP run on the ABI 3100 at 18°C and 24°C (Table 
3.4).
3.2.4 Screening Conductin/axin2
Primer pairs were designed to cover the entire coding sequence plus intron/exon boundaries 
of conductin/axin2 (Table 3.5). The entire conductin sequence was not available on a public 
database and was therefore derived by performing a BLAST search of the cDNA against the 
HTGS sequence database. SSCP was performed on the Phast system. Aberrant bands were 
sequenced directly.
3.2.5 Screening SMAD4 and BMPR1A
PRC-based germline SMAD4 and BMPR1A mutation detection and LOH was performed in 
collaboration with Dr Kelly Woodford-Richens. PCRs were performed using the primers
112
detailed in Tables 3.6 and 3.7 which cover all exons and exon/intron boundaries of SMAD4 
and BMPR1A. PCR fragments were then subjected to SSCP (Phast system). Samples with 
aberrant bands were re-amplified and sequenced. For LOH analysis, DNA extracted from 
tumour tissue was amplified alongside the blood DNA from the patient using three 
microsatellite markers, D10S573, ALK3CA and ALK3GGAA. Products were run on the 
ABI377 and results were analysed using Genotyper software, with areas under the peaks 
(including stutter bands) compared for all informative (heterozygous) markers. Allelic loss 
was considered present if the relative ratio of normal:tumour peak was less than 0.5, or 
greater than two, thereby allowing for contaminating normal tissue within the microdissected 
tumour.
3.3 Results
3.3.1 APC2
Two silent (nt 687 G—>A and nt 1317C—>T) and two novel missense (nt 419 T—>C; F140S 
and nt 967 G—►C; G322R) mutations were foundir'ithe 5’ region of APC2, which comprises 
the majority of the known beta-catenin binding/regulation domains (Table 3.2). The F140S 
variant in exon 4 occurred at an amino acid that is not evolutionarily conserved and does not 
create or abolish a splice site, so doubt must therefore be cast on its significance. The G322R 
missense variant was excluded as disease-causing due to its absence in other affected family 
members. Due to technical difficulties we were unable to amplify the last third of exon 14. 
This portion of the gene has the least (15%) homology to the APC gene; hence it is unlikely 
that mutations here would affect p-catenin binding or the function of the Wnt signaling 
pathway.
3.3.2 GSK3p
No germline variants, pathogenic or polymorphic, were detected in any of the 47 patients 
screened consistent with previous studies failing to detect pathogenic somatic mutations in 
colorectal adenomas/carcinomas (Sparks, Morin et al. 1998).
3.3.3 Conductin/Axin2
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Two conductin germline variants wee seen in our study population. One polymorphism in 
intron six (IVS6+19G—>T) was present in 8/47 (17.0%) of patients and one silent variant in 
exon6 (nt.635 C—>T) was present in 3/47 (6.3%) of patients. No clearly pathogenic changes 
were found.
3.3.4 SMAD4 and BMPR1A
Screening of the TGF-beta superfamily members, BMPR1A and SMAD4 identified a single 
putative pathogenic change in BMPR1A, a three base-pair deletion at codon 360 resulting in 
the loss of a histidine residue. This amino acid is highly conserved and lies within the kinase 
domain of the protein, which is essential for the activation of the downstream targets SMAD1 
and SMAD5 (Massague and Wotton 2000). In accordance with a pathogenic effect, LOH at 
the BMPR1A locus was detected in an adenocarcinoma from the patient (Fig 1.). The patient 
had no juvenile polyps and was diagnosed at the age of 58 with eight tubular adenomas of 
mild to moderate dysplasia, distributed throughout the colon. He had no family history of 
colorectal cancers or polyposis. Besides this alteration, two intronic polymorphisms (IVS6- 
26t/a and IVS11 -  11 T—>C), two silent point mutations (nt 435 G—>A and nt 777 G—>A) and 
one previously reported missense polymorphism (nt 4 C—►A; T2P) were detected in BMPR1A 
(Howe, 2001) . No pathogenic sequence changes or polymorphisms were detected in
the SMAD4 gene. To further clarify the involvement of BMPR1A mutations in causing a 
‘multiple’ adenoma phenotype, a second series of 48 APC and MYH mutation-negative 
patients was screened for SMAD4 and BMPR1A changes, but no additional pathogenic 
variants were identified.
3.4 Discussion and Conclusions
No pathogenic mutations were found in the Wnt pathway components conductin, GSK3/3 and 
APC2 in the germline DNA of patients with a multiple colorectal adenoma phenotype and 
without APC germline variants. This is despite our understanding of the Wnt pathway’s 
central role in the pathogenesis of many colorectal cancers. Lack of degradation of beta- 
catenin results in its increased translocation to the cell nucleus leading to up-regulation of 
transcription of a number of genes involved in proliferation and growth within the colonic 
epithelium. Why then is APC the only piece of the pathway which is inactivated by mutations 
in the germline leading, ultimately, to the FAP and MA phenotypes?
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One explanation may be our limited knowledge of the roles of APC and other Wnt pathway 
components within the cell. It may be that the functions of APC outside the Wnt pathway are 
the crucial ones for preventing adenoma formation, possibly those involving chromosome 
segregation, spindle orientation and microtubule integrity, mediated by the -COOH terminal 
of the gene. Since the APC2 gene appears to have a high homology with APC except for the 
COOH terminal region, mutations in APC but not in APC2 may be detrimental to the cell.
The putative role for APC in maintaining chromosomal stability within the cell may not be 
shared by APC2. It also remains possible that the role of APC2 may be so great that a 
pathogenic germline mutation is lethal or that it is in truth a functionally redundant gene in 
the human.
GSK3p showed no variation at all in the 47 patients examined. No polymorphisms were 
seen. There is a possibility that mutations or allelic differences are not tolerated well and that 
truncating mutations may not be compatible with life. The findings are consistent with 
previous studies failing to detect pathogenic somatic mutations in colorectal 
adenomas/carcinomas (Sparks, Morin et al. 1998).
As previous studies have excluded germline beta-catenin and axin 1 variants in a similar 
population of multiple adenoma patients, the analysis of genes whose products comprise the 
Wnt pathway provides little evidence implicating their involvement in this condition. This 
finding is supported by previous studies excluding germline beta-catenin variants in 
‘multiple’ adenoma patients (Albuquerque, Cravo et al. 2002). This finding contrasts with 
that in the somatic mutation of spectrum of sporadic cancer. A large proportion of colorectal 
and other tumours without inactivating APC mutations are found to have activating somatic 
beta-catenin variants (Samowitz, Powers et al. 1999; Shitoh, Furukawa et al. 2001; 
Albuquerque, Breukel et al. 2002). Beta-catenin activating mutations may well be lethal in 
the germline.
The histology of the polyps in this group of mutation-negative ‘multiple’ adenoma patients 
did not differ in any obvious way from that of sporadic or FAP adenomas and thus gives no 
clue as to a specific genetic aetiology. One interesting feature of this cohort was the number 
of affected persons who appeared to have no dominant family history of colorectal cancer or 
polyps (57%). The one individual who was found to have an apparently pathogenic mutation
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in BMPR1A had no juvenile polyps reported. He was diagnosed at the age of 58 with eight 
tubular adenomas of mild to moderate dysplasia distributed throughout the colon and had no 
significant family history. This may indicate that this gene contributes, albeit rarely, to a 
subset of patients who present only with multiple adenomas in a seemingly sporadic way.
The absence of mutations in genes involved in the Wnt and TGF-beta signaling pathways 
suggests that other, as yet unidentified, predisposition genes and pathways exist. Possible 
candidates include the CRAC1 locus on chromosome 15ql4-q22 (Jaeger, Woodford-Richens 
et al. 2003).
In conclusion, the ‘multiple’ adenoma phenotype cannot generally be attributed to germ-line 
mutations in genes involved in the Wnt and TGF-beta signaling pathways. Patients and 
families who present in this manner could be offered mutation analysis of the APC (AAPC- 
associated mutations), MYH, and perhaps BMPR1A genes, although the number of 
pathogenic mutations identified in the last of these will be relatively small. It is probable that 
a larger proportion of these patients (10-15%) will be attributable to MYH mutations and a 
smaller number due to attenuated APC variants. Further work is needed to unravel the 
genetic aetiology of multiple colorectal adenomas, but given the heterogeneity of the 
phenotype, this is likely to require a combination of genetic linkage analysis, examination of 
candidate genes in alternative pathways leading to adenoma formation and examination of 
tumours and adenomas from such patients to establish type and pathways of somatic 
mutations.
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Table 3.1 Clinical Characteristics of Multiple Adenoma Patients.
Patient
characteristics
Number of 
patients
Mean Median Range
Sex M:F 24:23
Age of diagnosis 48.5 50 18-72
Family history 39/47 (83%)
Dominant family 
history
27/47
Adenomas 47/47 (100%)
Adenoma count 21.8 12 3-100
No. with >15 
adenomas
18/47
Hyperplastic polyps 12/47 (25%)
Colorectal cancer 9/47 (19%)
Table 3.2 APC2 Germline Variants
Patients Gene/exon Mutation
Predicted effect of 
mutation
D1 APC2 exon 4 nt. 419 T->C F130S
E6 APC2 exon 6 nt 687 G->A silent
Al APC2 exon 8A nt 967, G->C G323R
D3,H6 APC2 exon 10 nt. 1317 C->T silent
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Table 3.3 Oligonucleotide Sequences and PCR Conditions for APC2 Primer Pairs.
Exon Sequence
Product 
size (bp)
MGC1
(mM)
Annealing 
Temp (C)
1
accatcagctgaaccctctg
tagccacctcctccatga
220 1.0 55
3
ggagcagctgaagggtga
gcgaattagagggcagagc
365 1.0 55
4
gccatgttgcctgttaacct
atcgagaactgctggcaaag
361 1.0 55
5
cactcagggtgcgggaag
ccgcccataatatctgcact
285 1.5 60
6
gggtcagctccagcacttg
cgggcagaactcgaggag
193 1.0 60
7
tgggtgctctgggactgta
acctgatcccccttccag
205 2.0 55
8A
gaccgggtttccaggtgt
ctgcgagaagacgatgttgt
323 2.0 55
9
gtcacctgggacatttcctg
agaggacctgggacactcac
172 2.0 60
10
accttgttgggtcctcacag
tccctggaagactggatgag
213 1.0 55
11 + 12
gctgcataacccccaacag
ccagtgactgaagaagcatcc
436 1.0 60
13
gtgagcgtgggagccttt
cattcacgggaggacagtg
369 2.0 55
14
(PTTA)
ggatcctaatacgactcactataggaacag
accaccatgctccgggatcacaactgtct
1699 + 42 1.5 55*
14
(PTTB)
ggatcctaatacgactcactataggaacag
accaccatggagaactacgtgcaggagacac
1721+42 55*
14
(PTTC)
ggatcctaatacgactcactataggaacag
accaccatgaattgtcacgtggctgcac
1837 + 42 55*
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Table 3.4 Oligonucleotide Sequences and PCR Conditions for GSK3P Primer Pairs.
Exon Sequence Size (bp)
MgCl
(mM)
Annealing
Temp.
1
aaaggtgattcgcgaagaga
tattttaagggcgaggtgga
164 2.0 55
2
ttcctacagttctcgtgaaaaa
tgtattacggcagcacaaaaa
284 3.0 50
3
tgttatttcagaagcatcttgttca
ttatgagcggtggggagatta
245 2.0 60
4
aagaggctctccttggttca
gaccagttctaatctgtttgtttt
228 1.0 55
5
ctttgatactgtgaaaggatagca
aaattaccaaaatcaagaagca
259 3.0 55
6
caaacacttttcagctcaagctat
gcacaaaaattccttccagttc
206 1.0 60
7
cagtgaatccaatgcctgaa
catgcacaactgcttgtattcat
293 1.0 55
8
atgtttctgtcacatggtgggaat
acccagggtgtagctttcct
343 2.0 55
9
gcccggcataaactggtagt
gctgctgtggcatttgtg
209 1.0 60
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Table 3.5 Oligonucleotide sequences and PCR conditions for Axin2 primer pairs.
Exon Sequence Size (bp)
MgCl
(mM)
Annealing T
1A ccagactcagtgggaagagc
cagaggggaatccggagat 254 2
IB cggaacgaagatgggttg
tgcttcttgatgccatctctt 323 2 55
1C cctgccccaccaagacctacat
aagtcggcacaagtccactc 266 2 60
ID ctccccaccttgaatgaaga
tctgcaaagtccacagcatc 191 1 55
2 ggtttctggtgagggtccagt
tctggctaactgctcaggtg 258 1 60
3 cccatgtgatgtgctgaaaa
tcaacatggcagaaaacagc 213 2 60
4 ctcctccctttcctttccac
gacggaagcaggaagaagg 204 1 60
5A ccttctgacgtcttccctttc
ggagtggtactgcgaatggt 260 1 55
5B gccagtctccaggcgtag
ggcatggtggtggatgtagt 215 1 55
5C ccttgtgaccaagcagacga
ggcacttacccaaactgctc 210 1 60
5D aatgcaaaagccactccaag
gctggtgaccacgaaagacc 225 1 55
5E ttctaagagggcggcagag
tgcgacctgtctccttcc 300 1 60
5F caaacgcaatgggaaagg
cagccaattcccacaatacct 245 2 55
6 tctgtttctctctgctcattcc
gcctcaacctaggacccttc 297 1 60
I X aattctctggggacaacag
agcactcggcagatctcagt 195 2 60
7Y tgctaaacttgttccattcca
tctggctcttggttctgagc 260 2 60
7Z cctcagtcctccatgttggt
cagttcaccaaagccagacc 241 2 60
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Table 3.6 Oligonucleotide Sequences for SMAD4 Primer Pairs.
Exon Sequence Product Size (bp)
1
ttgcttcagaaattggagaca
gcttgaaaggaaacgtagcaa
385
2
tgtatgacatggccaagttag
caatactcggtttagcagtc
530
3
ctgaattgaaatggttcatgaac
gcccctaacctcaaaatctac
308
4
ttttgctggtaaagtagtatgc
ctatgaaagatagtacagttac
509
5 + 6
catctttatagttgtgcattatc
taatgaaacaaaatcacaggatg
557
7
tgaaagttttagcattagacaac
tgtactcatctgagaagtgac
224
8
ggatgttctttcccatttat
acaatcaataccttgctctc
224
9
tattaagcatgctatacaatctg
cttccacccagatttcaattc
332
10
aggcattggttttaatgtatg
ctgctcaaagaaactaatcaac
293
11
ccaaaagtgtgcagcttgttg
attgtattttgtagtccacc
570
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Table 3.7 Oligonucleotide Sequences for BMPR1A Primer Pairs.
Exon Sequence
1
tccaaaattcagttgtattcc
cacatacattactaaaatgaacactg
2
gtcacgaaacaaatgagcttt
ttaagaagggctgcataaaa
3
cattcagactcaaatttcgtt
tctcatgggtcccaaatta
4
ccaaaccatttctaattttatca
catgctccgacttttctc
5
ccaggctacctagaattgaa
aacagcggttgacatctaat
6
cctcaggttttcttaggg
tcaacacaccaattcatgtct
7
tcatcaagagctcaaacctt
acctcactagccttgtcaaa
8
ccctagcctatctctgatga
aacagtggggcaaagaac
9
tattttattttggccctca
tgatgagtaaatcaacataatcag
10
atttttgtgcccatgtttt
aatcacttcttcaggggact
11
actcagtcccctgaagaagt
ctagagtttctcctccgatg
A Normd
I Normal
ircinama
Figure 3.1 Loss of heterozygosity analysis
LOH at the BMPRIA locus in an adenocarcinoma from a patient with a germline BMPRIA 
mutation. Shown are the results from microsatellite (A) ALK3CA and (B) ALK3GGAA 
lying 43 Mb and 73Mb proximal to the BMPRIA gene, respectively. The allele showing 
LOH is arrowed.
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Chapter 4 The Multiple Colorectal Adenoma Phenotype, Familial Adenomatous 
Polyposis and Germline Mutations in MYH
4.1 Introduction
Patients with five to about one hundred colorectal polyps are very heterogeneous group. 
Although APC mutations account for a proportion of individuals who develop such a 
multiple adenoma (MA) phenotype, the majority remain without genetic diagnosis at this 
time. Dominant and recessive family histories, early and late ages of onset and different 
prevalence of hyperplastic and adenomatous polyps all exist within this group. One of the 
main aims of this work has been to account for cause of polyposis in some of these 
individuals and families.
Amongst those individuals diagnosed with FAP on the basis of adenoma numbers (>100) and 
characteristic histology about 30% do not have a detectable germline APC mutation. 
Although some of this group can be accounted for by large genomic deletions and cryptic 
APC mutations a significant number remain without known genetic cause (Lamlum, Al 
Tassan et al. 2000). The phenotypes of persons diagnosed with FAP or MA on clinical 
grounds has much overlap. Extra-colonic features and autosomal dominant inheritance of 
polyposis are the major features to suggest the likelihood of an APC mutation as the cause of 
disease.
A further distinct group of patients is known to develop predominantly hyperplastic polyps. 
Although it is common to have a few small hyperplastic polyps in the distal colon or rectum, 
a group of patients develop, large, multiple and/or proximal hyperplastic lesions and are at 
increased risk of colorectal cancer (Whitelaw, Murday et al. 1997; Rashid, Houlihan et al. 
2000; Hyman, Anderson et al. 2004). The syndrome of hyperplastic polyposis does not 
appear to have a dominant inheritance and few such families have been described. Most cases 
are isolated or recessive and present at all ages.
The previously described candidate gene analysis (Chapter 3) was the first step taken to try to 
account for the MA presentation in some of these individuals. In February 2002 Al-Tassan et 
al described a family in which three siblings developed multiple colorectal adenomas and 
cancer (Al-Tassan, Chmiel et al. 2002). They did not have a germline mutation in APC
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detected. Whilst screening tumour samples form these patients for somatic changes in APC, 
including the El 317Q missense change it was noted that there appeared to be an excess of 
somatic G—>T transversion mutations compared with the normal somatic APC mutation 
spectrum. Since oxidative damage is a major cause of G:C—>T:A mutations, genes 
responsible for the repair of such damage were then examined for mutations in the germline 
of these siblings.
8-oxo-7, 8-dihydro2’deoxyguanosine (8-oxodG) is the most stable and mutagenic product of 
oxidative DNA damage. It readily mispairs with A residues leading to G:C—>T:A mutations 
in repair deficient bacteria and yeast (Olinski R 1992; Okamoto K 1994). The products of 
three human base excision repair genes, MTHl, OGGI and MYH, act synergistically to 
prevent 8-oxo-dG induced mutagenesis. In the nucleotide pool, the human MutT homologue, 
MTH1 hydrolyses 8-oxo-dGTP to 8-oxo-dGMP, preventing incorporation of the oxidised G 
nucleotide during DNA replication (Nakabeppu 2001). The human MutM homologue,
OGGI detects and removes 8-oxoG adducts that have been mis-incorporated into the DNA 
opposite C residues leaving a single strand gap (Slupska, Baikalov et al. 1996). The human 
MutH homologue, MYH, an adenine-specific DNA glycosylase, scans the daughter strand 
after replication, removing adenines mispaired with 8-oxo-dG or guanines (Slupska M.M 
1999; Lu, Li et al. 2001; Gu, Parker et al. 2002)(Fig. 4.1).
Al-Tassan found that the live affected members of the family were compound heterozygotes 
for the missense mutations Y165C and G382D in the human homologue of the bacterial 
MutY gene -  MYH. These variants are in exons seven and 13 respectively. These positions 
are highly conserved in MutY across species.
Chmiel et al performed analysis of the corresponding mutations in E. coli Mut Y, Y82C and 
G253D (Chmiel 2003). This revealed a reduction in the adenine glycosylase activity of the 
enzymes, especially Y82C. In vivo complementation assay using the mutant human MYH 
alleles in Mut Y E.coli cells showed that complementation by these alleles was possible and 
that the mutations significantly decreased enzyme activity. Y165C was markedly more 
deleterious in its effect on BER than was G382D.
We set out to establish whether these or other variants in the MYH gene existed in MA 
patients and in APC mutation negative FAP patients and, if so, in what proportion. Patients
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found to be double mutation carriers had cancer and adenoma DNA examined for evidence of 
BER disruption in the form of an excess of G: C—>T: A mutations in the APC gene. We also 
wished to fully describe the clinical condition and variants if any arising from such 
mutations. Lastly we wished to exclude any contribution from other genes involved in 8- 
oxodG repair in the MA phenotype and classical polyposis phenotype.
4.2 Methods
4.2.1 Patient Population
The patient group was recruited by Dr Ian Frayling and Dr Ella Barclay and I.
For the MA subgroup we identified 156 patients with multiple (five to 100) synchronous or 
metachronous colorectal adenomas from Genetics Departments in the United Kingdom (St 
Mark’s Hospital, Harrow; Oxford; and Guy’s Hospital, London) . Patients had been referred 
either owing to a family history of colorectal tumours or after they themselves had presented 
symptomatically with multiple polyps. All patients had consented to provide a blood/DNA 
sample and access to archival tissue specimens.
Clinicopathological data were ascertained from patients’ records to confirm diagnoses. In all 
cases, either a precise adenoma count had been reported, or more rarely, a rounded or 
approximate count was given. Family histories (of tumours or other major disease) were 
recorded as reported by the patients and were confirmed, where possible, from hospital 
records, although precise adenoma counts in patients’ relatives were rarely available. We 
used 107 anonymous, random United Kingdom controls, derived from tumour-free 
individuals from a national study unrelated to cancer. We also analysed germline DNA from 
26 patients with multiple adenomas from Finland and Denmark, all of whom had been 
reported as having between 5 and 100 adenomas.
For the mutation-negative FAP subgroup we contacted polyposis registries in the United 
Kingdom, Switzerland, Finland, Portugal and Denmark with a request to study all APC 
mutation-negative patients with more than 100 adenomas (synchronous or metachronous).
We ascertained 110 probands and confirmed that local laboratories had rigorously excluded 
germline APC changes. Full clinicopathological details and family history were obtained.
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For some patients, exact polyp counts at colectomy had been recorded; for others, counts 
were given in a range (for example, “100-1000” or “several thousand” to distinguish mild 
and severe classical polyposis respectively); and for yet others, counts were provided 
essentially for diagnostic purposes (that is, >100).
A group of 42 patients with hyperplastic polyposis was ascertained from St Mark’s Hospital, 
Harrow (Table 4.1). Information regarding their polyp number, size and histology was 
assessed such that all patients included in the analysis had either >10 polyps with more 
hyperplastic than adenomatous polyps or at least one large (>10mm) hyperplastic polyp.
4.2.2 Mutation Detection
All mutation detection was performed equally by Dr Oliver Sieber and I.
Germline DNA was extracted form lymphocytes (see chapter 2). F-SSCP with direct 
sequencing of aberrant bands was used for germline MYH (GenBank NM_012222), hMTH 
(AB025241), OGGI (NM 002542, NM_016821) mutation detection (see chapter 2). Primer 
pairs to amplify overlapping fragments were designed for the coding regions including exon- 
intron boundaries of the MYH, hMTH and OGGI genes (Tables 4.7-9). Patients found to 
have a single MYH mutation had direct sequencing of the entire MYH gene performed to rule 
out a second mutation. Tumour tissue was extracted from archival or fresh frozen specimens 
by standard methods (see chapter 2). APC mutation testing on tumour specimens was 
performed using F-SSCP and dHPLC. The standard APC primer set for exons 15A to 15L 
was used for analysis of fresh frozen tissue (Table 4.10). For paraffin-derived DNA, a set of 
overlapping primers was used to examine the APC gene from codon 1219 (exon 15F) to 
codon 1609 (exon 15J), the area incorporating the mutation cluster region (MCR) and where 
the majority of somatic APC mutations had been found by Al-Tassan’s group in the 
previously described sibship.
4.2.3 Loss of Heterozygosity and Genotyping Analyses at D1S2677
Loss of heterozygosity (allelic loss) and genotyping analyses at the microsatellite D1S2677 
(2.5 kb from MYH) were performed using standard protocols, dye-labeled oligonucleotides 
and the AB1377 sequencer. Allelic loss was scored if the dosage of one allele in the tumour
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decreased by 50% or more relative to the other allele, after correcting for the relative allele 
peak areas using constitutional DNA.
4.3 Results
4.3.1 Germline M YH  Mutations in Multiple Adenoma Patients
The 156 United Kingdom patients with multiple adenomas (Table 4.2) presented at median 
age 56 (range 16-77) years. To the date of follow-up (31st December 2001), the mean 
number of synchronous or metachronous adenomas developed throughout life was 16 
(median 7, range 3-100). Twenty-eight patients presented with a synchronous colorectal 
carcinoma, but none was known to have developed a cancer subsequently, all patients having 
been placed on regular surveillance colonoscopy. A family history of colorectal cancer (with 
any inheritance pattern) was reported by 94 patients. Of these, 65 families displayed 
dominant inheritance with two generations only known to be affected. In 17 families more 
than two generations were affected and in 12 families inheritance was compatible with 
autosomal recessive inheritance. A further 52 individuals reported no family history of 
colorectal cancers or adenomas. No patient had a family history of adenomas without also 
having a family history of colorectal cancer. No patient reported consanguineous origins.
Ten patients carried bi-allelic MYH mutations (Table 4.2). Of these, six were compound 
heterozygotes, as shown by sequencing of cloned PRC products; the remaining four were 
presumed homozygotes. The previously reported missense changes, Y165C (494 A>G) and 
G382D (11145 G>A), were the most common alterations representing 16/20 (80%) of all 
mutant alleles in biallelic mutation carriers. Both Y165C and G382D target highly conserved 
residues, the former mapping to the helix-hairpin-helix protein domain which confers 
specificity of mismatch recognition and the latter affecting the catalytic core of the 
glycosylase (residues 366-497). The novel frameshift changes, 1103delC (codon 368) in 
patient IV and 1419delC (codon 473) in patient III were also identified which are predicted to 
abolish glycosylase function. The sister of III was also diagnosed with two synchronous 
cancers and multiple adenomas at the age of 71 and had the same two mutations in MYH. 
Patient IX and his brother were affected with rectal cancer and multiple adenomas in their 
thirties and were both homozygotes for the nonsense mutation E466X (1396 G>T). This 
variant in exon 14 of MYH has since been found to occur primarily in persons of Indian
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extraction (Jones, Emmerson et al. 2002). In the youngest double mutation carrier adenomas 
developed at 15 years of age and he died of metastatic gastric cancer at age 16 (Patient VII).
None of 107 United Kingdom controls carried two MYH mutations. Y165C was found in just 
two controls and none of the other disease-associated mutations was present in the control 
group. The previously described MYH polymorphisms in exon 2 (64 G>A;V22M), exon 12 
(972 G>C; Q324H) and exon 16 (1502 C>T; S501F) were detected with respective allele 
frequencies of 10 percent, 21 percent and 2 percent in our patients, similar to the control 
population previously reported (Al-Tassan, Chmiel et al. 2002).
In order to provide further evidence of the pathogenicity of the MYH mutations, available 
relatives were screened for the changes carried by the proband (Table 4.3). In all cases, the 
results were consistent with recessive inheritance. For patient I, an affected sister was a 
mutant homozygote. For patient II, an unaffected daughter was a heterozygote. For patient 
III, her sister was affected as stated. For patient VI, only unaffected siblings survived and 
they were both heterozygotes. For patient IX, an affected brother was a mutant homozygote 
(Figure 4.1).
All but one (patient IX) of the United Kingdom patients with bi-allelic MYH mutations was 
of northern European ancestry. In order to determine the frequency of Y165C and G382D in 
different populations, 26 Finish and Danish individuals with multiple adenomas were 
investigated. Two (8%) of the patients were compound heterozygotes for Y165C and 
G382C. In the entire patient set, Y165C and G382C were not consistently associated with 
specific alleles at D1S2667, thus providing no evidence for these being ancestral rather than 
recurrent changes.
Six patients were heterozygous for an MYH mutation and the wild type allele (Table 4.3). In 
these individuals, we sequenced the entire MYH gene, but found no further changes. We 
screened seven adenomas from one of the G382D carriers for somatic APC mutations and 
found two changes, one C>G transversion (S1346X) and one lbp deletion (4244 delG). 
Neither change involved G>T transversion and hence was not suggestive of defective MYH 
activity. A further screen of APC exons 15 A to L in five patients with colorectal cancer and 
heterozygous for Y165C (one) or G382D (four) revealed one G>T mutation (E1378X) in the 
Y165C carrier.
133
4.3.2 MTH1 and OGGI Screening in Multiple Adenoma Patients
No carriers of obviously pathogenic or bi-allelic MTH1 or OGGI mutations were detected in 
127 and 42 multiple adenoma patients respectively. For MTH1, the allele frequency of the 
previously described C>T codon 160 polymorphism was not significantly different from 
previously described controls accounting for 18% of alleles in our cohort. In addition, a 
novel MTH1 missense variant (92 G>A;R31Q) was identified in one patient, but not in the 
controls, but this mutation did not co-segregate with the multiple adenoma phenotype. For 
OGGI, besides the well-described polymorphism in exon 7 which accounted for 27% of 
alleles (977 C>G;S326C) no further DNA alteration were detected (Kohno, Shinmura et al. 
1998), (Wikman, Katballe et al. 2000; Hanaoka, Sugimura et al. 2001) .
4.3.3 Genotype-phenotype Associations in Multiple Adenoma Patients
Eight of the ten patients with bi-allelic MYH mutations presented at a similar age (median 56 
years, range 45-59) to the other multiple adenoma patients in our study (Tables 4.2 and 4.5). 
Two presented at younger ages (16 and 34 years). Nine individuals had symptoms at 
presentation and one was found to have polyps at colonoscopy performed owing to a family 
history of colorectal tumours. Polyps were predominantly small, mildly dysplastic tubular 
adenomas, with a minority of tubulovillous adenomas and very few hyperplastic polyps.
Five of the ten patients had colorectal cancer at presentation. Seven of the ten had a family 
history of colorectal cancer, in five cases involving more than one generation. Carries of bi- 
allelic MYH mutations were no more likely to have a family history of colorectal cancer than 
other patients in the study (p=0.10, Fisher’s exact test). Four MYH patients had confirmed 
family histories of multiple adenomas, but these were found only in siblings, consistent with 
recessive inheritance of MYH-associated disease. One extra-colonic tumour, a gastric 
cancer, was reported. No other clinical features were reported.
The one phenotypic difference which clearly distinguished patients with bi-allelic MYH 
mutations from single mutation carriers and MYH mutation-negative individuals in our 
multiple adenoma patient set was the number of tumours (medians of 40 vs. 4 vs. 7 
respectively; p=0.023, Kruskal-Wallis test) (Table 4.2). Of 27 patients with 15 to 100 
adenomas, ten (38.4 percent) harboured bi-allelic MYH mutations.
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The colorectal cancer frequency (6 out of 10) in bi-allelic MYH mutations carriers was 
greater than that in the other patients in our study (p=0.05; Fisher’s exact test) as well as the 
general population (3.86 percent for 0 to 80 years of age; http://seer.cancer.gov/). These data 
suggest an increase risk of bowel cancer in bi-allelic MYH mutants, although this result 
should be interpreted with much caution, because, whilst these patients wee recruited on the 
basis of their adenoma phenotype alone, they were more likely to have come to clinical 
attention if they had a synchronous carcinoma.
Following the study of this group of multiple adenomas patients, two further bi-allelic MYH 
carriers were found on screening multiple adenoma probands. The first patient, a compound 
heterozygote for Y165C/G382D was, diagnosed at 68 with colorectal cancer and had two 
siblings diagnosed with colorectal cancer at 46 and 61. There was no record of adenomas 
being present in this family. The second patient was male and diagnosed at 50 with a Stage I 
carcinoma of the rectum and 25 adenomas. He had one sister diagnosed with CRC at 54 
years and one brother who had a few small adenomas at the age of 56 years.
4.3.4 M YH  Mutation Testing in Patients with Classical FAP
Eight of 107 probands with classic polyposis (7.5 percent) carried biallelic pathogenic MYH 
mutations (Tables 4.4 and 4.5). Y165C and G382D were again the most common changes. 
Three other mutations were found: a frame shift (252delG at codon 84); an unusual in-frame 
duplication (41 IdupATGGAT at codon 137, 137insIW); and a non-conservative missense 
change (G->T at position 694, V232F). Four patients carried single MYH mutations (Y165C 
in two patients, 1209V in one, and G382D in one).
All probands with polyposis who had biallelic MYH mutations had a family history 
compatible with recessive inheritance, in that only the proband or siblings in a single 
generation were affected by polyposis. Although it is necessary to exercise some caution, 
given the variation among centers in clinical practice and in the precision of the counting of 
polyps, it is probable that patients with MYH mutations had mild classic adenomatous 
polyposis: none had more than 1000 polyps; two had exact counts of 115 and 210 adenomas; 
and none had early-onset cancer. All patients with two MYH mutations had been treated by
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total colectomy with ileorectal anastomosis or deal pouch, at a mean age of 47.6 years 
(median, 47; range, 30 to 70), as compared with a mean of 28 years (median, 23; range, 13 to 
65) among patients with APC mutations who were included in the polyposis registry of St 
Mark's Hospital (data not shown) (1998).
In several respects, the clinicopathological features of patients with biallelic MYH mutations 
were the same as those of patients with polyposis resulting from APC mutations: 
macroadenoma morphologic features were the same (largely small tubular lesions with mild 
dysplasia); microadenomas were present, despite the fact that such lesions were previously 
thought to be pathognomonic of classic adenomatous polyposis; and some patients had 
extracolonic disease. Severe (Spigelman stage IV) duodenal polyposis developed in Patient 
15, and Patient 16 had duodenal polyps at diagnosis. Congenital hypertrophy of the retinal 
pigment epithelium was diagnosed in Patient 13 (although it was not specifically noted to be 
of a type associated with polyposis). No desmoid tumors were reported.
4.3.5 M YH  Testing in Patients with Hyperplastic Polyposis
42 patients with hyperplastic polyposis were tested for variants in MYH (Table 4.1). The 
mean age of diagnosis was 54 (median 58, range 19-72 years). The exact polyp number was 
available for 34 patients with others being recorded as ‘multiple’. Mean number of polyps 
where available was 44 (median 35, range 6 to 100). Overall 16/39 patients (41%) were 
found to have only hyperplastic polyps whereas the others also developed adenomatous 
polyps including tubular, tubulovillous, villous and serrated adenomas. 23/37 patients (62%) 
had right sided polyps and 21/36 patients (58%) had hyperplastic polyps >_lcm diameter). 
Family history of colorectal cancer or polyps was reported in only 10/42 (23%) of cases, 
some of which were not first degree relatives. No patient was found to carry any pathologic 
MYH variant.
4.3.6 Somatic APC  Mutations in Adenomas and Cancers from M YH  Double Mutants.
115 adenomas and 8 cancers from 15 MYH bi-allelic mutations carriers (table 4.5) were 
screened for somatic APC mutations from codon 1219 (exon 15F) to codon 1609 (exon 15J). 
Five further cancers from five patients were screened for exons 15A to 15L. Six out of 14
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(43%) of cancers and 22/105 (21%) of adenomas showed somatic APC mutations. Details of 
somatic APC mutations are shown in table 4.6. All are G:C>T:A transversion mutations.
Loss of heterozygosity at MYH was found in seven of 62 informative adenomas from the 
MYH mutant compound heterozygote patients. Given that G382D reportedly retains some 
enzyme activity, the low frequency of allelic loss may indicate that absent MYH function is 
not necessary for tumourigenesis (Chmiel 2003).
4.4 Discussion
Conclusions drawn from the study were made by me, Dr Oliver Sieber and Professor Ian 
Tomlinson.
Germline MYH mutations, both missense and truncating, predispose to apparently recessive 
inheritance of multiple colorectal adenomas and classical adenomatous polyposis in both 
European Caucasian and Asian populations. All patients with bi-allelic MYH mutations 
probably have raised risk of colorectal cancer. Of patients with 3-100 adenomas, about 5% 
had disease ascribable to bi-allelic MYH mutations, and of those with over 15 adenomas, over 
one third had bi-allelic MYH mutations. In patients with a phenotype of classical polyposis 
and no detectable APC mutation, about 8% of cases had two germline MYH mutations. 
Extra-colonic disease was present in some patients with MF/Z-associated polyposis, showing 
that these features are not restricted to those with germline APC mutations. The presence of 
extra-colonic disease is consistent with the model of mutant MYH action in the colon, 
namely hypermutability of APC (and possibly of other genes also). This is bome out by the 
frequency of somatic APC mutations seen in tumours from patients with MYH associated 
polyposis.
It appears from this study that patients with bi-allelic MYH mutations tend to have mild 
colonic disease relative to most patients with classical familial adenomatous polyposis, but 
more severe disease than most multiple adenoma patients. It is certainly difficult to 
distinguish between patients with APC and bi-allelic MYH mutations on the basis of 
clinicopathological features, although family history can be useful. MYH mutations appear to 
be a more frequent cause of the multiple adenoma (or ‘attenuated polyposis’) phenotype than 
are APC mutations, but are evidently a less frequent cause of classical adenomatous
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polyposis (Lamlum, Al Tassan et al. 2000). Compared with hereditary non-polyposis colon 
cancer, carriers of bi-allelic MYH mutations develop more tumours, but taking the limited 
clinical data from this study, progression from adenoma to carcinoma appears to be slower. It 
remains difficult to comment on the tempo of disease development and progression in MYH 
associated polyposis for several reasons. Firstly, due to the recessive seeming nature of the 
condition, patients are diagnosed late and often require colectomy for multiple polyps at the 
time of diagnosis, preventing follow-up. In these persons it is impossible to say how quickly 
polyps developed. Secondly without large studies of populations undergoing mutation 
detection and colonic surveillance it is difficult to estimate the true risk to the biallelic 
mutation carrier and true average age of polyp onset. Thirdly if persons with MYH associated 
polyposis are detected at a time when polyp numbers are few because of screening programs 
they may continue to have small ‘crops’ of polyps removed and never present a ‘polyposis’ 
phenotype and hence not be drawn to the attention of family cancer clinics.
Six patients with one mutated MYH allele only were identified in the multiple adenoma 
cohort and four in the classical polyposis cohort. MYH mutant heterozygotes may have a 
weak susceptibility to bowel tumours, given that allelic loss on chromosome arm lp is 
apparently an early event in colorectal tumourigenesis which could inactivate the wild type 
MYH allele (Tanaka, Yanoshita et al. 1993; Lothe, Andersen et al. 1995; Praml, Finke et al.
1995). In this patient set, there was no over-representation in general of heterozygotes as 
compared to our and published controls. In a recent publication however, a group of over 
400 Finnish controls have been screened for the Y165C and G382D variants with neither 
being present (Enholm, Hienonen et al. 2003). The estimate of one to two percent of the 
population found in our study and that of Al-Tassan et al may be falsely high or may 
represent the British (Largely Caucasian) population only (Al-Tassan, Chmiel et al. 2002).
The two somatic APC mutations in polyps from an MYH heterozygote individuals were not 
G:C—>T:A transversion mutations. Nevertheless, several of our patients had family histories 
suggesting dominant inheritance of colorectal cancer (although not of multiple adenomas). 
Formal exclusion of MYH as a weak susceptibility allele will require a large set of colorectal 
cancer cases and controls. This remains an important issue as regards screening of family 
members. If MYH mutations are present in 1-2% of the population at large it may indeed 
represent a low penetrance allele responsible for a not insignificant proportion of colorectal 
cancer.
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Many questions remain regarding the specificity of MYH in causing colorectal adenomas and 
cancers. We cannot yet answer the question of why MYH, rather than MTH1 or OGGI, is 
important for tumour predisposition and development. Specifically, we cannot exclude the 
possibility that carriers of bi-allelic MTH1 or OGGI mutations are predisposed to tumours, 
although we found no such individuals in our patient set. Neither is it clear why the colon 
primarily appears to be affected rather than other tissues exposed to damage by reactive 
oxygen species such as the lung. It is entirely possible that we have missed an effect of MYH 
mutations in the genesis of other cancers in this study. We have targeted a group of persons 
with colorectal adenomas and cancers and often with a family history of such which has 
brought them to the attention of the family cancer clinic. Other cohorts of persons with 
different types of cancers and family histories need to be assessed to rule out an effect, 
particularly of the heterozygote state, on predisposition to other cancer types.
It does appear likely that bi-allelic MYH mutations do not account for the syndrome of 
hyperplastic polyposis. The sample used was well representative of such patients and most 
showed a sporadic/recessive pattern of disease with none having a dominant family history of 
polyposis, hyperplastic or other. These patients form a distinct and interesting group for 
further study.
Genetic testing for MYH mutations should be performed in patients with tens or hundreds of 
colorectal adenomas with or without colorectal cancer, subject to the proviso that almost all 
patients with MYH-associated polyposis will have a family history consistent only with 
recessive inheritance of multiple adenomas. Families may have an apparently dominant 
history of colorectal polyps because of a heterozygote effect or because of phenocopies in a 
disease common in the population. The study by Enholm et al and others by Wang, 
Fleischman and Zhou indicate that persons with under 10 adenomas may still be biallelic 
mutation carriers (Enholm, Hienonen et al. 2003; Fleischmann, Peto et al. 2004; Wang, 
Baudhuin et al. 2004; Zhou, Djureinovic et al. 2005). It seems probable that as population 
screening programs for colorectal cancer develop more patients with MYH associated 
polyposis will be seen at younger ages and with lower adenoma numbers. Screening of APC 
and MYH may be performed in parallel in some patients, such as isolated or recessive 
appearing cases of polyposis or those with tens to 100’s of polyps. In a majority of cases 
with bi-allelic mutations one of the mutant alleles is Y165C or G382D, therefore it is a
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simple matter to screen for these to changes first and then proceed to a whole gene screen if 
one mutation is found. In the Indian and Pakistani populations however, where there is 
evidence of common variants in exon 3 and 14 respectively these should also be screened. 
Evidently, if bi-allelic MYH mutations are identified in a proband, testing of siblings is
th  thworthwhile, even if they are asymptomatic in their 6 or 7 decade. It should, however, be 
borne in mind that in up to 2% of cases, a carrier of two MYH mutations will produce 
children with a spouse/partner who carries a single mutation; in this case the disease will 
appear to be dominantly inherited. The question remains open as to whether it is worthwhile 
to undertake genetic testing in the spouses/partners of MYH associated polyposis patients.
All but three of our patients with bi-allelic MYH mutations proceeded to colectomy, since 
their disease could not be controlled by colonoscopic polypectomy. For patients with 
relatively mild disease, regular screening by colonoscopy may be used initially -  although 
optimal screening intervals must be determined empirically -  and may prevent colectomy. In 
our cohort two patients with fewer than 50 adenomas and one with 100 could be managed by 
sequential colonoscopy and multiple polypectomies. Unfortunately, as mentioned, the 
recessive nature of the disease means that it will prove difficult to identify MYH mutation 
carriers at an early enough age to prevent colectomy in all cases. Management of single 
mutation carriers is currently unclear. Until population based studies are done it may be 
prudent not to abandon screening in these persons. Yet, in the absence of any evidence for an 
increased risk of colorectal tumours in MYH heterozygous mutation carriers, there is 
currently little justification for aggressive screening colonoscopy of any heterozygote family 
member. All individuals with two, identified MYH mutations probably should have regular 
endoscopy of the upper-gastrointestinal tract using a side-viewing endoscope, primarily for 
the detection and management of duodenal polyposis.
Molecular methods should now be used to classify disease in patients with multiple 
adenomas or adenomatous polyposis. Patients with identified germline mutation(s) should be 
classified as having APC or MK//-associated disease. Risks for relatives and the likely 
severity of disease can then be accurately assessed. Patients with polyposis but no identified 
germline mutation may then be further classified as presumed familial adenomatous 
polyposis if they have a dominant family history of classical disease and/or severe polyposis 
(>1000 colorectal adenomas). Other patients with no detected germline mutation in APC or
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MYH, and with either mild polyposis (100-1000 adenomas) or multiple (<100) adenomas 
should be classed as having ‘polyposis/multiple adenomas of unknown origin’.
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Table 4.1 Patients Ascertained with Hyperplastic Polyposis.
HPP = hyperplastic polyp, TA = tubular adenoma, TC = transverse colon, HF = hepatic 
flexure, AC = ascending colon, DC = descending colon, SC = sigmoid colon, CM = caecum.
Patient Age at 
Diagnosis
Total
Polyp
no. HPP TA
Polyp
Site
Largest
HPP
(mm)
Colon
Cancer
Colon
Cancer
Site
Family
History
CRC
1
55 53 yes no
all
colon 30 yes TC no
2 23 10 yes no right 16 yes TC no
3
28 multiple yes no
all
colon no nF
4 60 multiple JP 30 no
5 61 50 yes no left 5 no no
6
37 100+ yes yes
all
colon 15 no yes
7 38 multiple yes yes left 8 yes
8
67 50-100 yes yes
all
colon 8 no yes
9
69 40+ yes yes
all
colon no yes
10 56 30+ yes yes TC on 5 no yes
11
70 92 yes yes
all
colon 18 yesx2 HF+AC no
12
64 25+ yes yes
all
colon 10 no no
13 58 30 yes no left 5 no
14
60 20 yes no
all
colon 7 no no
15
19 multiple yes no
all
colon 4 yes AC yes
16 65 35 yes no TC on 3 no no
17 56 multiple yes no left no yes
18 70 6 yes no left no no
19
72 30+ yes yes
all
colon 6 yesx3 SC,TC,HF no
20 58 55 yes yes TC on 9 yes TC no
21
44 7 yes no
all
colon 10 no yes
22 60 47 yes no TC on 5 no no
23
71 70+ yes yes
all
colon 14 yes SC no
24
69 28 yes yes
all
colon 20 yes caecum
25
27 40 yes no
all
colon 10 yes no
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26
48 108 yes yes
all
colon 20 yes CM no
27
58 13 yes yes
all
colon 10 no yes
28 26 50+ yes yes left 10 no no
29
58 50-100 yes yes
all
colon 15 yes
30
63 multiple yes no
all
colon 10 yes TC no
31 60 100+ yes yes right 12 yesx2 HF+DC no
32
68 50-100 yes no
all
colon 40 no yes
33 57 25 yes yes 3 yes HF no
34 32 25+ yes yes left 10 no
35 61 50+ yes yes 12 yes CM no
36 54 ? yes no rectum ? yes rectum no
37 68 16 yes yes 7 yes DC no
38 52 multiple y yes right 4 no no
39 54 30+ yes yes left 6 no no
40
42 multiple yes yes
all
colon 18 no yes
41
42 30+
all
colon 13 no no
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Table 4.2 Clinical Features of Multiple Adenoma Patients from the United Kingdom in
Relation to Germline MYH  Mutation Status.
Patients Germline MHY 
mutation status
Negative
(percentage)
Single mutation 
(percent)
Bi-allelic
mutation
(percent)
Total
Number
140 6 10
Age at 
presentation
Known 139 (99) 6 (100) 10(100)
Median 56 64 50
Range 18-77 25-72 16-59
Polyp
number
Precise count 
given
114(81) 6 (100) 9(90)
Median 7 4 40
Range 3-100 3-12 18-100
Colorectal
Cancer
Yes 19 (14) 2(33) 6(60)
None Reported 121 (86) 4(67) 4(40)
Family 
history of 
colorectal 
cancer
Positive 83 (59) 4(67) 7(70)
None reported 57 (41) 2(33) 3(30)
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Table 4.3 Multiple Adenoma Patients from the United Kingdom with Germline M YH
Mutations
Note that two of the single mutation carriers had novel MYH variants, R83X (247 C>T) and 
R295C (883 C>T). It is not known whether or not these variants would be pathogenic as 
compound heterozygotes or homozygotes, although R83X is likely to be so. CRC = 
colorectal cancer; N = none reported; n/d = none detected
Patient ID MYH 
mutation 1
MYH 
mutation 2
Gender Age at 
diagnosis
Polyp
number
CRC Family history 
of adenomas 
and/or CRC
Extra-colonic
cancer
IGB Y165C Y165C M 52 40 Y Y N
II PB Y165C G382D F 45 100 Y N N
III IF Y165C
nt 1419 
delC
F 57 18 Y Y N
IV VB
nt 1103 
delC
G382D M 55 70 N Y N
VASM G382D G382D M 56 40 Y Y N
VI AMc
G382D G382D F 59 100 N Y N
VII Y165C G382D M 45 50 N Y N
VIII Y165C G382D M 15 39 N N Y Gastric
IX E466X E466X M 34 30 Y Y N
X Y165C G382D M 48 40 Y N N
XI R83X n/d F 69 6 Y Y N
XII Y165C n/d M 72 3 N Y N
XIII Y165C n/d F 58 5 N Y N
XIV R295C n/d F 25 3 N N N
XV G382D n/d M 52 3 Y Y N
XVI G382D n/d F 70 12 N N N
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Table 4.4 Clinical Features of Classical Adenomatous Polyposis Patients in Relation to 
Germline M YH  Mutation Status
Patients Germline MHY 
mutation status
Negative
(percentage)
Single mutation 
(percent)
Bi-allelic
mutation
(percent)
Total
Number
95 4 8
Age at 
presentation
Known 55 (58) 4 (100) 8 (100)
Median 30 31 47.5
Range 7-72 30-54 30-70
Polyp
number
100-1000 68 (72) 30-54 30-70
>1000 27 (28) 0(0) 0(0)
Family 
history of 
colorectal 
cancer
Positive 29 (31) 0(0) 4(50)
None reported 66 (69) 4(100) 4(50)
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Table 4.5 Classical Adenomatous Polyposis Patients with Germline MYH  mutations
CRC = colorectal cancer; CHRPE = congenital hypertrophy of the retinal pigment 
epithelium;
N = none reported; n/d = none detected
Patien
tID
MYH 
mutation 1
MYH
mutation
2
Gend
er
Age at
diagn
osis
Polyp
number
CR
C
Fam
ay
histo
ry
Extracolonic
features
1 Y165C Y165C M 41 100-1000 N Y CHRPE
II Y165C G382D F 50 100-1000 N Y N
III G392D G382D M 30 100-1000 N N
duodenal
adenomas
IV nt252 delG 137insIW M 38 100-1000 Y N
duodenal
adenomas
V Y165C Y165C F 45 100-1000 Y Y N
VI Y165C V232F M 70 100-1000 N N N
VII Y165C G382D M 51 210 Y N N
VIII Y165C G382D F 69 115 Y Y N
IX G382D n/d M 32 100-1000 N Y N
X I209V n/d F 54 100-1000 N N osteoma
XI Y165C n/d M 30 100-1000 N N N
XII Y165C n/d M 30 750 N Y N
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Table 4.6 Somatic APC Mutations in Cancers and Adenomas from Biallelic MYH
Mutation Carriers.
Patient ID
MYH 
mutation 1
MYH 
mutation 2
Tumour
type
Mutation
VB nt 1103 delC G382D
TA*
TAx3
TA
E1461X
S1315X
E1560X
PB Y165C G382D
TA
TAx3
E1560X
S1315X
IF nt 1419 delC Y165C
TAx3
TAx2
E1560X
S1315X
JC G382D G382D CA**+TAx3 E1560X
697 G382D G382D
CA
CA
E868X
E1552X
761 Y165C G382D CA E1353X
4303 Y165C Y165C TA S1315X
965 Y165C G382D CA E1538X
**CA = Cancer 
*TA=Tubular Adenoma
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Table 4.7 Oligonucleotide Primers Used for Screening MYH
Exon Prim er sequence Size (bp) Label Annealing T Mg conc.
1 tgaaggctacctctgggaagaggagacggaccgcaagt 141 FAM 55 1
2 ggctgggtctttttgtttcaggccacaacctagttcctt 164 HEX 60 1
3A ctgtgtcccaagaccctgatttggtcgtaccagttagca 187 HEX 55 3
3B agctgaagtcacagccttcccaccactgtccctgctc 110 FAM 60 1
4 cctccaccctaactcctcatcaaagtggccctgctctcag 110 FAM 55 1
5 caggtcagcagtgcctcatgtctgaccatgacccttcc 152 FAM 60 2
6 gtctctttctgcctgcctgttcacccgtccagtccctctat 125 FAM 60 2
7 cgggtgatctctttgacctcgttcctaccctcctgccatc 134 FAM 60 2
8 tcttgagtcttgcactccaatc 164 HEX 55 1
9 gctaactctttggcccctctcacccttgttaccccaacat 150 FAM 60 3
10 ctgcttcaccagcagtgttccgaccttctcactgccccttcc 208 HEX 60 2
11 acactcaaccctgtgcctctggaatggggcttctgactg 147 FAM 60 1
12A cttggcttgagtagggttcgggctgttccagaacacaggt 179 HEX 60 1
12B gagtggtcaacttccccagacacgcccagtatccaggta 146 FAM 60 1
13 agggaatcggcagctgaggctattccgctgctcactta 209 HEX 60 1
14 aggcctatttgaaccccttgcaacaaagacaacaaaggtagtgc 210 HEX 60 1
15 ccctcacctccctgtcttcttgttcacccagacattcgtt 159 HEX 55 3
16A ctacaaggcctccctccttcgctgcactgttgaggctgt 158 HEX 55 1
16B gctgcactgttgaggctgtacatagcgagacccccatct 181 HEX 60 2
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Table 4.8 Oligonucleotide Primers for Screening OGGI
Exon Prim er sequence Size (bp) Label Annealing T Mg cone
1
gggtaggcggggctactac
ccccaaattcctttgtaccc
266 HEX 55 1
2
aattgagtgccagggttgtc
ctaaccccagcccaggtc
313 FAM 55 1
3
cagcaggtacctctcctaccc
tcttgaaagctgatggaagg
269 FAM 55 2
4
ttgaagatgcctgatgcttg
tagagagggcagctcctacc
258 HEX 55 1
5
tcttccacaagggctcattc
tctaccatcccagcccact
232 HEX 55 1
6
tcacagaaggggtcagataactt
ggctggaagagtcctttaggg
197 HEX 60 3
7
gaccccagtgtaccctcctc
atatccccaccccatctt
311 FAM 55 1
8
cattattccgctatgcctca
caacaaacactcccaacacct
189 FAM 55 1
9
attctccatgctgccttcct
gtaagctggcttgcatcaca
346 FAM 55 1
Table 4.9 Oligonucleotide Primers for Screening MTH1
Exon Prim er sequence Size (bp) Label Annealing T Mg cone
0
gccttatcgcaaaggacagag
ccgacctccaggggaaaaat
186 HEX 55 2
1
tgactctgccctctcacctt
cggttctatggccagacct
224 FAM 60 1
2
tccctgggctgtgtgtagat
agacaggccctgtgagact
270 HEX 60 1
3
ctcttcccccattggtacag
ctgttcagcagccacgtct
240 FAM 60 1
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Table 4.10 Oligonucleotide Primers for Screening APC  in Paraffin-Derived Tissue
Exon Prim er sequence
Size
(bp)
Label Annealing T Mg cone
15 F-G
caagcagtgagaatacgtcca
ttcttggttaatagaagaaactttgc
134 FAM 55 1.5
15 G
gaagtggtcagcctcaaaag
agaatctgcttcctgtgtcg
178 HEX 55 1.5
15 G
ttcattatcatcttgtcatcagc
ggatttggttctagggtgct
177 FAM 55 1.5
15 G-H
gatcctgtgagcgaagttcc
ctgagcaccactttggagg
149 HEX 55 1.5
15 G-H
agaatcagccaaggcacaaag
gcaatcgaacgactctcaaa
173 FAM 55 1.5
15 H
cactatgttcaggagacccca
tggaagatcactggggctta
149 FAM 55 1.5
15 H
gtgaaccatgcagtggaatg
acttctcgcttggtttgagc
135 HEX 55 1.5
15 H-I
aaacacctccaccacctcct
agcatctggaagaacctgga
145 HEX 55 1.5
151
cctaaaaataaagcacctacgctg
cactcaggctggatgaacaa
165 FAM 55 3
151
cacttttgccacggaaagta
ggctgctctgattctgtttc
158 HEX 55 2
151
caggaaaatgacaatgggaat
tgtattatttctgccatgcca
126 FAM 55 2
151-J
ggacctattagatgattcagatgatg
ctgtggcaaggaaaccaagt
102 HEX 55 2
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Figure 4.1 Pedigree family I
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152
Figure4.2Family II
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Figure 4. 3 Family HI
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Figure 4. 4 Family IV
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Chapter 5 Pathways of Carcinogenesis in MYH associated tumours
5.1 Introduction
Colorectal carcinomas develop according to varying genetic pathways or routes (Chung
2000). The most common pathway is characterised by mutations of the APC and TP53 
genes, by 18q allelic loss, by mutation of K-ras and SMAD4 in some cases, and by an 
aneuploid/polyploid karyotype (Vogelstein, Fearon et al. 1988). These tumours are often 
said to have followed the CIN (chromosomal instability) pathway. Other cancers are 
characterised by microsatellite instability (MSI+), aberrant DNA mismatch repair, a near­
diploid karyotype and low levels of TP53, SMAD4 and K-ras mutations, but higher 
frequencies of BAX, TGFBIIR and BRAF mutation (Rajagopalan, Bardelli et al. 2002), 
(Young, Simms et al. 2001). Such cancers include those occurring in HNPCC kindreds and 
sporadic colorectal cancers with somatic epigenetic silencing of MLH1. Still further 
colorectal cancers have neither MSI nor an aneuploid/polyploid karyotype and are termed 
MSI-CIN- (Georgiades, Curtis et al. 1999). These cancers appear to form a minority of 
around 10%. Superimposed on these three pathways are further levels of complexity; some 
colorectal cancers, for example, may have tendency to high levels of promoter methylation 
(so-called CIMP+ pathway) (Toyota, Ahuja et al. 1999).
Germline APC mutations generally lead to a phenotype of profuse colonic polyposis (FAP). 
One ore more of these adenomatous polyps usually progresses to cancer by the fourth or fifth 
decade, probably owing to second hits at the remaining APC allele and mutations in the 
same genes involved in the development of sporadic CIN+ colorectal cancers (Debinski, 
Love et al. 1996; Tomlinson, Ilyas et al. 1998; Shibata and Aaltonen 2001). It is likely -  
although not conclusively demonstrated -  that FAP polyps can become cancerous owing to 
progression along any of the CIN+, MSI- CIN- pathways (Konishi, Kikuchi-Yanoshita et al. 
1996). In HNPCC, by contrast to FAP, the phenotype is predominantly one of colorectal 
carcinoma, with only a small increase in incidence of colorectal adenomas (Lynch 1999).
As described in chapter three, MYH associated polyposis (MAP) is a newly described 
syndrome predisposing to colorectal adenomas (multiple or polyposis). Phenotype is often 
indistinguishable from a classical or attenuated form of FAP, but MAP appears to be 
inherited as a recessive trait, with consequent implications for the risk of disease in other
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family members (Sieber, Lipton et al. 2003). MYH encodes a glycosylase which is involved 
in base excision repair and primarily targets oxidative DNA damage to guanine residues. In 
keeping with the role of MYH, colorectal tumours from MAP patients show an excess of 
G—>T transversion mutations in the APC gene owing to the failure to repair lesions induced 
by the variant base 8-oxo-guanine (Al-Tassan, Chmiel et al. 2002; Sieber, Lipton et al. 2003). 
Whilst changes in MYH expression may have some role in the pathogenesis of sporadic 
colorectal tumours, there is current^) evidence to show that the gene is mutated or silenced 
in bowel cancers outside MAP (Halford, Rowan et al. 2003).
MYH is the first base excision repair gene to be shown to predispose to colorectal cancer 
when mutated in the germline. It is, in many ways, an unexpected gene to cause colorectal 
polyposis. Many puzzles regarding its role in tumourigenesis remain. It is not clear, for 
example, why germline MYH mutations lead to tumours of the gastrointestinal tract, or why 
MAP differs in its phenotype and inheritance from HNPCC. In order to gain further clues to 
explain how germline MYH  mutations lead to a phenotype of multiple colorectal tumours and 
cancer, a study was made of the somatic genetic changes in 130 colorectal adenomas and 19 
carcinomas from 22 MAP patients.
5.2 Methods
5.2.1 Selection of MAP Tumours
Collection of tumours, DNA extraction, sequencing and immunohistochemistry were done by 
me. Miss Victoria Johnson helped in performing immunohistochemistry for p53 and beta- 
catenin.
The 22 patients with bi-allelic germline MYH were identified through Family Cancer clinics 
and Polyposis Units in the United Kingdom (St Mark’s Hospital, Harrow), Finland, Denmark 
and Switzerland. MYH  mutation testing had been done by myself and Dr Oliver Sieber as 
part of a previous study (18 patients) and a population based study performed in Finland 
(four patients) (Enholm, Hienonen et al. 2003). Mutation testing for the latter was performed 
by me. All patients were known to have multiple colorectal adenomas, although precise 
adenoma counts were not available for some patients. Most of our patients had developed
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one or more colorectal cancers, although only 19/26 of these tumours were available for 
study (Table 5.1).
5.2.2 DNA Extraction
Constitutional DNA was extracted from peripheral blood lymphocytes by standard methods. 
Both fresh-frozen and fixed, paraffin-embedded tumour tissues were used for the analysis, 
depending on their availability. DNA was extracted using standard methods (chapter 2.).
5.2.3 Mutation Analysis
For mutation analysis of APC, SMAD4, beta-catenin and TP53 in tumour DNA, F-SSCP 
analysis was used. dHPLC was additionally used for APC. Primer pairs for APC codons 
1219 to 1609 (exon 15 regions F to I) were used as in chapter four. Where DNA derived 
from fresh-frozen tissue was available, the tumour was analysed fox APC mutations from 
exon 15A to 15L. Primer pairs were similarly designed for the coding regions and exon- 
intron boundaries of TP53 exons 4 to 8, SMAD4 (all exons and flanking regions), beta- 
catenin exon 3, K-ras exon 3 and BRAF exon 14 (Tables 5.2-6).
For F-SSCP analysis, each 25 plPCR reaction contained lxPCR reaction buffer without 
MgCh, 200 pM dNTPs, 200 nM of each primers, 50 ng of genomic DNA and 1U of Taq 
DNA polymerase (Qiagen), and the PCR conditions consisted of 95°C for 5 min, followed by 
35 cycles of 95°C for 1 min, 55°C or 60°C for 1 min, 72°C for 1 min, and a final extension 
step at 72°C for 10 min. The resulting PCR products were screened for variants by being run 
at 18°C and 24°C on the ABI3100 and analysed using Genotyper 2.5 software (Perkin-Elmer 
Applied Biosystems). The latter was performed in the CRUK Equipment Park.
DHPLC was performed using the 3500HT WAVE nucleic acid fragment analysis system 
(Transgenomic, Crewe, UK). The same primer set was used as for the F-SSCP analysis. To 
enhance the formation of the hetroduplexes prior to analysis, the PCR products were 
denatured at 94°C and re-annealed by cooling to 50°C at a rate of 1°C per minute. dHPCL 
was carried out at the melting temperature predicted by Wavemaker (version 4.0) software 
(Transgenomic) with a 12% acetonitrile gradient over 2.5 minutes. DHPLC analysis was 
carried out by the CRUK Equipment Park.
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For tumour samples showing aberrant SSCP or dHPLC bands, the relevant region of the gene 
was re-sequenced directly from a new PCR product alongside constitutional DNA. For 
samples without mutations seen on standard sequencing, TA cloning was performed on the 
PCR fragment using pGEM-T Easy Vector System (Promega) following the manufacturer’s 
instructions. A minimum of 10 clones was then sequenced.
K-ras exon one was sequenced directly in 15 cancers and a subset of 30 adenomas. BRAF 
exon 14 (the region around the mutation hotspot at codon 599, GTG (Val) was sequenced 
directly in a subset of 12 cancers and 55 adenomas.
5.2.4 LOH and MSI Analysis
For loss of heterozygosity (LOH) and MSI analyses, the tumour DNA was PCR-amplified 
alongside the constitutional DNA from the patient using microsatellite markers MYCL, 
D2S123, D5S346, D10S197, D15S659, D18S69, D18S487 and D20S100, with the forward 
primer fluorescently labeled with FAM, TET or HEX. For LOH, areas under the peaks 
(including stutter bands) were compared for all informative (heterozygous) markers. LOH 
was reported where normal:tumour peak areas were less than 0.5, or greater than two, thereby 
allowing for contaminating normal tissue within the microdissected tumour.
For assessing MSI, the eight markers above were used, together with mononucleotide repeats 
TGFBIIR (transforming growth factor-beta type II receptor) and BAT26. A tumour was 
considered MSI+ if four or more markers showed novel alleles. Whilst the significance of 
lower levels of MSI is unclear, we noted tumours which had one to three markers unstable.
5.2.4 Immunohistochemistry
Immunohistochemistry was performed for TP53 over-expression and aberrant (nuclear) beta- 
catenin expression. Five pm tumour sections were analysed using the M7001 (Dako) and 
GC19220 (Transduction Laboratories) antibodies respectively at 1/100 dilution (beta-catenin) 
or 1/1000 dilution {TP53) after microwaving the sections for 10 minutes. After 
counterstaining with haematoxylin, the slides were examined by three independent observers 
(I, V Johnson and A.T. Eftekhar Sadat). Beta-catenin expression was scored as positive if
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nuclear staining was present in more than 10% of dysplastic cells. For TP53, a tumour was 
scored as positive if there was no staining of normal tissue and more than 20% of dysplastic 
nuclei were stained. Tumours were reported as negative for p53 if normal tissue showed no 
staining and <20% of dysplastic nuclei were stained. Tumours with other p53 staining 
patterns were excluded from analysis.
5.2.5 Flow Cytometry
Flow cytometry, was performed on tumour/normal tissue pairs with the help of the FACS 
laboratory and CRUK, Lincoln’s Inn Fields (see chapter 2).
5.3 Results
5.3.1 Clinical Features
The 22 patients (Table 5.1) presented at a mean age of 55 years (median 55, range 38-71). 
The mean number of adenomas in the 13 patients for whom precise counts were obtained was 
70 (median 70, range 5-210). Adenomas were of tubular or tubulovillous morphology, with 
occasional hyperplastic polyps and serrated adenomas were also present. Microadenomas or 
oligocryptal adenomas were present in some patients. Several patients were seen to have 
areas of flat dysplastic mucosa without histological features of discrete adenomas. For all 
patients there was great variation in the size o f adenomas (range one to 40mm where 
reported). No patient in this series was known to have developed extra-colonic tumours. 
Fourteen patients had developed one colorectal cancer and six had developed two cancers 
(five synchronous, one metachronous). Two patients had developed adenomas only. The 
colorectal cancers in the study were predominantly left-sided (17/24 reported), with most 
occurring in the rectum (Table 5.1). In five of the patients with two cancers, both occurred in 
the recto-sigmoid region. The cancers had no characteristic histological pattern, with only 
three reported as showing a mucinous histology. Where it was reported, grade 2 cancers 
predominated, with 2/23 (9%) grade 1,16 (70%) grade 2 and 5 (22%) grade 3 histology.
Stage varied widely amongst cancers (Table 1). Carcinomas were present together with 
adenomatous elements in many specimens suggesting transformation of adenoma into 
carcinoma.
5.3.2 Molecular Features and Somatic Mutation Profile of Tumours
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All protein-truncating APC mutations in our MAP tumours were G>T transversion 
mutations. Only one tumour showed LOH at APC. Although the quantity of tumour tissue 
available permitted only part of the APC gene to be screened, 22 of 105 (21%) adenomas and 
six of 14 (43%) cancers had at least one APC mutation (Table 5.2). The most commonly 
found changes were the nonsense mutations S1315X (nine adenomas) and E1560X (one 
cancer and 11 adenomas). It is noteworthy in passing that four of the 19 MAP patients 
harboured the germline missense APC variant E1317Q (Lamluxn, Al Tassan et al. 2000). This 
variant, which has a population frequency of about 1% is of uncertain significance, but also 
provided the original cause for investigation of the first MAP family reported (Al-Tassan, 
2002). None of the 105 adenomas and 14 colorectal cancers that underwent F-SSCP analysis 
of beta-catenin exon 3 showed any mutations. Immunohistochemistry revealed aberrant 
(nuclear) beta-catenin staining in 12/17 (71%) cancers and 16/38 (42%) adenomas studied, 
consistent with loss of APC function in these lesions (Table 5.7).
For K-ras, the same mutation (GGT—>TGT, G12C) was found in 10 of 15 (67%) cancers and 
13 of 30 (43%) adenomas tested (Figure 5.1, Table 2). No other K-ras mutations were found.
No BRAF mutations were found in exon 14, the site of the most common variant V&00 E.
We tested 14 cancers and 115 adenomas for mutations in TP53 exons four to eight. Three 
changes were found, all in carcinomas. One mutation, delAGTACTGT nt380, is highly 
likely to be pathogenic. Two changes, P152T (C—>A, nt463) and FI34V (T—►G), have 
previously been reported as rare changes in cancers, and have potential functional importance 
(Beroud and Soussi 2003). Of these three mutations, only P152T involves a G>T change. 
Immunohistochemistry revealed abnormal nuclear p53 staining in 8/15 (53%) cancers and in 
2/41 (5%) adenomas studied# TP53 mutations and immunohistochemistry were concordant 
(Table 5.2).
Four out of 12 informative cancers (33%) and 14/79 (18%) informative adenomas showed 
LOH at one or more 18q markers. We found no coding SMAD4 changes. No mutations were 
found in the TGFBIIR repetitive oligonucleotide tract.
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None of the 149 MAP tumours showed MSI (Table 5.2). In keeping with this, none of 12 
adenomas and nine cancers studied showed loss of MLH1, MSH2 or MSH6 expression 
(details not shown). Nine adenomas (7%) and one cancer (6%) showed microsatellite 
slippage at a single marker, and one other cancer showed slippage at two markers. We 
deemed that these data did not suggest any particular tendency to MSI-low in our tumour set 
(Halford, Sasieni et al. 2002; Laiho, Launonen et al. 2002). LOH was also uncommon in the 
cancers at the markers studied (maximum of 4% of informative cases with loss at each 
marker, excluding the chromosome 18 microsatellites) (Table 5.7).
Consistent with the relatively low frequency of LOH, flow cytometry showed that 12 out of 
13 (92%) MAP cancers tested were near-diploid (Figure 5.2). The remaining cancer 
appeared near-tetraploid. This cancer had the characteristic K-ras mutation and 18q LOH, 
but no other detectable genetic changes (Table 5.2). In order to provide corroboration of the 
flow cytometry, two of the near-diploid cancers were screened for changes using a genomic 
microarray, and no detectable changes were found (data not shown).
As expected, cancers showed a higher frequency of changes overall than adenomas. For 
certain changes, such as APC mutations, this may, at least in part, have reflected the 
problems of studying smaller lesions using molecular methods. Methodological problems 
could not, however, readily explain other differences between adenomas and carcinomas, 
such as the more frequent aberrant expression of beta-catenin and p53 in the malignant 
lesions. We found no other associations between clinical, pathological and molecular data, 
including the presence of K-ras mutation.
We compared the features of our MAP tumours with those of 107 unselected sporadic 
colorectal cancers studied in our laboratory using similar methods (Table 5.8). Whilst 
statistical comparisons must be undertaken cautiously -  partly because sporadic cancers 
comprise a mixture of MSI+ CIN-, MSI- CIN+ and MSI- CIN- lesions -  our unselected 
series had molecular features in accordance with findings from other studies (details below) 
and had been analysed using the same methods as the MAP cancers (Miyaki, Konishi et al. 
1994; Konishi, Kikuchi-Yanoshita et al. 1996; Fujiwara, Stolker et al. 1998; Sakao, Noro et 
al. 1998). Certain features of the MAP tumours were striking. Whilst no specific 
histological features distinguished the MAP tumours (details not shown), MAP carcinomas 
occurred at a relatively young age (median 55, range 38-71) compared to the sporadic group
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(median 66, mean 66, range 27-103) ((x2i=15.9, p=0.0001, Mann-Whitney test). APC 
mutations occurred at a similar frequency in MAP and sporadic cancers (6/14 versus 44/99, 
p=0.58, Fisher’s exact test). As expected, the mutation spectrum in th&APC gene was 
overwhelmingly biased to G—>T in MAP cancers compared with the sporadic lesions; G—>T 
changes comprised 6/6 truncating mutations in the MAP cancers (and 22/22 in MAP 
adenomas) compared with 4/44 in the sporadic cancers (p=0.0001, Fisher’s exact test). Beta- 
catenin mutations were very uncommon in both the MAP tumours (0%) and the sporadic 
cancers (1%), consistent with other studies (Sparks, Morin et al. 1998; Hao, Frayling et al. 
2002). Nuclear beta-catenin was seen in 47/72 sporadic and 12/17 MAP cancers (p=0.46, 
Fisher’s exact test).
K-ras mutations were present in 9/14 MAP cancers (and 13/30 MAP adenomas) and 33/104 
sporadic cancers (p=0.02, Fisher’s exact test), but the spectrum in the former was restricted to 
a single change in codon 12 which was found in only 3/33 sporadic colorectal cancers 
(p=0.0001, Fisher’s exact test). This comparison holds true when mutation frequencies from 
the RASCAL study are compared with those of the MAP cancers (Andreyev, Norman et al.
2001). Three of 14 MAP cancers had pathogenic TP53 mutations compared with 33/92 
sporadic cancers (p=0.23 Fisher’s exact test). Abnormal p53 over-expression was similar 
(p=0.50, Fisher’s exact test) in MAP cancers (8/15) and sporadic lesions 26/53). SMAD4 
mutations were not found in the MAP cancers, although such mutations were also uncommon 
in the sporadic cancers (p=0.89, Fisher’s exact test). 18q LOH was as common in the MAP 
as the sporadic cancers (7/15 versus 33/74, p=0.55, Fisher’s exact test). MSI was notably 
absent from the MAP cancers, although this was not significantly different from the 11% 
(12/107 of MSI cancers in our set of unselected colorectal carcinomas (p+0.127, Fisher’s 
exact test). Diploidy was much more common in the MAP, occurring in 12/13 cancers 
compared with 43/90 sporadic lesions (p=0.002, Fisher’s exact test).
5.4 Discussion
This study suggests that colorectal tumours developing in patients with bi-allelic germline 
MYH mutations follow a distinct genetic pathway. Although MAP is an uncommon 
condition and hence, at the present time there are not a large number of DNA samples 
available from MAP cancers and adenomas, this data does allow some firm conclusions to be
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drawn. The spectrum of somatic mutations in the APC gene largely comprises G—>T 
transversion mutations. These mutations are present in both adenomas and carcinomas.
They are particularly frequent at codons S1315X and at the known hotspot, E1560X, 
although we have not found mutations at the previously reported hotspots of codons 836 and 
932 (Al-Tassan, Chmiel et al. 2002). The later two mutations were found in a single family 
however and may not be representative of the MAP cancer mutation spectrum as a whole.
The high frequency of the germline APC variant E1317Q (21% compared to the population 
frequency of 1%) is an interesting if unexplained finding. Lamluxn et al found this variant at 
a frequency of 8% in a cohort of 164 multiple adenoma patients and concluded that is was 
associated with the multiple adenoma phenotype (Lamlum, Al Tassan et al. 2000). It may be 
that the raised frequency in that population was an indication that there were a significant 
proportion of MAP patients within the cohort. It is possible that the association of El 317Q 
with colorectal tumours may be due to its co-occurrence with MYH mutations.
From the data is appears that the genetic instability resulting from MYH deficiency not only 
targets APC, but also affects other genes. K-ras mutations were common in tumours from 
these MAP patients and were all the same G12C (G—>T) change. Previous reports had 
suggested that in the MYH deficient genome, AGAA or TGAA motifs were preferentially 
targeted. Such motifs occur with great frequency in APC. This motif is not present at the 
critical sites within K-ras, but the G—>T mutations in K-ras preferentially involved the first 
guanine reside of codon 12 (TGGT), despite there being three other guanines within codons 
12 and 13 which could have served as targets for mutation. Thus, whilst MYH mutations lead 
to an excess of G—>T changes, the surrounding sequence affects the probability of this 
change, and the resulting somatic mutation spectrum reflects both selection and 
hypermutation. It is interesting to note that in a large study of 1993 incident colorectal 
cancer cases and 22410 controls, a family history of colorectal cancer was not associated 
with k-ras mutations overall but was associated with G—>T mutations in codon 12 (Slattery, 
Curtin et al. 2002).
The role of TP53 in the MAP patients’ tumours is unclear. TP53 over-expression was about 
as frequent as in sporadic cancers. TP53 mutations were detected in MAP cancers, but -  
unlike APC and K-ras -  there was no clear bias to G—>T changes in TP53. SMAD4 mutations 
and TGFBIIR mutations tract appear to play at most a minor role in the genesis of MAP 
tumours, although 18q LOH was as common as in sporadic cancers. It is not known as to
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whether or not other components of the transforming growth factor beta pathway are 
inactivated in MAP cancers. This sets these BER tumours clearly apart from HNPCC 
tumours due to MMR which frequently show TGFBIIR variants and rarely show TP53 
changes (Konishi, Kikuchi-Yanoshita et al. 1996) .
All of our MAP patients’ cancers were MSI- and almost all were near-diploid (CIN-). It may 
be the case that MYH deficiency confers sufficient genomic instability to make additional 
forms of instability unnecessary or disadvantageous for tumourigenesis. We found no 
evidence of unusual levels of MSI-low in MAP cancers, even though it has been suggested 
that MYH deficiency might lead to MSI-low because the MutSa complex is involved in 
mismatch recognition for both base excision repair and mismatch repair, and hence might be 
overloaded by an excess of G—>T changes (Gu, Parker et al. 2002).
It can be concluded that the MAP pathway of carcinogenesis is distinct from both the CIN 
and MSI pathways (Table 5.9). MAP tumours have high frequencies of APC mutation and 
low frequencies of beta-catenin mutations. Like MSI+ cancers, MAP cancers tend to be 
near-diploid and to have low frequencies of overall LOH. MAP cancers do not, however, 
have TGFBIIR mutations, as sporadic MSI+ cancers do, probably as an alternative to SMAD4 
mutations. We have not determined whether or not MAP cancers harbour BAX mutations, as 
MSI+ cancers do, largely owing to the presence of mononucleotide tracts within the gene 
(Simms, Radford-Smith et al. 1998). We do not predict that these genes would be particularly 
susceptible to the G—»T changes found in MAP patients. Many of these are, in fact, polyA 
tracts. The relatively high frequencies of k-ras mutations and 18q LOH in MAP cancers 
more closely resemble tumours following the CIN pathway than the MSI pathway. With 
respect to K-ras, controversy does exist regarding mutation frequency in HNPCC cancers and 
some investigators put this as high as 40% (Oliveira, Westra et al. 2004).
Overall, we can hypothesise that despite overlap in the genes which are mutated, colorectal 
cancers generally have only one major type of instability, whether CIN, MSI or, in MAP, 
base excision repair deficiency. It is not yet known whether aneuploidy and polyploidy are 
rare in MSI+ and MAP cancers because there is no ‘need’ for LOH as frameshift and G—>T 
changes respectively occur at sufficiently high frequencies -  or because too much genetic 
instability harms the cell or prevents survival and proliferation. For MSI+ cancers, both 
sporadic and HNPCC, the subsequent genetic pathways can partly be explained because
167
certain genes with short repetitive sequences are susceptible to mutation. There is currently 
no good evidence to show that certain genes are especially prone to the incorporation of 8- 
oxo-guanine or to resistance to repair of an 8-oxoG:A mismatch, although certain sequences 
are preferentially mutated in MAP tumours. The possibility remains that MAP cancers 
resemble MSI+ cancers in their gross genetic features such as karyotype, but are more like 
CIN+ cancers in the genes which are mutated.
With regard to the clinical syndrome of MAP, this study highlights several important points. 
Distinct frem HNPCC, and sporadic MSH+ cancers, tumours in MAP tend to be left sided 
and rarely mucinous. The number of persons diagnosed with synchronous cancers is likely to 
relate to multiple pre-neoplastic lesions and late diagnosis. A similar scenario may be seen in 
FAP. The risk of metachronous colorectal cancer in HNPCC remains high after an initial 
CRC diagnosis in HNPCC with new adenomas rapidly forming and malignancy developing. 
It is currently not known what the risk of new advanced adenomas is in MAP patients after 
initial clearance of polyps and cancers. Thus in phenotype as in genotype this syndrome 
seems to fall between HNPCC and FAP with the management paradigm of neither seeming 
entirely appropriate.
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Table 5.1 Patient and Tumour Characteristics
CRC = colorectal cancer, R=rectum, S=sigmoid colon, H=hepatic flexure, C=caecum, SF=splenic flexure, TA=tubular adenoma, 
TVA=tubulo villous adenomas, VA=villous adenomas, HPP=hyperplastic polyps, N/R=not reported
Patient MYH 
mutation 1
MYH 
mutation 2
Age
atdx
No. of 
CRC’S
CRC stage CRC grade CRC site No. of 
adenomas
Size of 
adenomas
Predominant
adenoma
pathology
1 DelC, nt 1452 Y165C 57 2 B and A 2 (both) R(both) 28 2-30mm TA and TVA, 
microadenomas
2 DelC, nt 1452 Y165C 71 2 B (both) 2 (both) Rand S 18 N/R TVA and HPP
3 G382D G382D 49 0 100 2-5mm TA
4 G382D G382D 51 1 C 2 H ‘multiple’ 3-25mm TA
5 DelC, nt 1136 G382D 55 0 70 l-25mm TA and TVA, 
microadenomas
6 G382D G382D 56 1 C 1 (mucinous) C 40 2-30mm TA
7 Y165C Y165C 52 1 N/R N/R N/R 40 l-5mm TVA
8 Y165C Y165C 55 2 B and A 2 (mucinous) and 2 R ‘multiple’ 5-30mm VA and TVA
9 Y165C G382D 69 1 B 2 (mucinous) C 115 l-40mm TA, TVA and 
HPP
10 Y165C Y165C 58 2 C (both) 2 and 3 SFandC ‘numerous’ 2-15 mm TA and TVA
11 Y165C Y165C 45 1 B 2 R ‘numerous’ 2-15mm TA and TVA
12 DelGGA, nt 
1395
G382D 53 1 D 3 H 14 2-25mm TA
13 G382D G382D 66 1 D 2 R 5 N/R N/R
14 Y165C G382D 40 1 D 3 R ‘several’ N/R N/R
15 Y165C G382D 55 1 D 2 C 80 N/R N/R
o
Patient MYH 
mutation 1
MYH 
mutation 2
Age
atdx
No. of 
CRC’S
CRC stage CRC grade CRC site No. of 
adenomas
Size of 
adenomas
Predominant
adenoma
pathology
16 Y165C G382D 52 1 A 2 R 50-100 N/R N/R
17 Y165C G382D 51 2 B and A 1 and 2 S and R 210 5-25mm TA and TVA
18 Duplication 
ATGGAT, nt 
411
nt 252 delG 38 1 C N/R R >100 N/R T A and TVA
19 G382D G382D 58 2 C(both) 3 and 2 RandS ‘multiple’ 5-30mm TA and TVA
20 Y165C G382D 49 1 B 2 C N/R N/R N/R
21 Y165C G382D 68 1 C 3 S N/R N/R N/R
22 Y165C G382D 65 1 N/R N/R N/R N/R N/R N/R
Table 5.1 (Continued) Patient and tumour characteristics
CRC = colorectal cancer, R=rectum, S=sigmoid colon, H=hepatic flexure, C=caecum, SF=splenic flexure, TA=tubular adenoma, 
TVA=tubulovillous adenomas, VA=villous adenomas, HPP=hyperplastic polyps, N/R=not reported
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Table 5.2 TP53 Primer Sequences
EXON SEQUENCE
5A atctgttcacttgtgccctg
ctcacaacctccgtcatgtg
5B ttgccaactggccaagacct
atcagtgaggaatcagaggc
6 gcctctgattcctcactgat
ggagggccactgacaacca
7A cttgccacaggtctccccaa
tgatgatggtgaggatgggcc
7B atctcctaggttggctctgac
aggggtcagcggcaagcaga
8 ttccttactgcctcttgctt
tgaatctgaggcataactgc
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Table 5.3 SMAD4 Primer Sequences
EXON SEQUENCE
1A ttgcttcagaaattggacaaaactttcaattgctcttttgc
IB gcaaaaagagcaattgaaagtttctgccaccatagagggtat
2A atataaaagtgtcttgcataatgtgactggattcacacagacactatcac
2B tggcctgatcttcacaaaaatgagatccttttccctttatgttt
3 tgtttcatttgttttcccctttctgccgctcacacaaactaa
4 gaatatgtgtgcatgactttgaggttctagaactcacttgtggaagc
5 catgttaatgtcttcttgttcctcggctgcctactttttctcaa
6 acccatgtgggccttaatttgcccttacaacaaaaacaagag
7 tttactgaaagttttagcattagacaagcctgtgtttgtcgtttcaa
8 tttctcatgggaggatgttctgtggacattggagagttga
9A gcatgctatacaatctgaagtaaaatcgcccagcttctctgtctaa
9B gggtcaggtgccttagtgactccttccacccagatttcaa
10A ggcattggtttttaatgtatggactgggccagggatgtttc
10B caggcggctactgcacaatgctcaaagaaactaatcaactgag
11A atcaccctgtccctctgatgttcaatccagcaaggtgtttc
1 IB cggattacccaagacagagctttgtagtccaccatcctga
Table 5.4 Beta-catenin Primer Sequence
EXON SEQUENCE
3 gaaccagcagaaaagcggctg
actcatacaggacrrgggagg
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Table 5.5 BRAF  Primer Sequence
EXON SEQUENCE
14 tcataatgcttgctctgatagga
ggccaaaaatttaatcagtgga
Table 5.6 K-ras Primer Sequence
EXON SEQUENCE
1 aaggcctgctgaaaatgact
agaatggtcctgcaccagtaa
Table 5.8 Features of Sporadic and MAP Cancers
MAP cancers 
(% )
Sporadic cancers 
(%)
P Value
Median age at diagnosis 55 66 0.0001
MSI+ 0/15 (0) 12/107 (11) 0.172
Diploid 9/10 (90) 43/90 (48) 0.011
APC mutations 6/14 (43) 4 4 /9 9  (4 4 ) 0.58
Kras mutations 9/14 (64) 33/104 (32) 0.02
Kras G>T transversions 9/9 (100) 4/44 (9) 0.0001
P53 mutations 3/14 (21) 33/92 (36) 0.39
P53 immunstain 7/12 (58) 26/53 (49) 0.50
B-catenin immunostain 12/14(86) 47/72 (65) 0.46
18q LOH 4/10 (40) 33/74 (44) 0.53
175
Table 5.9 Comparison of Genetic Features in the Known Colorectal Cancer ‘Pathways’
CIN+ MSI+ BER+
MSI - ++ -
Ploidy aneuploid diploid diploid
LOH ++ - -
APC mutation ++ + ++
Kras mutation ++ + ++
P53 mutation ++ + +
TGFRB mutations - ++ -
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Table 5.7 Molecular data for MAP colorectal carcinomas Blank cells=no result or experiment not done.
Patient CRC
No.
APC mutation APC
LOH
Beat mutation Beat
immunohx
K-ras mutation p53 mutation p53
immunohx
SMAD4
mutation
18Q
LOH
Ploidy
2
CA1 None found No None found + G12C, G>T None found None found Yes Polyploid
CA2 None found No None found + G12C, G>T None found None found No Diploid
4 CA E1560X No None found - G12C, G>T FI 34V, T>G + None found Yes Diploid
6 CA None found No None found + None found None found - None found No Diploid
7 CA None found No None found + None found None found - None found No Diploid
8 CA None found No None found G12C, G>T None found None found No
9 CA E1494X, S1315X No None found - G12C, G>T None found + None found No Diploid
10
CA1 S1315X No None found + G12C, G>T None found + None found Yes Diploid
CA2 None found No None found + None found - None found Yes Diploid
l i CA None found + None found + Diploid
12 CA None found No None found + G12C, G>T None found - None found No Diploid
13 CA E1552X, E868X None found + None found None found + None found No Diploid
14 CA E1353X None found G12C, G>T
delAGTACTGT
nt380
None found Diploid
15 CA E1353X None found + G12C, G>T P152T, C>A + None found Diploid
16 CA None Found None found + None found None found + None found No
19 CA + -
20 CA No - G12C, G>T - Yes
21 CA No - + Yes
22 CA No - - Yes
Figure 5. lCommon K-ras Mutation in MAP Tumours
Fig. 2
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Figure 5. 2 Flow Cytometry of Cancers from patients 9 and 12 (diploidy)
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Figure 5. 3 Flow Cytometry from Patient 2 (polyploidy)
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Chapter 6 Molecular Study of Adenomas from Patients with Multiple 
Adenomas or Polyposis and without Identified Genetic Predisposition
6.1 Introduction
Following the theme of previous work done on MYH associated polyposis (MAP) it became 
apparent that this syndrome accounted for a significant percentage (30%) of patients with 
over 15 colorectal adenomas and who did not have detectable mutations in APC. It remains 
apparent that many individuals and families with a multiple adenoma or polyposis phenotype 
still remain without genetic diagnosis. This makes it almost impossible to give evidence- 
based advice regarding screening and risk to family members. Because of the striking 
phenotype of multiple colorectal adenomas I and others felt that other germline changes must 
exist which could predispose to such disease. A number of strategies may be used to find new 
genes responsible, yet none is by any means perfect. One method, which has proved fruitful 
in the past, is the documentation of the ‘footsteps’ or outcome of the germline genetic 
disorder in the somatic mutation spectrum of tumours. The mismatch repair (MMR) genes 
were targeted in HNPCC when it became apparent that instability of microsatellites or 
repetitive DNA sequences was a hallmark of tumours from families fulfilling the Amsterdam 
Criteria. Such instability occurs due to defective MMR. In a serendipitous occurrence, the 
over-representation of G—>T transversion mutations in the tumours from a multiple adenoma 
sibship lead to the investigation of the genes involved in the base excision repair (BER) 
pathway which usually prevents such mutations. Thus germline missense MYH mutations 
were uncovered.
The APC gene frequently undergoes mutation or loss as an initiating event in adenoma 
formation. It appears to act as a gatekeeper, its loss permitting a cascade of deleterious 
changes. Thus it forms an excellent starting point to assess the somatic mutation spectra in 
adenomas from patients who do not have detectable APC or MYH germline variants yet 
develop tens to hundreds of adenomas. In FAP tumours APC may be lost (LOH) or develop 
protein-truncating changes, with pathogenic missense mutations being very rare (Ilyas and 
Tomlinson 1996; Sieber, Heinimann et al. 2002; Crabtree, Sieber et al. 2003). Protein 
truncating variants tend to occur in the somatic mutation cluster region (MCR), which lies 
between codons 1286 and 1513 (Rowan, Lamlum et al. 2000). This part of the gene contains
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a set of 20-amino-acid repeats thought to be critical for beta-catenin binding and degradation. 
Such a tight clustering of mutations implies that of all the functions downstream to the MCR 
which are lost, the loss of functions which are immediately adjacent to the 3’ limit of the 
MCR may be more important in tumour development. A series of three SAMP (Ser-Ala-Met- 
Pro) repeats which mediate Axinl binding occur 3’ to the MCR and mutations in this area 
may well be under-recognised. In FAP, the site of ‘second hits’ is dependent on the site of the 
germline change (Albuquerque, Breukel et al. 2002). LOH tends to occur in adenomas of 
persons with germline mutations near codon 1300 and truncating changes in the MCR in 
those with other germline variants. It has been postulated that a combination of 
mutational/LOH events that leave one or two intact 20-amino -acid repeat sequences may be 
optimal for adenoma development (Lamlum, Ilyas et al. 1999; Albuquerque, Breukel et al. 
2002; Groves, Lamlum et al. 2002; Crabtree, Sieber et al. 2003). Evidence also exists for a 
strong association in sporadic colorectal cancers between truncating mutations in codons 
1200 to 1400 and loss of the remaining non-mutant allele (Rowan, Lamlum et al. 2000).
As a result of work by myself and others in my laboratory and the St Mark’s familial cancer 
clinic with multiple adenoma patients it has become apparent that a large number of those 
with higher polyp counts (>15) appear to be isolated cases within the family or have an 
apparently autosomal recessive family history. Families without known germline mutations 
in our cohort fall into two broad groups, those with fewer polyps and an autosomal dominant 
picture of inheritance including colorectal cancer and those with isolated affected persons or 
sibships with large numbers of polyps. A number of persons when followed for some years 
develop both hyperplastic and adenomatous polyps. In the current study I have elected to 
examine the adenomas from those with over five synchronous or metachronous polyps both 
from isolated and from familial cases.
The major question to be investigated involved the nature of the pathway of tumourigenesis 
in polyps from multiple adenoma patients without germline APC/MYH mutations. Adenomas 
are known to develop secondary to Wnt pathway disruption due to inactivating APC or, more 
rarely, activating beta-catenin mutations, or to lack of mismatch repair function due to 
mutation in MMR genes. The initiating event in the latter is less clear but adenomas from 
patients with HNPCC appear to have lower rates of Wnt pathway gene mutations. It is 
probable that adenomas in MAP arise following somatic mutations in APC also, particularly 
given the results from my own and other investigations (Al-Tassan, Chmiel et al. 2002;
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Lipton, Halford et al. 2003) . Activating beta-catenin mutations do not seem to contribute to 
adenoma formation in MAP or FAP although they have been found in adenomas without 
APC mutation especially in HNPCC (Morin, Sparks et al. 1997; Samowitz, Powers et al. 
1999). Are there other components of Wnt signalling susceptible to adenoma-causing 
mutations? Although somatic mutation of Axin2/conductin is seen in about 10% of MS. I-H 
colorectal cancers, it has not been documented in adenomas and may well be a by-product of 
defective mismatch repair rather than an initiator of dysplasia (Liu, Dong et al. 2000). Other 
genes such as GSK3fi and Axinl have been screened by ourselves and others both in the 
germline and in colorectal tumours and have been shown to have a small role if any 
(Webster, Rozycka et al. 2000; Lipton, Sieber et al. 2003). The question of whether other 
pathways or events that predict the type of APC/Wnt involvement that occurs may be 
involved in adenoma formation in multiple adenoma patients without germline APC and 
MYH mutations has not been adequately investigated. We wished to explore the contribution 
(or lack of it) of disruption to the Wnt/wingless pathway in these lesions.
The spectrum of any APC mutations in MAP adenomas and cancers is distinct from that in 
FAP or sporadic adenomas. We hoped to find in the mutation-negative multiple adenoma 
patients a predominance of different mutation types rarely seen in sporadic or FAP adenomas 
which might give clues regarding defects in DNA replication and repair (primarily), cell 
cycle regulation or control of apoptosis leading to certain candidate genes for investigation in 
the germline. Mutation spectrum was examined in individual patients as well in the group as 
a whole, as it is likely that heterogeneity will exist in any such collection of patients. An area 
of the APC gene including the mutation cluster region (MCR) was examined in 286 
adenomas from 32 patients. Since patients without germline APC mutations require two ‘hits’ 
which may be mutations, allelic loss or transcriptional silencing of the gene for its 
inactivation, it is likely that in many cases mutations will occur in the MCR thus this is an 
appropriate initial screening strategy. Although sequencing of the entire APC sequence may 
be considered preferable, constraints exist when working with DNA derived from adenomas. 
It is very difficult to collect fresh frozen tissue as pathologists are required to examine a 
complete specimen for the presence of invasion. Also, patients classed as having multiple 
adenomas may develop dozens during their life in crops of two or three, and therefore at any 
given colonoscopy the practitioner may not recognise their phenotype. For this reason, our 
adenoma work is done on paraffin derived tumours. Most adenomas of average size can only
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provide a small amount of DNA and this is generally enough to examine only part of a large 
gene such as APC.
Although APC is almost certainly a gatekeeper, APC mutations are not the only event to 
occur during the genesis and progression of adenomas. Other genes are likely to contribute at 
an early stage of adenoma formation although few of the changes commonly seen in colon 
cancers appear to be frequent in adenomas. Possibly some such changes occur in a subset of 
adenomas (K-ras mutations for example) and others only follow on from specific initiating 
events. Although it is known that BRAF mutations occur commonly in sporadic MSI-H 
colorectal cancer, it is rare to see MSI in sporadic adenomas. Common somatic mutations 
such as those in K-ras, TP53, BCL-2, SMAD4 and BAX may occur at different stages in 
adenoma formation although they are only rarely uncovered. Such mutations may be present 
in small subsets of adenoma cells unable to be appreciated except in single crypt mutation 
studies. TP53 mutations and down-regulation of apoptosis occur early in flat adenomas and 
cancers occurring in inflammatory bowel disease but are generally a late event in sporadic 
adenomas (Yamamura-Idei, Satonaka et al. 1994; Rubio and Rodensjo 1995; Suzuki, Honma 
et al. 2002). It is probable that at some stage of all advanced there is unbalanced
proliferation and apoptosis.
Beta-catenin expression and cellular localisation were determined in a large number of 
adenomas using immunohistochemical staining. Aberrant nuclear beta-catenin staining may 
give some indication of abnormal activation of the Wnt pathway in adenomas (Munemitsu, 
Albert et al. 1995; Clements, Lowy et al. 2003). The oncogenic properties of Wnt/beta- 
catenin signaling stem from alteration in phosphorylation-dependent protein degradation and 
subcellular localization of beta-catenin from cell membrane to the nucleus, where it binds to 
T-cell factor (TCF) to form a bipartite transcription factor. The beta-catenin/TCF complex 
facilitates transcription of target genes that encode effectors for activation of cell proliferation 
and invasion and inhibition of apoptosis, leading to colorectal cancer development. The over­
accumulation of beta-catenin in the nucleus leads to activation of a number of TCF- 
associated transcriptional pathways involved in colorectal tumourigenesis. The major known 
cause for such accumulation is inactivation of APC. Although theoretically, mutations or loss 
causing lack of function in other Wnt pathway genes may have the same result, few such 
changes have yet been uncovered. Other potential causes of dysregulation of beta-catenin 
expression include inhibition of PI3 kinase (PI3K) and AKT by prostaglandin and
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extracellular factors including sodium butyrate (Castellone, Teramoto et al. 2005). There 
remains some controversy as to what conclusions can be drawn from these results. Several 
authors have written in support of a ‘top down’ progression of dysplasia within colonic crypts 
with dysplastic features and nuclear staining in luminal cells only (Shih, Wang et al. 2001; 
Jass, Whitehall et al. 2002). Others have noted that nuclear P-catenin expression is associated 
with increased tubular branching or crypt fission and appears predominantly in the crypt base 
(Kirchner and Brabletz 2000; Brabletz, Jung et al. 2001; Preston, Wong et al. 2003). It is 
likely that the amount and site of nuclear beta-catenin staining changes with the morphology 
of the tumour and the cell’s state in terms of its position in the crypt, cycling and function. It 
is also possible that the pattern of nuclear staining -  the adenoma’s molecular morphology -  
depends to some extent on the type of APC mutation or other Wnt pathway disruption 
involved. In this study, the presence or absence of beta-catenin nuclear staining in adenomas 
has been correlated with the APC mutation status and APC LOH.
Evidence for the involvement of the SMAD4/TGFp pathway and TP53 mutations was sought 
using immunohistochemistry to assess levels of corresponding protein expression. Loss of 
SMAD4 expression occurs in most polyps from germline SMAD4 mutation carriers, even 
those with pathogenic missense germline mutations. It is, in contrast, very rare to see lack of 
staining in polyps from patients without germline mutations in SMAD4 (<5%) although 
sporadic colorectal cancers show loss of staining in 20-40% of cases (Woodford-Richens, 
Rowan et al. 2001; Salovaara, Roth et al. 2002). Thus immunohistochemistry for SMAD4 
protein is an effective method of excluding a major role for SMAD4 mutations in this group 
of patients.
TP53 mutations are identified in 50% or more of colorectal cancers. Mutations are primarily 
found in exons 5 to 8. The gene product TP53 is a sequence-specific transcriptional activator 
in the regulation of cell cycle progression and apoptosis. Thus it can be equated to a 
‘gatekeeper’ of the cell cycle, its loss allowing cell survival in circumstances 
disadvantageous to the host. Most TP53 mutations result in a protein with an abnormally long 
half-life, and the accumulation of protein from mutant TP53 can be detected using 
immunochemical staining. TP53 mutations are a later event than APC mutations in sporadic 
tumours, occurring during the adenoma to carcinoma transition. They are seen in adenomas 
at a low frequency (Ichii, Takeda et al. 1993). Hao et al showed that in adenomas with mild,
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moderate, or severe dysplasia, mutation or allelic loss at TP53 occurred in 4.8%, 16.7%, and 
52.6% (Hao, Frayling et al. 2002).
6.2 Methods 
6.2.1 Patient Selection
Patients were recruited by me, Dr Ian Frayling and Mrs Carole Cummings. Patients were 
selected from those attending the Cancer Research UK Family Cancer Clinic and the 
Polyposis Unit at St Mark’s Hospital, Harrow. A proband from each patient’s family had 
been examined for germline MYH mutations (Chapter 4) and APC mutations by F-SSCP of 
the entire gene and real-time PCR to exclude large deletions mAPC  (Table 6.1). All patients 
had developed five or more colorectal adenomas over their lifetime. 289 adenomas were 
available for study from 32 multiple adenoma patients from 32 families. Probands from 
families with apparent autosomal dominant and recessive inheritance as well those with no 
family history of colorectal adenomas and cancers were included in the study. Individuals 
with juvenile polyps or hyperplastic polyps only were not included.
6.2.2 DNA Extraction
Germline DNA extraction was performed by myself and Dr Emma Jaeger and tumours were 
microdissected and DNA extracted by myself. Germline DNA was extracted from 
lymphocytes or cell lines by standard methods. DNA was extracted from paraffin embedded 
adenoma tissue by microdissection from 10 pm slides using the corresponding H&E section 
as guidance. Adenoma pathology was assessed by Professor Nicholas Wright and me.
6.2.3 APC  Mutation Detection
APC mutation detection was performed by me. F-SSCP was used to examine codons 1209 to 
1604 of the APC gene in adenomas. The primers used are detailed in Table 4.10. This area 
includes the mutation cluster region. Samples were run on the ABI 3100 at 18°C and 24°C 
and samples showing aberrant bands were re-amplified and sequenced directly. In one patient 
with a number of somatic APC mutations in an area close to a common polymorphism,
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cloning of the PCR product for this region was performed to determine the allele being lost 
(chapter 2).
6.2.4 APC  LOH Analysis
LOH analysis was performed by me. For LOH analysis, the tumour DNA was PCR-amplified 
alongside the constitutional DNA from the patients using the 5q markers D5S346, D5S421 
and D5S656, with the forward primer fluorescently labelled with FAM or HEX. For LOH, 
areas under the peaks (including stutter bands) were compared for all informative 
(heterozygous) markers. In informative cases, allelic loss was considered present if the 
relative ratio of normal:tumour peak areas was less than 0.5, or greater than 2. Samples 
appearing to have LOH had the analysis repeated and if not confirmed were reported as 
lacking LOH.
6.2.5 MSI Analysis
MSI analysis was performed by me. All adenomas included in the study were assessed for 
MSI using the mononucleotide marker BAT 26. Adenomas were said to be stable if there was 
no base slippage.
6.2.6 Immunohistochemistry
Immunohistochemistry was performed for p53 over-expression, aberrant (nuclear) beta- 
catenin expression and loss of SMAD4 protein by Miss Victoria Johnson and me. 5pm 
tumour sections were analysed using the M7001 (Dako), GC19220 (Transduction 
Laboratories) and SC7966 (Santa Cruz) antibodies respectively at 1/100 dilution (p-catenin, 
SMAD4) or 1/1000 dilution (p53) after microwaving the sections for 10 min. After 
counterstaining with haematoxylin, the slides were examined by two independent observers, 
Professor Nicholas Wright and me. Beta-catenin expression was scored as 0 to 4 if nuclear 
staining was present in 0, <10%, <25%, <50% or >50% dysplastic cells respectively. For 
p53, an adenoma was scored as positive if there was no staining of normal tissue and more 
than 20% of dysplastic nuclei were stained. Tumours were reported as negative for p53 if 
normal tissue showed no staining and <20% of dysplastic nuclei were stained. Tumours with
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other p53 staining patterns were excluded from analysis. SMAD4 protein expression was 
scored as loss if there was absence of nuclear and cytoplasmic staining in dysplastic nuclei 
only with staining seen in normal cells.
6.3 Results
6.3.1 Patient Characteristics
The 32 patients represented a fairly diverse group (Table 6.1) with a median age at diagnosis 
of 50 years (mean 44, range 18-74). The majority 17/30 (57%) had not developed colorectal 
cancer and 22/31 (71%) had not required colectomy. The majority of these patients had a 
family history of colorectal cancer significant enough for them to have been offered 
screening colonoscopy. This is in contrast to MAP patients, the majority of whom appear to 
require colectomy at diagnosis due to the recessive nature of disease leading to late diagnosis 
with fairly extensive and advanced adenomas, possible with a higher CRC risk.. The median 
age at diagnosis was the mid 50’s and hence considerably older than FAP patients but 
comparable to MAP. Polyp number ranged between 5 and 110 (median 17, mean 33). A total 
of 286 polyps were studied. Polyps were mostly tubular adenomas, although a number of 
tubulovillous adenomas and villous adenomas were also present. They ranged in size from 1 
to 35 mm (median 4mm, mean 5.8mm). Hyperplastic polyps were present in some cases, but 
no serrated adenomas or juvenile polyps were noted. None of the patients had predominantly 
hyperplastic polyps. Although some individuals appeared to have a dominant inheritance of 
colorectal cancer, none had documented dominant inheritance of multiple adenomas. Sixteen 
patients had developed colorectal cancer Tissue from colorectal cancer was available in eight 
cases and this was examined alongside adenomas.
6.3.2 APC  Mutation Screening.
APC codons 1209 to 1604 were screened for mutations in 247 adenomas (Table 6.2). Of 
these, 34 harboured probable pathogenic mutations (13%). A further nine adenomas had 
aberrant bands on F-SSCP but did not have detectable mutations on sequencing. As part of an 
ongoing study, these adenomas are undergoing more detailed analysis using cloning 
techniques. The majority of variants were insertions or deletions of one or more bases
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causing frameshifts to occur. Nonsense (protein truncating) mutations were apparently very 
uncommon comprising 1/33 (33%) of mutations. Apart from the common codon 1309 
mutation, del AAAGA, all frameshifts were found between codons 1430 and 1580. This is in 
keeping with the pattern of somatic mutations in sporadic rather than FAP tumours (Rowan, 
Lamlum et al. 2000). No adenoma had the common R1450X variant. The proportion of 
adenomas with somatic APC mutations found was lower than that found in another group of 
156 adenomas from mutation positive FAP patients 33/247 (13%) vs. 52/156 (33%), Fisher’s 
exact test, p<0.01 (Crabtree, Sieber et al. 2003). This may not be a strictly representative 
result as Crabtree et al used fresh frozen adenoma tissue which is likely to yield DNA of 
better quality with more mutations found. The proportion of adenomas with pathogenic APC 
mutations, 33/247 (13%) was not significantly lower than that for MAP patients (22/105, 
21%, Fisher’s exact test, p=0.09) (Lipton, Halford et al. 2003). The mutation spectrum was 
very different in the two groups, however.
Overall, 12 patients had at least one somatic APC mutation detected. Eighteen patients had no 
APC mutations detected in adenomas or cancers. Of these 18, twelve had five or more 
adenomas analysed and three had a colorectal cancer analysed. The median age of patients 
with APC mutations was 53 (mean 52) compared with a median age of 49 (mean 46) for 
those without mutations. Only one patient, 13, had an APC mutation in an invasive tumour. 
Of the patients without APC mutations, nuclear beta-catenin expression was seen in a 
proportion of adenomas in 9/18 (50%) of patients. This may imply that APC mutations were 
missed in a number of adenomas, that these adenomas had other changes such as LOH 
missed in this study due to poor DNA quality or epigenetic silencing leading to the 
dysregulation of the Wnt pathway or that beta-catenin may accumulate in the cell without 
loss of Wnt pathway mediated suppression.
None of the characteristic G—>T transversion mutations were seen in this group of patients 
whilst they predominated in the MAP adenomas.
Patient two was found to have ten frameshift mutations from ten separate adenomas, eight of 
these in an area of only 62 codons (codon 1431-1493). There was no consistent pattern of 
changes otherwise. This individual was heterozygous for the common polymorphism codon 
1493 G>A. It was therefore possible to clone this area in a number of adenomas to determine
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whether the mutations were consistently affecting one allele, to explore the possibility of a 
cryptic APC mutation on the other allele. Somatic mutations in this area of the APC gene (3’ 
to codon 1400) would typically be associated with a germline mutation 5’ to codon 1280. The 
six polyps cloned harboured the mutations; codon 1489 ins T (two polyps), codon 1489 ins 
C, codon 1493 del A, codon 1472 del 55 bp and codon 1488-89 del TT (Figure 6.). At least 
15 clones were sequenced for each mutation. Overall it appeared that frameshift mutations 
were occurring only on the G allele of the polymorphism (Table 6.2). For unknown reasons, 
three mutations were not seen in any clone. In two of these, the A allele predominated with 
the wild-type leading to a possible association of the G allele with the mutation. In one set of 
clones, however, no mutation was seen and the G allele predominated. F-SSCP and direct 
sequencing have been used to screen this patient’s germline DNA for mutations in the entire 
coding sequence of the gene yet it remains possible that an occult mutation is present. These 
results are not conclusive. All of these adenomas were microsatellite stable.
Another patient (20) was found to have an identical mutation, codon 1355 del GA, in seven 
of his adenomas but not in another 11. As these adenomas were all taken from the same 
paraffin block it may imply that there were several portions of one adenoma tested. Normal 
tissue DNA did not contain this mutation.
When adenomas w ith^PC mutations and SSCP changes were taken together, it appeared that 
adenoma size had a small effect only. Of the forty-three adenomas in this category, 17 were 
<5mm and 26 were >5mm.
6.3.3 Beta-catenin Immunohistochemistry
146 adenomas were successfully stained for aberrant nuclear beta-catenin expression. Of 
these 61/146 (41.8 %) showed no nuclear staining in dysplastic cells, 10/146 (6.8%) showed 
<10% of nuclei stained, 23/146 (15.7%) showed <25% of nuclei stained, 23/146 (15.7%) 
showed 25-50% of nuclei stained and 29/146 (19.9%) showed >50% stained (Table 6.3).
Thus 58.2% of patients showed some degree of nuclear staining. This was not greatly 
different to the incidence seen in sporadic colorectal adenomas (Kinzler and Vogelstein 1996; 
Brabletz, Herrmann et al. 2000). It is also not significantly different from the rate of nuclear
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staining in MAP adenomas (16/38 vs 85/146, Fisher’s exact test, p=0.21) or the rate of 
nuclear staining in sporadic colorectal cancers (Lipton, Halford et al. 2003). Adenomas and 
aberrant crypt foci from FAP patients also show similarly frequent nuclear p-catenin 
immunostaining (Takayama, Ohi et al. 2001).
A group of nine colorectal cancers from the patient group were also stained for p-catenin. Of 
these, 6/9 (66%) showed no nuclear staining and three (34%) showed nuclear staining (Two 
had 2+ staining and one had 4+ staining). None of those without nuclear p-catenin staining in 
their tumour showed staining in adenomas whereas the three patients whose cancers showed 
nuclear staining all had a proportion of adenomas showing such staining. None of the three 
cancers with nuclear p-catenin staining had detectable APC mutations. Pathologists 
examining the stained adenomas felt that there was convincing evidence that P-catenin 
staining was generally stronger in crypts than at the luminal surface and in some cases was 
only present in crypt bases.
Size, more than any other variable appeared to influence the incidence and intensity of 
nuclear p-catenin immunostaining (table 6.4). Of the 61 adenomas of 5mm or less in 
diameter, 22 (36%) had some degree of nuclear staining whereas 62/85 (73%) of those over 
5mm had aberrant nuclear staining (p=0.00001, Fisher’s exact test). This is in keeping with 
data collected by Brabletz et al in sporadic adenomas. This group found that nuclear p- 
catenin expression was strongly correlated with adenoma size and c-myc expression but not 
with proliferative activity (Brabletz, Herrmann et al. 2000).
6.3.4 5q LOH and MSI Analysis
Of the 199 adenomas informative for at least one 5q marker, 43 (22%) showed LOH. The 
association between LOH and mutation status is shown in table 6.5. Seventy-one adenomas 
were not informative at any of the three 5q markers. This rate of LOH was equivalent to that 
found in adenomas from FAP patients with known germline mutations in APC (Lamlum, 
Papadopoulou et al. 2000). Only 5% of informative adenomas could clearly be seen to have 
two hits at APC, in all cases one mutation and one loss. A further 31% had one detectable hit, 
fairly evenly divided between mutation (14%) and loss (17%). Sixty-four percent of
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adenomas had no detectable change at the APC locus. In this latter group 68/129 (53%) were 
<5mm and 61(47%) were >5mm in diameter. Of the adenomas with two detectable hits, five 
were <5mm and five were >5mm. The adenomas without evidence of APC changes did not 
appear to have an increased involvement of other pathways. Five of 31 (16%) adenomas in 
this category examined for p53 expression showed aberrant nuclear staining and none had 
loss of SMAD4 protein. 18 of 51 (35%) adenomas examined for p-catenin expression had 
aberrant nuclear staining, less than the group as a whole.
No adenomas were found to be microsatellite unstable at BAT 26. This is in keeping with the 
finding that the presence of a person in a family with more than five adenomas is negatively 
associated with mutation-positive HNPCC (Chapter 7).
6.3.5 SMAD4 and P53 Immunohistochemistry
Ninety-three adenomas were examined for aberrant nuclear p53 expression. Only adenomas 
showing nuclear staining in more than 20% of dysplastic cells were scored as positive. 
Overall 14/88 (16%) of adenomas had aberrant nuclear staining. This is similar to the 
percentage reported in sporadic adenomas. Estimates vary between 20 and 40% depending on 
the grade of dysplasia in adenomas (Kaklamanis, Gatter et al. 1993; Hosaka, Aoki et al.
2002). It is higher than that seen in adenomas from MAP patients 14/88 vs 2/41 (Fishers 
Exact test, p=0.005). Six cancers were examined and 3/6 (50%) had strong aberrant nuclear 
staining. Loss of SMAD4 staining did not occur in any of the 156 adenomas studied in this 
series with immunohistochemistry. Six cancers from persons in the study were stained for 
SMAD4 protein and 2/6 (33%) had lost SMAD4 expression.
6. 4 Discussion
The evidence gathered in this study appears to support the hypothesis that there may be 
pathways to the development of dysplasia in the colon distinct from those involving 
dysregulation of the Wnt and MMR pathways. I have taken a group of patients who have a 
multiple adenoma phenotype with no known genetic cause and hypothesise that there may be
195
more than one way to dysplasia than through APC mutation and MSI+. A subset of adenomas 
has been shown to exist without two detectable hits at APC and without accumulation of 
nuclear p-catenin but also without evidence of impaired DNA mismatch repair. Although 
using SSCP with direct sequencing some APC mutations may have been missed, the great 
majority of adenomas tested, 204/247 (83%) did not have APC mutations and at least 64% of 
those informative for both did not have APC LOH or mutations. Of these, changes in TP53 
and SMAD4 were as infrequent as in the group as a whole (16% and 0% of adenomas 
respectively). The observation that all APC mutations detected were clustered in less than 
half of the patients leaves a substantial number for whom a different mechanism may be 
initiating adenoma formation. Although this is a very interesting hypothesis, several factors 
make it a highly guarded one. Firstly, only a proportion of APC was sequenced and mutations 
in other places could putatively play a role. Secondly the quality of paraffin derived DNA is 
somewhat lower than that derived from fresh frozen tissue and mutations may be missed. 
Thirdly, it would be narrow-minded to believe that only mutation and loss in the APC gene 
can inactivate the Wnt pathway. Events such as large genomic deletions, post translational 
modification of APC or epigenetic silencing as well as changes in other involved genes need 
to be ruled out before concluding that the Wnt pathway does not contribute to carcinogenesis.
It is possible that in some cases the Wnt pathway may be activated by mechanisms other than 
APC mutation or loss. Of the 59% of adenomas showing abnormal accumulation of p-catenin 
in the nucleus, only 13/85 (15%) showed APC LOH and 17/85 (20%) had APC mutations. 
Activating mutations in beta-catenin are one possible explanation. These have been found in 
small adenomas (<10mm) with a frequency of 12.5% and larger adenomas with a frequency 
of 2.5% and only 1.4% of invasive cancers (Samowitz, Powers et al. 1999). It is possible that 
the some of these adenomas are MSI-H from sporadic or inherited causes as several studies 
have shown an association between MSI in tumours and somatic beta-catenin mutations 
(Kim, Kang et al. 2003; Johnson, Volikos et al. 2005). There is apparently a strong 
correlation between adenoma size and Wnt pathway activation as shown by the progressive 
increase in aberrant nuclear beta-catenin staining with increasing adenoma size. This is 
supported by a study showing a strong increase in nuclear beta-catenin staining between 
aberrant crypt foci and adenomas from the same individual (Takayama, Ohi et al. 2001). 
Interestingly, there was not such a strong trend for increasing numbers of APC mutations 
with adenoma size. This lends support to the notion that A PC mutations may not be the only
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method of aberrant Wnt activation . These results as a whole imply the existence of non- 
APC, non-Wnt pathways in adenoma development as well as some evidence for the 
involvement of Wnt signalling and beta-catenin accumulation independent of APC mutation 
or loss.
Can we then derive evidence from the APC mutation spectrum in these adenomas as to 
underlying mechanisms of adenoma development? The APC mutation database lists some 
762 somatic APC mutations (Beroud 2006). Of these 309 (41%) are transversion and 
transposition mutations. The majority of these are protein truncating (270/309, 87%) with the 
remaining 39/309 (13%) made up of missense amino acid changes. The remaining 453 
somatic mutations on the database are frameshift mutations, insertions and deletions. In the 
group of adenomas reported here, there is a definite predominance of frameshift changes over 
truncating and non-truncating missense changes with only four of the latter found and only 
one definite nonsense mutation. Mutations at codon 1309 made up 6/33 (18%) of those in the 
cohort. This is a common mutation in sporadic tumours making up 55/761 (7.2%) of somatic 
mutations reported in the APC database (Beroud 2006). Frameshift changes may have been 
discerned more easily than missense changes in this cohort as contamination of dysplastic 
epithelial tissue with normal cells may have made the missense changes less easy to 
appreciate with smaller peaks in the sequencing read-out whereas the disruption caused by a 
frameshift change is w&reobvious. Thus the somatic mutation spectrum in this group of 
adenomas appears to be different from that of adenomas from APC mutation carriers and 
from sporadic adenomas developing after somatic APC mutations. A marked difference also 
exists between the APC mutation spectrum in these and MAP adenomas. The latter tend to be 
almost exclusively G>T transversion changes occurring at GAA motifs and causing the 
creation of a stop codon, with almost no frameshift mutations detected (Lipton, Halford et al.
2003).
Unfortunately the predominance of frameshift mutations in our current group of adenomas 
does not point specifically to any one mechanism of DNA maintenance and repair, as might 
an increase of certain nonsense changes (given that there is no evidence of defective 
mismatch repair/MSI in the tumours studied) . The lack o f. ‘ nonsense changes in
itself is unusual although if one accepts that APC mutations are unnecessary for adenoma 
initiation and progression in these probands, the low overall number of APC mutations and 
the limited spectrum may be explained. Also, as has been previously mentioned, the use of
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DNA derived from paraffin embedded tissue for mutation detection is likely to give an 
underestimate of true mutation frequency due to DNA quality. As many studies have used 
paraffin derived tissue, it would be useful to know by what extent the ability to pick up APC 
mutations is reduced
It is certainly possible that patients such as no. 2 with a larger number of APC mutations may 
be harbouring germline APC mutations or deletions which have not been uncovered with 
careful testing including analysis for genomic deletions. Since this study’s inception, MLPA 
for APC deletions has become commonplace and we know that a number of families 
previously thought to be APC mutation negative harbour such changes. No other patient 
displayed such frequent mutations, yet this proband had been tested on several different 
occasions, and using different methods, for germline mutations. When a cloning technique 
was used to attempt to show segregation of the detected somatic mutations to one APC allele, 
results were not conclusive but there was some suggestion that one allele may have been 
consistently mutated in the soma. This gives indirect evidence of an occult germline mutation 
in APC in this proband.
In none of the adenomas tested was more than one pathogenic APC mutation detected. 
Because an area of about 400 codons only was examined, mutations in the 3’ and 5’ areas of 
the gene will invariably be missed (and colorectal adenomas rarely have the two hits in the 
same region of the gene, so missing at least one was almost inevitable). Our aim in 
concentrating on this region was to find the maximum number of mutations possible as it 
would be expected that a more 3’ or 5’ mutation or allelic loss would almost always be 
accompanied by a loss of function mutation in the MCR. It is difficult to obtain enough DNA 
from many small adenomas to perform extensive screening. One way to do so would be to 
obtain fresh frozen samples of adenomas. This is a difficult task given the ethics and logistics 
of such collection but hopefully an increased number of hospitals will persist in formalising 
such procedures. DNA from fresh frozen tumour material would also be more likely to allow 
deleterious mutations in a subset of adenoma cells to be appreciated.
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Table 6.1 Clinical Characteristics of Patients
N/R = data not available
Patient Age 
at dx
Polyp
no.
Colon
Cancer
Cancer site FHx Colectomy Polyps
studied
Cancer
studied
1 68 28 no recessive Yes 9
2 50 30 yes none Yes 33 1
3 19 75 no none Yes 25
4 52 50 yes none No 2 1
5 48 24 no none Yes 12
6 62 15 yes none No 8 1
7 70 26 yes dominant No 8 1
8 29 80 yes rectum dominant Yes 5 1
9 36 15 yes dominant No 5 1
10 72 110 no none Yes 5
11 56 15 no none No 7
12 40 18 no dominant Yes 8
13 55 10 yes sigmoid No 3 1
14 30 32 No none No 9
15 29 >100 yes none Yes 6 1
16 24 18 no dominant No 3
17 69 10 no dominant No 11
18 18 80 no dominant No 8
19 45 15 yes dominant No 14
20 52 10 yes dominant No 18
21 44 15 yes dominant No 7
22 55 15 no none No 9
23 64 >100 no none No 9
24 64 60 yes Carcinoid none No 19 1
25 61 20 yes none No 14
26 45 15 no dominant No 6
27 74 16 yes none No 4 1
28 62 12 yes dominant No 7 1
29 N/R 10 N/R No 8
30 N/R 8 N/R No 1
31 45 7 yes dominant No 1 1
32 62 6 no recessive No 2
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Table 6.2 Results of Cloning Seven Frameshift Mutations for Patient 2
Original
mutation
No. of clones with 
polymorphism codon 
1493 G>A
No. of mutations at 
each allele in 
clones.
Comment
codon 1489 ins T A in 8 clones 
G in 7 clones
0 with A allele 
7 with G allele
Mutation appears to occur at G allele 
only.
codon 1489 ins T A in 12 clones 
G in 3 clones
0 with A allele 
3 with G allele
Addition missense seen GAA>AAA 
codon 1494 in 2 clones.
Mutation appears to occur at G allele.
codon 1489 ins C A in 3 clones 
G in 3 clones
0 with A allele 
3 with G allele
Mutation appears to occur at G allele.
codon 1493 del A A in 13 clones 
G in 2 clones
0 with A allele 
0 with G allele
No mutations seen but A:G ratio 
suggests mutation occurs at G allele.
codon 1472 del 55 bp A in 13 clones 
G in 2 clones
0 with A allele 
0 with G allele
No mutations seen but A:G ratio 
suggests mutation occurs at G allele.
codon 1488-89 del TT A in 0 clones 
G in 15 clones
0 with A allele 
0 with G allele
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Table 6.3 Beta-catenin  Im m unohistochem istry w ith Levels o f  N uclear Stain ing and A ssociation with APC 
LO H  and M utation Status
P-catenin nuclear staining Number (%) 5q LOH (%) APC mutation 
(%)
0 none 61/149 (40.9) 2/61 (3) 9/61 (15)
1+ <10% 10/149 (6.7) 1/10(10) 3/10 (30)
2+ 10-25% 23/149(15.4) 3/23 (13) 3/23 (13)
3+ 25-50% 23/149 (15.4) 3/23 (13) 2/23 (9)
4+ >50% 29/149 (19.4) 6/29 (21) 9/29(31)
Table 6.4 The A ssociation B etw een  APC  L O H  and APC M utation Status
APC mutation + APC mutation -
LOH 10/199 (5%) 27/199 (14%)
No LOH 33/199 (17%) 129/199 (64%)
Table 6.5 Correlation Betw een A denom a Size and N uclear Expression o f P-catenin
P-catenin immunohistochemistry. Level of Nuclear staining.
Size (mm) 0 1+ 2+ 3+ 4+
<5 38 6 9 5 2
>5 23 4 14 17 27
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Table 6.4 P rim ary data for all adenom as studied
N paraffin = normal colorectal epithelial DNA
Tissue APC mutation 5q LOH B-cat immuno
TP5
3 SMAD4
Size (mm) Median and 
mean 
polyps 
number
Patient 1 3 and 4
N paraffin
adenoma 1 no 3+ 0 3
adenoma 2 no 1+ 3
adenoma 3 yes 0 no loss 2
adenoma 4 no 0 no loss 3
adenoma 5 no 0 no loss 2
adenoma 6 no 0 no loss 3
adenoma 7 no 2+ no loss 10
adenoma 8 no 3+ 0 3
adenoma 9 yes 0 8
Patient 2 no 6 and 7
N paraffin no
adenoma 1 SSCP change no 0 no loss 12
adenoma 2 no 0 no loss 13
adenoma 3 SSCP change no 0 no loss 8
adenoma 4 no 0 0 2
adenoma 5 codon 1580 del T no 0 0 2
adenoma 6 yes 0 1+ 10
adenoma 7 codon 1489 ins T no 3+ no loss 6
adenoma 8 no no loss 8
adenoma 9 no no loss 6
adenoma 10 codon 1431 del A 2+ 20
adenoma 11 codon 1489 ins C no 1+ no loss 10
adenoma 12 codon 1489 ins T no 1+ 10
adenoma 13 codon 1493 del A no 0 0 15
adenoma 14 no 0 no loss 5
adenoma 15 codon 1472 del 55 bp no 0 no loss 12
adenoma 16 2+ 26
cancer yes 2+ no loss cancer
Adenoma/ cancer 2+ 0 20
adenoma 17 SSCP change no 0 no loss 7
adenoma 18 codon 1488-89 del TT no 0 no loss 8
adenoma 19 no 0 no loss 4
adenoma 20 0 no loss 14
adenoma 21 yes 0 9
adenoma 22 no 0 3
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adenoma 23 no 0 3
adenoma 24 0 2
adenoma 25 1+ 2
adenoma 26 no loss 2
adenoma 27 no loss 2
adenoma 28 no loss 2
adenoma 29 no loss 2
adenoma 30 no loss 2
adenoma 31 0 0 2
adenoma 32 0 2
adenoma 33 0 2
Patient3 10 and 10
N paraffin
adenoma 1 no no loss 11
adenoma 2 no 4+ 0 no loss 11
adenoma 3 no 4+ 0 no loss 9
adenoma 4 no 0 0 no loss 10
adenoma 5 no 0 no loss 9
adenoma 6 no 0 no loss 3
adenoma 7 no no loss 5
adenoma 8 no no loss 11
adenoma 9 yes no loss 8
adenoma 10 yes no loss 8
adenoma 11 no no loss 6
adenoma 12 yes no loss 5
adenoma 13 yes 8
adenoma 14 NI 8
adenoma 15 NI no loss 11
adenoma 16 NI 12
adenoma 17 NI 12
adenoma 18 NI 4+ 15
adenoma 19 codon 1309 del 5 bp yes 4+ 1+ no loss 8
adenoma 20 4+ 0 12
adenoma 21 SSCP change 4+ no loss 13
adenoma 22 no 4+ 1+ 10
adenoma 23 no 4+ no loss 22
adenoma 24 no 4+ 0 10
adenoma 25 no no loss 4
Patient 4 18 (mean)
N paraffin no
adenoma 1 no 2+ no loss 30
cancer no 2+ no loss
adenoma 2 no 0 6
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Patient 5 L1331L, A>T nt 3993 6 and 7.5
IN paraffin
adenoma 1 NI 0 2
adenoma 2 1472 del C NI no loss 10
adenoma 3 NI 16
adenoma 4 NI 6
adenoma 5 NI 3+ 0 5
adenoma 6 NI 4
adenoma 7 NI 0 0 3
adenoma 8 NI 0 6
adenoma 9 NI 4
adenoma 10 NI 2+ no loss 6
adenoma 11 NI 2+ no loss 10
adenoma 12 SSCP change NI 2+ no loss 18
Patient 6 NI 2 and 4
N paraffin NI
adenoma 1 NI 0 no loss 6
adenoma 2 NI 0 15
cancer NI 0 no loss cancer
adenoma 3 0 2
adenoma 4 0 2
adenoma 5 0 2
adenoma 6 0 2
adenoma 7 0 2
adenoma 8 0 2
Patient 7 2 and 2
adenoma 1 no 0 2
adenoma 2 no 0 0 2
adenoma 3 yes 2
adenoma 4 yes no loss 2
adenoma 5 C1397X yes no loss 2
cancer yes 2+
adenoma 6 0 2
adenoma 7 0 2
adenoma 8 0 2
Patient 8 5 and 8
adenoma 1 NI 2+ 0 5
adenoma 2 NI 2+ 0 9
adenoma 3 NI 0 4
adenoma 4 NI 0 2
cancer NI 0 1+ cancer
adenoma 5 codon 1556 del A NI 2+ 21
Patient 9 5 and 5
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normal
adenoma 1 no 0 cancer
cancer no 4
adenoma 2 no 7
adenoma 3 no 0 7
adenoma 4 no 5
adenoma 5 no 3
Patient 10 3 and 3
adenoma 1 no 0 0 3
adenoma 2 no 0 0 4
normal no
adenoma 3 no 0 0 3
adenoma 4 no 0 3
adenoma 5 no 0 3
Patient 11 no 3 2 and 2
normal
adenoma 1 0 2
adenoma 2 V1404C, O G  nt4211 yes 1+ 1
adenoma 3 yes 1+ 2
adenoma 4 yes 1+ 2
adenoma 5 yes 2
adenoma 6 yes 2
adenoma 7 yes 2
Patient 12 4 and 4
adenoma 1 NI 0 6
adenoma 2 NI 0 4
adenoma 3 NI 3
adenoma 4 NI 3
adenoma 5 NI 0 0 3
adenoma 6 NI 2+ 0 3
adenoma 7 NI 2+ 0 9
adenoma 8 SSCP change NI 2+ 0 4
Patient 13 11 and 14
adenoma 1 yes 2+ 11
adenoma 2 no 0 0 8
cancer no 0 cancer
cancer no 0 cancer
Adenoma 3+ 
invasion no 0 18
Adenoma 4+ 
invasion codon 1556 del A 1+ 24
adenoma 5 no 11
Patient 14 3 and 3
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adenoma 1 no 7
adenoma 2 no 1+ 3
adenoma 3 no 3
adenoma 4 no 1+ 3
adenoma 5 no 2
adenoma 6 no 2
adenoma 7 no 2
adenoma 8 no 5
adenoma 9 no 4
Patient IS 6 and 6
adenoma 1 no
adenoma 2 no 4
adenoma 3 no 9
Cancer no 0 cancer
cancer no cancer
adenoma 4 no 0 6
adenoma 5 no 9
adenoma 6 no 0 6
cancer no cancer
Patient 16 9 and 8
adenoma 1 NI no loss 10
adenoma 2 NI no loss 9
adenoma 3 NI 2+ no loss 6
Patient 17 8 and 9.5
adenoma 1 NI 3+ no loss 15
adenoma 2 NI 3+ no loss 7
adenoma 3 NI 3+ 10
adenoma 4 NI 3+ 6
adenoma 5 NI 3+ 1+ 15
adenoma 6 NI 3+ 8
adenoma 7 NI no loss 7
adenoma 8 NI no loss 8
adenoma 9 NI no loss 6
adenoma 10 NI 2+ 15
adenoma 11 NI 7
Patient 18
adenoma 1 no 0 3
adenoma 2 yes 3
adenoma 3 yes no loss 1
adenoma 4 yes no loss 1
adenoma 5 yes no loss 1
adenoma 6 yes 0 1
adenoma 7 yes 0 1
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adenoma 8 yes 0 1
Patient 19 6 and 6
Normal
adenoma 1 NI 0 0 2
adenoma 2 NI 0 0 2
adenoma 3 NI 4+ no loss 8
adenoma 4 NI 4+ no loss 6
adenoma 5 NI 4+ no loss 3
adenoma 6 NI 4+ 0 10
adenoma 7 NI no lesion
adenoma 8 NI 4+ 0 15
adenoma 9 NI 3+ 0 5
adenoma 10 NI 3+ 0 7
adenoma 11 NI no loss 1
adenoma 12 NI 0 no loss 6
adenoma 13 NI 0 no loss 5
adenoma 14 NI 0 no loss 9
Patient 20 8 and 8.5
normal no lesion
adenoma 1 del GA codon 1355 no 4+ no loss 6
adenoma 2 del GA codon 1355 no 4+ no loss 10
adenoma 3 no 4+ no loss 10
adenoma 4 no 4+ no loss 8
adenoma 5 del GA codon 1355 no 4+ no loss 6
adenoma 6 del GA codon 1355 no 4+ no loss 4
adenoma 7 del GA codon 1355 yes 4+ no loss 8
adenoma 8 no 4+ no loss 8
adenoma 9 yes 4+ no loss 8
adenoma 10 del GA codon 1355 yes 4+ no loss 8
adenoma 11 no 4+ no loss 8
adenoma 12 del GA codon 1355 no 4+ no loss 8
adenoma 13 no 4+ no loss 8
adenoma 14 no 3+ 1+ 16
adenoma 15 yes 3+ 10
adenoma 16 no 3+ 8
adenoma 17 no 3+ 13
Patient 21 3 and 3
adenoma 1 no 0 no loss 4
adenoma 2 no no loss 3
adenoma 3 yes no loss 3
adenoma 4 no 0 no loss 3
adenoma 5 SSCP change no 0 3
adenoma 6 no 3
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adenoma 7 no 2
Patient 22 2 and 3
adenoma 1 no 2
adenoma 2 no 2
adenoma 3 yes 8
adenoma 4 codon 1309 del 5bp no 4
adenoma 5 codon 1309 del 5bp no 5
adenoma 6 yes 1
adenoma 7 no 1
adenoma 8 SSCP change no 1
adenoma 9 codon 1560 ins C no 1
Patient 23 4 and 4
adenoma 1 codon 1464 del AG no 2
adenoma 2 yes 3
adenoma 3 no 4
adenoma 4 no 6
adenoma S no 4
adenoma 6 no 6
adenoma 7 no 7
adenoma 8 no 1
adenoma 9 no 5
Patient 24 4 and 5
cancer no cancer
adenoma 1 no 8
adenoma 2 T>A nt 4107, G1369G yes 15
adenoma 3 yes 15
adenoma 4 no 3
adenoma 5 no 4
adenoma 6 no 3
adenoma 7 codon 1309 del 5bp yes 15
adenoma 8 codon 1309 del 5bp yes 3
adenoma 9 codon 1309 del 5bp yes 3
adenoma 10 no 4
adenoma 11 no 2
adenoma 12 no 4
adenoma 13 no 6
adenoma 14 no 4
adenoma 15 no 2
adenoma 16 no 2
adenoma 17 no 2
adenoma 18 no 1
Patient 25 2 and 2
adenoma 1 SSCP change no 2
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adenoma 2 no 2
adenoma 3 codon 1309 del 5bp yes 2
adenoma 4 yes 2
adenoma 5 no 2
adenoma 6 no 4
adenoma 7 no 3
adenoma 8 T>A nt 4107, G1369G no 2
adenoma 9 no 2
adenoma 10 no 2
adenoma 11 no 2
adenoma 12 no 2
adenoma 13 no 2
adenoma 14 no 1
Patient 26 3 and 3
adenoma 1 no 0 2+ 4
adenoma 2 no 0 0 3
adenoma 3 no 0 0 2
adenoma 4 no 0 0 2
adenoma 5 no 0 5
adenoma 6 no 0 4
Patient 27 3 and 3
adenoma 1 5
cancer 0 no loss
adenoma 2 3+ 0 no loss 3
adenoma 3 0 2
adenoma 4 0 3
Patient 28 8 and 7
adenoma 1 no 0 no loss 10
cancer no 4+ 0 cancer
cancer no 2+ loss cancer
adenoma 3 no 0 no loss 6
adenoma 4 no 0 5
adenoma 5 no 0 no loss 5
adenoma 6 codon 1411 del T no 0 0 12
adenoma 7 codon 1411 del T no 3+ 0 11
Patient 29 2 and 2
adenoma 1 2+ 2
adenoma 2 2+ no loss 3
adenoma 3 2+ no loss 2
adenoma 4 0 2
adenoma 5 0 0 2
adenoma 6 0 2
adenoma 7 0 2
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adenoma 8 no loss 2
Patient 30 3
adenoma 1 codon 1569 del 5bp, ATGAT no 0 3
Patient 31 6
cancer no 0 2+
adenoma no 0 2+ 6
Patient 32 12
adenoma 1 NI 3+ no loss 10
adenoma2 NI 3+ no loss 15
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Chapter 7 Refining the Amsterdam Criteria and Bethesda Guidelines -  
testing algorithms for the prediction of mismatch repair mutation status in 
the Familial Cancer Clinic
7.1 Introduction
HNPCC is currently diagnosed on molecular grounds using MMR mutation screening, aided 
by MSI testing of tumour DNA and immunohistochemistry for MMR proteins as outlined in 
chapter one. Selection of families for molecular investigation of HNPCC is usually based on 
imperfect methods (Amsterdam Criteria or Bethesda Guidelines -  Chapter one and tables 
7.1-3). Expense and resources prohibit germline mutation testing on all persons with 
suspicious personal or family histories. Wijnen et al have shown that these algorithms can be 
increased in sensitivity using additional clinical data in a quantitative model (Wijnen, Vasen 
et al. 1998). Wijnen’s model, whilst appealing had not been validated in an independent data 
set. We wished to see whether it remained valid in these circumstances and also to see if 
using the detailed information we could collect regarding family history and tumour 
pathology we could improve on this algorithm.
A family history of CRC is one of the most common reasons for referral to the Genetics or 
Familial Cancer clinic. Regular surveillance, generally using colonoscopy, can greatly reduce 
the risk of disease (Jarvinen, Aamio et al. 2000). However, families with apparently similar 
histories may have quite genetic different origins and CRC risks, including a variety of single 
gene disorders, ‘complex’ genetic inheritance or aggregation resulting from shared 
environment or chance. It is important to diagnose the underlying cause of familial CRC, 
wherever possible, because there are implications for screening regimens and risks to 
relatives.
One of the most common Mendelian CRC syndromes is HNPCC which results from 
germline mutations in DNA mismatch repair (MMR) genes, principally MSH2, MLH1 and 
MSH6 (Peltomaki 2003). HNPCC is characterised by early-onset carcinomas of the large 
bowel and endometrium, with more modestly increased risks of cancers of other sites (see 
Chapter one). Almost all colorectal and endometrial cancers and most colorectal adenomas in
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HNPCC show MSI, as a result of defective MMR (Wheeler, Bodmer et al. 2000)(Loukola, 
Eklin et al. 2001). HNPCC tumours also usually show loss of the protein derived from the 
mutated gene (Lindor, Burgart et al. 2002). About 10-15% of sporadic CRCs are MSI+ 
owing to loss of MLH1 expression, although sporadic adenomas rarely show these features 
(Lindor, Burgart et al. 2002)(Loukola, Salovaara et al. 1999)(Iino, Simms et al. 2000).
Most Mendelian CRC syndromes have distinct clinical features, such as profuse polyposis, 
but the tumours in HNPCC cannot readily be distinguished from their sporadic counterparts. 
Both HNPCC and sporadic MSI+ cancers, tend to be right sided, mucinous, show tumour 
infiltrating lymphocytes and have a pushing margin. It is increasingly recognised, therefore, 
that HNPCC should be a molecular diagnosis, for example based on: (i) a pathogenic MSH2, 
MLH1 or MSH6 germline mutation; or (ii) multiple cancers (or a colorectal adenoma) from a 
family with MSI or loss of MLH1 expression; or (iii) loss of MSH2 and/or MSH6 expression 
in one or more of a family’s tumours. Even if the causative germline mutation is cryptic, 
making or excluding the molecular diagnosis of HNPCC is important not only for 
determining risks to relatives, but also for deciding the screening protocol for those at risk 
(Lynch, Smyrk et al. 1995).
It is impractical to screen every case of familial bowel cancer for molecular changes 
suggestive of HNPCC; screening must be targeted to certain families using the 
clinicopathological features of the pedigree, the proband and if possible tumour pathology. 
The so-called Amsterdam Criteria were originally used to diagnose HNPCC if at least three 
family members in two or more generations had CRC, one affected person was a first degree 
relative of the other two, and at least one individual was diagnosed before the age of 50 
(Vasen, Mecklin et al. 1991). The Amsterdam Criteria have been highly successful, with 
estimated sensitivity and specificity of 60% and 70% (Liu, Wahlberg et al. 2000)(Rodriguez- 
Bigas, Vasen et al. 1997). Certain deficiencies have, however, become increasingly 
recognised. For example, the original Amsterdam Criteria did not take account of extra­
colonic cancers, patients with new MMR mutations were not covered, and some families 
with multiple polyps, but without profuse polyposis, were erroneously classed as putative 
HNPCC. The Amsterdam Criteria II were introduced in 1999 (Chapter one and table 7.1) 
and Syngal et al estimated them to have sensitivity of 78% and specificity of 61% (Syngal, 
Fox et al. 2000)(Vasen, Watson et al. 1999). Even these criteria however, left out a number 
of HNPCC associated malignancies which we now recognise.
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The Bethesda Guidelines were introduced to indicate which families should proceed to MSI 
testing prior to screening for MMR mutations (tables 7.2-3) (Rodriguez-Bigas, Boland et al. 
1997). The Bethesda Guidelines were deliberately much less restrictive than the Amsterdam 
Criteria. Using known MMR mutation carriers, their sensitivity has been estimated as 94%, 
but with specificity of only 25% (Syngal, Fox et al. 2000). Recently, modified Bethesda 
Guidelines were produced (Chapter one and table 7.3). The criteria for MSI or IHC testing 
have been broadened such that a person diagnosed at the age of 59 and with no family history 
of cancer may be offered testing. These criteria will probably have impressive sensitivity 
with very low specificity.
Wijnen et al set out to provide a quantitative improvement on the Amsterdam Criteria and 
Bethesda Guidelines by setting up a logistic regression model to predict the probability of 
HNPCC mutation in a given family. 184 families were recruited and all had mutation testing 
for MLH1 and MSH2. 92 of the families met Amsterdam criteria and 47 were found to have 
pathogenic HNPCC mutations. All families had at least three colorectal cancers diagnosed 
and two thirds of families had at least one endometrial cancer diagnosed. He used the 
following predictive variables: mean age at diagnosis of CRC; Amsterdam Criteria-positive 
or -negative; number of family members with CRC; the number with endometrial cancer; 
presence of a patient with other cancers related to HNPCC; and presence of a patient with 
multiple synchronous or metachronous cancers (Wijnen, Vasen et al. 1998). In univariate 
analysis, factors strongly associated with mutations in HNPCC genes were younger age at 
diagnosis of colorectal cancer, fulfilment of the Amsterdam Criteria, a higher number of 
patients with colorectal cancer in a family, the presence of endometrial cancer, number with 
endometrial cancer, the presence of small bowel cancer, the presence of multiple colorectal 
cancers in one or more family members and the presence of endometrial and CRC in one 
person. In the multivariate analysis, mean age at diagnosis of CRC, fulfilment of the 
Amsterdam Criteria and the presence of endometrial cancer were the only independent risk 
factors.
The work of Wijnen et al established the principle of a practical, quantitative improvement 
on the Amsterdam Criteria and arguably the model has been under-used in clinical practice. 
Three potential problems remain. First, the model of Wijnen et al has not yet been verified in
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an independent data set. Second, there may be good historical reasons for including a 
composite variable such as the Amsterdam Criteria in the regression analysis, but this may 
lead to unnecessarily complex input data. Third, up to 30% of HNPCC cases have germline 
MMR mutations which are not detected using standard techniques and a model needs to take 
into account HNPCC diagnosed by MSI testing and/or immunohistochemistry (Scott, 
McPhillips et al. 2001).
I therefore set out both to test the Amsterdam Criteria II and the Wijnen model as predictors 
of HNPCC which has been diagnosed or excluded using a combination of germline mutation 
screening, MSI analysis and immunohistochemistry. I then set up new models of our own. 
Finally, I verified all the models in an independent set of families. Our models have potential 
for targeting molecular testing for HNPCC and for allowing accurate screening advice to be 
given to families in which no live affected persons are available for genetic testing.
7.2 Methods 
7.2.1 Selection of Families
Families were recruited by myself and Mrs Carole Cummings. Two hundred-and-fifty 
families were recruited from the Cancer Research UK Family Cancer Clinic, St Mark’s 
Hospital, Harrow and from the Family Cancer Clinic, Guy’s Hospital, London. Our inclusion 
criteria (Table 7.4) were similar to the Bethesda Guidelines. Probands from all families gave 
informed consent and approval was obtained form the relevant Human Ethics Committees. 
Families from whom archival tumour tissue specimens could not be retrieved were excluded; 
families without a living affected person were not specifically excluded as one of the study 
aims was to provide useful information to such families. Pedigree information was obtained 
from family members and the presence of cancer confirmed, wherever possible, from hospital 
records, pathology reports, cancer registry records or death certificates. Apart from 
distinguishing between colorectal adenomas and carcinomas, histological tumour sub-types 
were not taken into account when deciding whether or not to include a family. Each included 
family was given a score in each of 10 categories (Table 7.5).
7.2.2 Collection of Blood and Tumour Samples
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Blood samples were obtained by me, Dr Ella Barclay, Dr Isis Dove-Edwin and Mrs Carole 
Cummings. Informed consent was obtained from patients or their next-of-kin and 10ml blood 
sampled where possible. Samples of all colorectal tumours and endometrial cancers from 
each family were requested by myself from the pathology archive at the hospital in which the 
operation occurred. A maximum of 3 tumours from any one family was obtained and for 
most families, we were able to obtain at least two tumours. In a number of families this 
included advanced adenomas. Tumour histology was taken from pathology reports or 
assessed by myself and Dr A.T. Eftekhar Sadat (pathologist) where no reports were provided. 
DNA was extracted from blood by standard methods. Neoplastic and normal areas were 
microdissected by myself from archival tissue and DNA extracted using a simple proteinase 
K digestion. Neoplastic tissue was marked on slides with reference to an H&E stained section 
in order to minimise contamination of tumour with normal tissue.
7.2.3 Mutation Analysis
Screening for MLH1, MSH2 and MSH6 mutations was performed in all families by the 
Kennedy Galton Centre, Northwick Park Hospital, Harrow. Where possible, we screened the 
person affected by colorectal or endometrial carcinoma at the youngest age in the family. In 
some families, mutation screening was undertaken as part of a clinical service by the 
Kennedy Galton Centre. Genomic DNA was amplified for each of the exons of the MLH1 
and MSH2 genes and subjected to denaturing gradient gel electrophoresis followed by 
sequencing of bandshifts (Wijnen, Khan et al. 1996)(Liu, Wahlberg et al. 1998). If no 
mutation was found, MLPA was used for the detection of medium-sized deletions in MSH2 
(Ji and King 2001). MSH6 was then screened if no change was found in MSH2 or MLH1. 
Missense, truncating and deletion mutations could be uncovered using these methods, and 
assessed using positive control samples.
7.2.4 Microsatellite Instability Testing
All available colorectal and endometrial carcinomas and colorectal adenomas were tested for 
MSI by myself. MSI status was scored by looking at a combination of the mononucleotide 
markers BAT26 and TGFpRII and the dinucleotide markers D5S346, D18S487 and D18S46. 
MSI was scored if 2 or more markers or BAT26 alone showed instability in that tumour.
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Although it has become standard to use Bethesda markers for MSI testing, excellent data is 
available supporting the use of mononucleotide repeat markers alone to distinguish MSI-H 
cancers (Loukola, Eklin et al. 2001)(Cravo, Lage et al. 1999)(Samowitz, Slattery et al. 1999).
7.2.5 Immunohistochemistry
Immunohistochemistry was performed by Miss Victoria Johnson and myself. Colorectal and 
endometrial carcinomas and colorectal adenomas were tested for loss of MLH1, MSH2 and 
MSH6 expression. 5jam tumour sections were analysed using the PC56 (Merc Biosciences), 
PC57 (Merc Biosciences) and G70220 (Becton Dickinson) antibodies respectively at 1/100 
dilution after pressure cooking the sections for 4 min. After counterstaining with 
haematoxylin, all of the slides were examined by myself and a subset was examined by Miss 
Victoria Johnson and Dr Eftekhar Sadat. Protein expression was scored as negative if there 
was no nuclear staining in tumour areas and definite nuclear staining in normal tissue. For 
tumours without normal tissue, sections containing normal tissue were used on the same slide 
to provide a control. Sections which failed to show any staining were repeated once.
7.2.5 Determining HNPCC status
Assignment of HNPCC status was inevitably complex. I scored families as HNPCC-positive 
if they fulfilled one or more of the criteria shown in Table 7.6. Category 6 is justified by the 
facts that sporadic MSI+ cancers should all lose all MLH1 expression owing to 
transcriptional silencing and that there are no other known causes for sporadic MSI-H cancer. 
Thus, if a tumour is definitely MSI-H but MLH1 protein expression is retained, there must be 
a germline cause for disruption of MMR. Some such patients may have missense mutations 
which do not abolish protein expression but may produce a dysfunctional protein. Categories 
7 and 8 take account of the fact that occasional phenocopies can occur in HNPCC families 
and can be justified as follows. It is estimated that 10% -15% of sporadic colorectal and 
endometrial cancers are MSI+ or lose MLH1 expression through transcriptional silencing and 
that HNPCC accounts for 2-3% of all of these cancers. It follows that a single, unselected 
MSI+, MLH1-absent cancer is probably sporadic, that a family with two of two MSI+ or 
MLH1-absent cancers is almost certainly HNPCC, a kindred with two of three MSI+ or
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MLH1-absent cancers is probably HNPCC and a family with one of two MSI+ or MLH1- 
absent cancers is probably not HNPCC. Mutation-negative families in which one of two (or a 
smaller proportion) of cancers were MSI+ or MLH1-absent were therefore scored as non- 
HNPCC. Mutation-negative families/cases with only one cancer available and with MSI and 
MLH1 loss in this cancer were deemed unclassifiable and were excluded from the analysis. 
Category 5 is justified by the fact that sporadic adenomas show microsatellite instability in 
<3% of cases and sensitivity of MSI-H in an adenoma for HNPCC is 95%<.
7.2.6 Second Family Set
In order to verify each model obtained from our original 250 families, I tested it against an 
independent set of 94 kindreds from the Family Cancer Clinic, Oxford Regional Genetics 
Service. All Oxford families had undergone MMR gene mutation analysis only, as was 
typical at the time for many Departments of Clinical Genetics in the UK. We considered for 
the study all families who had undergone mutation testing and selected families using the 
same criteria as for the St Mark’s/Guy’s families (Table 7.6).
7.2.7 Statistical Methods
Statistical analysis was performed with the help of Ian Tomlinson and with advice from 
Richard Houlston and Mike Bradbum. STATA 7.0™ was used with the family as the unit of 
analysis. A comparison of the features of families with and without HNPCC was carried out 
initially using logistic regression, and then confirmed using the %2 test for categorical 
variables and the Kruskal-Wallis test for continuous variables. Multivariate analysis was 
performed by logistic regression using a stepwise approach to identify independent predictors 
of HNPCC. The final model selected was based on the values of the pseudo R and receiver- 
operator curves (ROCs).
7.3 Results
All 250 families from St Mark’s/Guy’s met the Bethesda Guidelines. One hundred-and-ten 
families met the Amsterdam Criteria II and 28 met the Criteria but had no affected person 
under 50 years of age. Thirty-eight families had a single family member affected with CRC at 
less than 45 years (Table 7). The 74 patients in the ‘other pedigrees’ group included sibships 
and parent-child pairs affected by CRC with one member under 45, and persons with two
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CRCs and/or endometrial cancers aged over 45. Sixteen percent of families contained 
persons diagnosed with endometrial cancer. HNPCC was diagnosed according to our criteria 
(Table 7.5) in 67/250 (27%) of families. Of these, 34 had pathogenic mutations (25 in MLH1, 
eight in MSH2 and one in MSH6); of the 33 mutation-negative families with HNPCC, 21 had 
loss of MSH2 expression and MSI+ cancers, five had absent MLH1 expression in two MSI+ 
cancers, two had two MSI+ cancers with loss of MLH1 expression confirmed in one of these, 
two had two MSI+ cancers but no immunohistochemistry data, two had one MSI+ cancer 
with no loss of MLH1 or MSH2 expression and one had adenomas which were MSI+. The 
features of patients diagnosed as HNPCC on the basis of germline mutations did not, in 
general, differ significantly (details not shown) from those diagnosed by MSI and/or 
immunohistochemistry (implying that cryptic MMR mutations have similar effects to 
detectable changes). The only exception was that families diagnosed by MSI and/or 
immunohistochemistry tended to have more individuals affected (x i-9.4, p=0.002), perhaps 
because a greater supply of tumours facilitated molecular diagnosis. Another reason may be 
that families who knew of a number of persons affected also knew details of the family 
history -  such as the treating hospitals - better than others.
Single variable analysis (Table 7.5) showed that those in pedigree group 1 (Amsterdam 
Criteria II) were more likely to be HNPCC, as were families with: apparently dominant 
inheritance; more persons affected by CRC; lower mean age at diagnosis of CRC; low 
youngest age at diagnosis of colorectal or endometrial cancer; more persons with two 
primary tumours (colorectal or endometrial cancer); and more women with endometrial 
cancer. Families with five or more adenomas were less likely to be HNPCC. Number of 
persons affected with other cancers and the location of CRCs (right/left-sided) were not 
associated with HNPCC.
The Amsterdam Criteria II (category 1 families) gave 78% sensitivity, 69% specificity, 48% 
positive predictive value (PPV) and 71% families correctly classified in the St Mark’s/Guy’s 
families. We then attempted to improve upon the Amsterdam Criteria II using multivariate 
analysis. Our first observation was that no individual in category 2 (fulfilling Amsterdam 
Criteria II except that all affected persons were >50 years) had HNPCC by any of the 
definitions in table 7.5. This was an important finding for genetic testing purposes, but it 
inevitably led to this category being dropped from the logistic regression analysis. Categories
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2, 3 and 4 were therefore combined for further analysis. We found that the Amsterdam 
Criteria II (variable 1/vl) were improved as a predictor of HNPCC by the incorporation into 
the model of: (i) v3 ‘number of individuals with more than one primary colorectal or 
endometrial cancer’ (OR=2.73, 95%CI 1.37-5.42, p=0.004); (ii) v6 ‘mean age of CRC in the 
family’ (OR=0.94, 95%CI 0.91-0.97, p<0.001); (iii) v4 ‘number of individuals with 
endometrial cancer’ (OR=2.46, 95%CI 1.24-4.89, p=0.010); and (iv) v9 ‘number of 
individuals with 5 or more adenomas’ (OR=0.24, 95%CI 0.12-0.49, p<0.001). The 
corresponding logit equation (Table 2) was
Ln(p/(l+p» = 1.04 + 1.89 vl + 1.00 v3 + 0.90 v4 -  0.06 v6 -  1.42 v9
This “Amsterdam-plus” model was associated with pseudoR of 0.35. The Hosmer- 
Lemeshow test showed non-significant residual variation, demonstrating a good fit of the 
model (x28=4.8, p=0.45).
We then determined whether a simpler “Alternative model” which did not include the 
Amsterdam Criteria as a variable might perform as well or better than the other models. The 
best fitting Alternative model resulted in use of variables v5 ‘number of CRCs in the family’ 
(OR=1.39, 95%CI 1.09-1.77, p=0.009) and v7 ‘age of youngest with colorectal or 
endometrial cancer’ (OR=0.93, 95%CI 0.90-0.96, p<0.001) instead of vl and v6. The other 
variables in the Alternative model were: v9 ‘number affected with more than five adenomas’ 
(OR=0.24, 95%CI 0.11-0.51, p<0.001); v3 ‘number of individuals with more than one 
primary colorectal or endometrial cancer’ (OR=2.97, 95%CI 1.48-5.96, p=0.002) and v4 
‘number of individuals with endometrial cancer’ (OR=3.27, 95%CI 1.75-6.13, p<0.001). The 
logit equation was
Ln(p/(l+p» = 1.06 + 1.09 v3 + 1.19 v4 + 0.33 v5 - 0.08 v7 -1.43 v9
This model was associated with pseudoR2 of 0.32. The Hosmer-Lemeshow goodness of fit 
test showed non-significant residual variation (%VT 1.17, p=0.193).
Figure 7.1a shows the ROCs which demonstrate the trade-off between sensitivity and 
specificity in our two models and, for comparison, the Wijnen model as applied to the St
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Mark’s/Guy’s data set. All three models performed well and similarly, with an area under the 
curve of about 0.86 (compared with the ideal of 1.0). For the Amsterdam-plus model, we 
suggest that a probability cut-off of p>0.15 could be used for further molecular investigation 
of families with suspected HNPCC; for the Alternative model, we suggest a threshold of 
p>0.12 (Figure 7.1a). For both models, these thresholds produce over 95% sensitivity, around 
50% specificity and 40% PPV. Using a cut-off of p>0.05, the Wijnen model had similar 
sensitivity, specificity and PPV to our two models. These sensitivity, specificity and PPV 
values seem pragmatic for use in a clinical setting and the higher sensitivity compared with 
the Amsterdam Criteria II was gained at the expense of only modestly decreased specificity. 
The extra sensitivity of the quantitative models was shown when considering the fifteen true 
HNPCC families which did not fulfil the Amsterdam Criteria II. Using the p>0.12 cut-off, the 
Alternative model correctly predicted 13/15 families to be HNPCC. Seven of the 13 were 
isolated, early-onset cases of colorectal cancer, the remaining pedigrees having a 
predominantly early-onset colorectal cancer phenotype without an extensive family history.
The Wijnen, Amsterdam-plus and Alternative models were then verified using the patient set 
from Oxford which comprised twenty mutation carriers (21%). One of the Oxford families in 
category 2 (no-one affected under 50, but otherwise Amsterdam II-positive) had a germline 
MMR mutation, although no patient with 5 or more adenomas did so. The Amsterdam 
Criteria II performed slightly better in the Oxford data set than in the St Mark’s/Guy’s 
families, with 85% sensitivity, 62% specificity and 38% PPV. The ROCs for the three 
quantitative models are shown in Figure 7.1b and are similar to those obtained using the St 
Mark’s/Guy’s data set, with the exception that the Wijnen model performed slightly worse. 
With a p>0.05 cut-off, the Wijnen model gave 85% sensitivity and 40% specificity; the 
Amsterdam-plus and Alternative models each gave sensitivity of 90-95% and specificity of 
30% using cut-offs of p>0.15 and p>0.12 respectively.
7.4 Discussion
The aims of all clinicopathological methods for predicting HNPCC are to improve diagnosis 
and avoid unnecessary laboratory investigations whilst not missing families who may appear 
to be at moderate risk only. These aims are often in conflict and the result is that no optimal 
model has emerged, owing to different opinions about the correct balance between sensitivity 
and specificity. The result is that historical or consensus criteria have predominated over
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analytical models such as that of Wijnen et al (Wijnen, Vasen et al. 1998). In our opinion, a 
model should have a minimum of about 90-95% sensitivity and then aim to maximise 
specificity within that constraint. The Bethesda Guidelines, for example, have great emphasis 
on sensitivity. It is likely however that a significant proportion of patients tested because they 
fit into the modified Bethesda Criteria may be found to be MSI-H or MLH1 absent due to 
somatic methylation of MLH1 leading to a waste of resources in genetic testing. On the other 
hand, the Amsterdam Criteria II is too specific and around one third of families with germline 
MMR mutations will be missed.
I have tested the Wijnen HNPCC prediction model and two new models in two data sets. The 
conclusions are four-fold. First, I have confirmed the general finding of Wijnen et al that the 
Amsterdam Criteria II can be improved upon using quantitative approaches. Whether such 
approaches will prove too cumbersome for the genetic clinic remains to be seen, but the 
calculations proposed by Winjen and ourselves require little more than a pedigree and a 
calculator. Second, I have shown that the Wijnen model using a cut-off of p>0.05 (rather than 
0.20 originally suggested) is an improvement on the Amsterdam criteria II and Bethesda 
Guidelines (when both of our data sets are considered). The Wijnen model also holds when 
HNPCC is detected using MSI analysis and immunohistochemistry in addition to mutation 
screening.
Third, our own models slightly out-perform the Wijnen model. Our Alternative model which 
does not require knowledge of or a pedigree large enough to obtain the Amsterdam Criteria 
also requires simpler input data than the Wijnen and Amsterdam-plus models (Table 8). The 
incorporation of new variables -  in particular, presence of multiple colorectal polyps and 
number of individuals with more than one primary colorectal or endometrial cancer -  can 
improve the prediction of HNPCC. It is also interesting that in the Alternative model, the 
youngest affected family member appears to be a better predictor of HNPCC than the average 
age affected, probably because one ‘phenocopy’ affected with cancer late in life can 
substantially distort the mean age affected within a family.
Fourth, I have shown that some aspects of the Amsterdam Criteria, such as the requirement 
for an individual affected at less than 50 years of age, were particularly well judged. 
However, the importance of other variables which have been supposed to be consistent,
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independent predictors of HNPCC, particularly in the Bethesda Criteria may need re­
assessment: there was, for example, no predominance of right- over left-sided colorectal 
cancers in our data set. Moreover, the presence of cancers apart from those of the colorectum 
and endometrium was not associated with HNPCC. This finding probably results from the 
relatively low risks of other cancers in HNPCC mutation carriers, although there may also 
have been some referral bias in our data set towards bowel cancer (Watson 2003).
Any of the three quantitative models could be substituted for the Amsterdam Criteria II in the 
family cancer clinic. Although the optimal cut-offs require refinement and may depend on the 
amount of mutation testing that a unit is prepared to do, all three models can give improved 
sensitivity (85-95%). Specificity (30-55%) and PPV (30-45%) are lower, but tolerable in a 
diagnostic setting and better than the Bethesda Guidelines. I suggest that all three quantitative 
models undergo further evaluation to assess their relative merits. If one is shown to be 
superior, it should be used, but if all are shown to have similar performance, then the 
Alternative model should be used.
In clinical practice, the family data should be ascertained and the chosen model applied. 
Families would be subject to further testing if an HNPCC risk greater than the threshold was 
predicted. Two alternative approaches can then be used. First, if the clinic has much easier 
access to germline mutation screening than to tumour analysis, mutation testing on the 
youngest available affected family member should be undertaken. If no mutation were 
detectable or no DNA from an affected individual were available, immunohistochemistry and 
MSI testing should be carried out and families classified as true HNPCC using the same 
diagnostic criteria which we have used above (Table 7.6). Second, if there exists ready access 
to local Histopathology expertise, I propose using MSI and immunohistochemistry to target 
mutation screening (and to diagnose HNPCC where mutations are cryptic) using the flow 
chart shown in Figure 7.3. The decision-making process attempts to take account of factors 
such as phenocopies in HNPCC families and the possibility that HNPCC adenomas might not 
be MSI+ which is around 50%, although high quality analysis is assumed. If the decision tree 
were felt to be too complex, it could be simplified by routinely performing 
immunohistochemical and MSI analyses together.
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In summary, I have shown that quantitative models can provide better prediction of HNPCC 
than the Amsterdam Criteria II or the Bethesda Guidelines. In my opinion, either the existing 
Wijnen model or our Alternative model should be used in clinical practice, a simple 
computer program being sufficient to calculate risks. Families for whom the probability of 
HNPCC exceeds a suitable threshold can then be subject to thorough investigation using a 
combination of mutation screening, MSI analysis and immunohistochemistry. Using these 
methods, a greater number of families can be correctly classified as true HNPCC and 
screening can be undertaken with confidence and an appropriate risk:benefit ratio.
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Table 7.1. Amsterdam Criteria II
All of the following must apply for a putative diagnosis of HNPCC to be made in a family
There are at least three relatives with an HNPCC-associated cancer (large bowel, endometrium, small bowel, ureter 
or renal pelvis, although not including stomach, ovary, brain, bladder or skin)
One affected person is a first degree relative of the other two 
At least two successive generations are affected 
At least one person was diagnosed before the age of 50 
Familial adenomatous polyposis has been excluded 
Tumours have been verified by pathological examination
00
Table 7.2. Bethesda Guidelines for MSI Testing
Tumours from any of the following should be tested for MSI (or by immunohistochemistry) and then positive cases should go forward for 
MMR testing.
Individuals with cancer in families that meet the Amsterdam Criteria
Individuals with two HNPCC-associated cancers, including synchronous and metachronous CRC or associated extra­
colonic cancers
Individuals with CRC and a first degree relative with CRC and/or HNPCC-related extracolonic cancer and/or a 
colorectal adenoma diagnosed at age <40 years
Individuals with CRC or endometrial cancer diagnosed at age <45 years
Individuals with right-sided CRC with an undifferentiated pattern (solid/cribriform) on histopathology diagnosed at 
age <45 years;
Individuals with signet-ring-cell-type CRC diagnosed at age <45 
Individuals with adenomas diagnosed at age <40 years
N>
Is)
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Table 7.3 Modified Bethesda Guidelines for MSI Testing
Tumours from any of the following should be tested for MSI (or by immunohistochemistry) and then positive cases should go forward for 
MMR testing.
CRC under the age of 50
synchronous or metachronous colorectal or other HNPCC-associated tumours regardless of age 
CRC with ‘MSI+ morphology’ under age 60
CRC with one or more first-degree relatives with CRC or other HNPCC-related tumour, with one of the cancers less 
than age 50
CRC with two or more first- or second-degree relatives with CRC or other HNPCC-related tumour (regardless of 
age), including cancers (endometrial, stomach, ovarian, cervical, oesophageal, leukaemia, thyroid, bladder, ureter and 
renal pelvis, biliary tract, small bowel, breast, pancreas, liver, larynx, bronchus, lung, and brain (glioblastoma)), 
sebaceous gland adenomas and keratoacanthomas
tou>o
Table 7.4 Inclusion Criteria for Families from St Mark’s and Guy’s Hospitals
A family (or isolated case) was included in the study if one or more of the following were fulfilled.
Amsterdam- or Amsterdam Criteria II-positive
Amsterdam- or Amsterdam Criteria II-positive, except no cancer in an individual under 50 years
One or more individuals diagnosed with CRC under 45 years
One or more individuals with two primary bowel and/or endometrial cancers
Individual(s) with one or more adenomas diagnosed under 40 years (fewer than 100 in number and having excluded 
germline APC and MYH mutations)
Three or more individuals affected by CRC in one generation
Table 7.5. Variables Used for Family Classification and Results of Single Variate Analysis in Predicting HNPCC Status of Family
Variable Odds 95% Cl □2i P
Pedigree group (relative to Group 1) vl 6.50 3.4-12.0 39.60 <0.0001
Dominant or recessive family history v2 1.91 1.01-3.64 4.18 0.041
No. in family with 2+ primary CRCs and/or endometrial cancers v3 3.52 2.07-6.01 27.70 <0.0001
No. in family with endometrial cancer v4 4.68 2.47-8.91 35.02 <0.0001
No. in family with CRC v5 1.42 1.15-1.67 12.12 0.0005
Mean age of diagnosis in family with CRC v6 0.95 0.93-0.96 19.20 <0.0001
Age of youngest with colorectal or endometrial cancer v7 0.93 0.90-0.95 33.32 <0.0001
Left/right-sided CRC predominance (R>L v L>R) v8 1.81 0.93-3.30 3.11 0.083
No. in family affected with >5 adenomas v9 0.46 0.26-0.80 12.72 0.0004
No. in family with other cancer (not CRC or endometrial cancer) vlO 1.13 0.95-1.40 1.61 0.20
Note. For v l, Group 1 = Amsterdam or Amsterdam Criteria II, Group 2 = as for Group 1 except all affecteds over 50 years, Group 3 -  isolated 
affected person under 45 years, Group 4 = all other included pedigrees.
K>u>to
Table 7.6. Criteria Used for Scoring a Family or Case as HNPCC
1 Proven pathogenic MSH2, MLHl or MSH6 mutation (nonsense, frameshift, or medium/large deletion)
2
Missense or putative splicing MSH2, MLHl or MSH6 change previously shown to have pathogenic effects or to occur at a 
site of other pathogenic mutations
3
Missense or putative splicing MSH2, MLHl or MSH6 change supported by MSI or loss of gene expression in that person’s 
tumour(s)), unless that change previously been reported as polymorphism (http://www.nfdht.nl/)
4 One or more tumours with absent MSH2 and/or MSH6 protein
5 A colorectal adenoma from that kindred MSI+
6 One or more tumours MSI+ with retention of MLHl expression
7 All cancers (minimum of two) MSI+ and/or MLHl-absent
8 Two of three cancers MSI+ and/or MLHl-absent
K>U>U>
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Table 7.7 Family Characteristics by Pedigree Group
Pedigree group 1: Modified 
Amsterdam
2: Modified 
Amsterdam, all >50 
years
3: Single person 
<45 years
4: Other 
pedigrees
Total number of families 110 28 38 74
Families classed as ‘HNPCC’ 52 (47%) 0(0) 7 (15%) 8(11%)
Dominant inheritance 110(100%) 28 (100%) 0 39 (53%)
Number of people per family with CRC Median 3 3 1 2
Mean 3 3 1 2
Average age at diagnosis of CRC Median 49 64 39 55
Mean 49 65 36 54
Age of youngest diagnosis of CRC Median 40 57 39 49
Mean 39 58 36 48
Families including person(s) with >5 
adenomas
30/105 (29%) 11/25(44%) 4/38(11%) 14/69 (20%)
Endometrial cancer present 30/104 (29%) 6/25 (24%) 1/38 (3%) 3/69 (4%)
Table 7.8 Input Data Required for Each of the Models for Predicting HNPCC
Criterion Modified
Amsterdam
Wijnen Amsterdam plus Alternative
No. of affected persons (>3) X X X
No. of generations affected X X X
1 affected is first degree relative of other 2 X X X
1 affected person diagnosed at <50 years X X X
Mean age of affected persons X X
Youngest with colorectal or endometrial cancer X
No. with CRC X
Any endometrial cancer X
No. with endometrial cancer X X
No. with >1 colorectal or endometrial cancer X X
FAP excluded X X
No. with >5 adenomas X X
toU)
Figure 7.1 ROC Curves for the Wijnen Model, the Amsterdam-Plus Model and the 
Alternative Model
(a) St Mark’s/Guy’s data, (b) Oxford data.
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Figure 7.2. Suggested flow chart for investigation and diagnosis of possible HNPCC 
families
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Chapter 8 Associations between Somatic Molecular Changes and Family 
History in HNPCC and Non-HNPCC Colorectal Cancer Families
8.1 Introduction
As discussed in previous chapters, epidemiological evidence suggests that about one third of 
all colorectal cancers have some inherited basis. About 5% of all CRCs arise as part of the 
known Mendelian syndromes, principally HNPCC, FAP and MAP (Kemp, Thirlwell et al. 
2004). Classically, ‘sporadic’ colorectal adenomas arise following two APC mutations or 
LOH, with carcinoma occurring after the adenoma has progressively acquired mutation in 
genes such as K-ras, loss of chromosome 18q and mutation and/or over-expression of p53 
(Fearon and Vogelstein 1990)(Vogelstein, Fearon et al. 1988). Some sporadic CRCs develop 
along a different pathway in which BRAF rather than K-ras mutations occur, there is a lower 
frequency of TP53 mutations and a higher frequency of BAX mutations, the karyotype is 
near-diploid, and deficient DNA mismatch repair due silencing of MLHl due to promoter 
methylation renders the tumour microsatellite-unstable (MSI+) (Kambara, Simms et al. 
2004)(Jass, Walsh et al. 2002).
FAP tumours appear to develop along similar genetic pathways to sporadic CRCs, probably 
because bi-allelic APC mutations are the initiating events in both cases, although FAP 
tumours have certain distinguishing features, such as a low frequency of K-ras mutations 
(Miyaki, Seki et al. 1990)(Miyaki, Konishi et al. 1994)(Lamlum, Papadopoulou et al. 2000). 
Tumourigenesis in HNPCC follows a pathway similar to MSI+ sporadic CRCs, although in 
some HNPCC cancers beta-catenin mutations substitute for APC mutations and HNPCC 
tumours generally have K-ras rather than BRAF mutations (Deng, Bell et al. 2004)(Johnson, 
Volikos et al. 2005). MAP CRCs follow another distinct pathway, being near-diploid and 
microsatellite-stable (MSI-), with a high frequency of APC mutations (but a low frequency of 
allelic loss), and a high frequency of K-ras mutation (Lipton, Halford et al. 2003). In general, 
the genetic pathways of HNPCC and MAP carcinogenesis reflect the underlying genetic 
instability specific to each condition, resulting from deficient DNA mismatch repair (MMR) 
and base excision repair (BER) respectively.
The differences between the genetic pathways of carcinogenesis in FAP, HNPCC, MAP and 
sporadic CRCs partly reflect three factors. First, owing to their DNA sequence, some genes 
are susceptible to certain types of mutation; thus, the 10 bp repetitive oligoadenine tract in
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TGFBR2 is prone to mismatch slippage in HNPCC and these mutations tend to occur rather 
than the SMAD4/SMAD2 mutations seen in MSI- CRCs, even though the former might 
provide a greater functional advantage (Markowitz, Wang et al. 1995)(Woodford-Richens, 
Rowan et al. 2001). Second, there is probably selection against co-occurrence of certain 
changes in CRCs; for example, a high frequency of allelic loss or aneuploidy/polyploidy 
rarely occurs together with defective MMR or BER, BRAF mutations appear mutually 
exclusive with K-ras and APC and beta-catenin mutations do not tend to co-exist within 
cancers (Jones, Douglas et al. 2005)(Deng, Bell et al. 2004)(01iveira, Westra et al. 
2004)(Rajagopalan, Bardelli et al. 2002). For example, in HNPCC tumours it appears that the 
higher incidence of beta-catenin mutations makes up for a lower incidence of APC changes 
(Miyaki, Iijima et al. 1999). Third, some changes - for example, the missense beta-catenin 
mutations in HNPCC - are probably co-selected with other mutations which have been driven 
by the underlying genetic instability (Johnson, Volikos et al. 2005).
The remaining 25-30% of CRCs with an inherited basis probably result from unknown 
moderate-penetrance and/or low-penetrance predisposition alleles. Heterozygosity for MYH 
mutation might certainly be one such low penetrance allele as may missense changes such as 
I1307K in APC (Sieber, Lipton et al. 2003)(Kambara, Whitehall et al. 2004)(Jenkins, 
Croitoru et al. 2006). Clusters of low penetrance genes may also be responsible. Very little is 
known about the somatic genetic pathways followed by cancers from high risk families 
outside the known Mendelian syndromes. Lindor et al undertook a study of 160 Amsterdam 
positive families classified for MSI+ or MSI- cancers and assessed cancer risk in relatives 
(Lindor, Rabe et al. 2005). Whilst the risk for relatives in MSI+ HNPCC families was as 
high as expected, it was markedly lower for families without MSI- cancers, particularly for 
colorectal and endometrial cancers. Mean age of cancer incidence amongst relatives was also 
much lower in relatives from MSI+ cancer families (48 versus 60 years). This suggests that 
Amsterdam positive families without MMR deficient cancers may have a very different 
genetic make-up and may be due to cluster of environmental exposure, moderate penetrance 
alleles or even chance alone.
In a large series of sporadic CRCs, no association was seen between family history, K-ras 
mutation status or MSI, but a weak association was seen between TP53 mutation status and a 
family history of CRC (Slattery, Curtin et al. 2002). Abdel Rahman et al have noted that 
aberrant nuclear beta-catenin expression and mutations are associated with cancers from
242
HNPCC families with a paucity of nuclear beta-catenin staining and TP53 mutations in the 
MMR mutation negative cancers (Abdel-Rahman, Ollikainen et al. 2005). This hints at novel 
pathways of tumourigenesis in these families. If some of these remaining inherited CRCs 
arose as a result of defective DNA repair, it would be expected -  by comparison with 
HNPCC and MAP -  that they would tend to have ploidy, mutation spectra and frequencies of 
allelic loss which reflected this fact. It would be predicted, for example, that in DNA repair- 
deficient CRCs, allelic loss at SMAD4 on 18q and at APC would be reduced in frequency, 
beta-catenin and K-ras mutations might be more frequent, p53 mutations would be less 
frequent and CRCs would tend to be near-diploid. If, however, some of the remaining 
inherited CRCs resulted from moderate-penetrance mutations in genes more similar to APC, 
genetic pathways of carcinogenesis would be similar to the sporadic, unselected CRC. It is 
also likely that CRCs resulting from genes with low penetrance (or CRCs which were present 
in chance familial clusters) would follow genetic pathways which could not readily be 
distinguished from unselected cases. It might be possible, moreover, to distinguish different 
groups of CRC families of unknown genetic origin, based on differences between their 
pedigrees, pathological and/or molecular features.
In this study, I have analysed CRCs from five series of patients/families: (i) HNPCC; (ii) 
MAP; (iii) patients with multiple colorectal adenomas, but without MAP or attenuated or 
classical FAP; (iv) patients presenting to a Family Cancer Clinic with evidence of inherited 
disease, but without a molecular diagnosis of HNPCC, MAP or FAP (FCC patients); and (v) 
a consecutive series of CRC cases with no information about their family history. Colleagues 
and I have screened the CRCs for mutations in K-ras and beta-catenin, for MSI, for allelic 
loss at APC and on chromosome 18q (close to the SMAD4, SMAD2 and DCC loci), and for 
the expression of beta-catenin and p53 proteins. We have compared the molecular findings 
with clinical, pedigree and pathological data, and tested for evidence that the FCC cases can 
be clustered or stratified on the basis of molecular features into more than one group.
8.2 Methods
8.2.1 Patient Ascertainment
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CRC cases were derived from those referred to the Cancer Research UK Family Cancer 
Clinic, St Mark’s Hospital and the Family Cancer Clinic, Guy’s Hospital. National research 
ethics guidelines were followed. Recruitment was performed by Dr Ian Frayling, Dr Emma 
Barclay, Mrs Carole Cummings and me. A variety of families was incorporated into the 
study, using inclusion criteria similar to the ‘Bethesda Guidelines’, specifically: (i) 
Amsterdam or modified Amsterdam Criteria; (ii) Amsterdam or modified Amsterdam criteria 
in all respects except no cancer occurring in an individual under 50 years; (iii) one or more 
individuals diagnosed with CRC under 45 years; (iv) one or more individuals with two 
HNPCC cancers (CRC or endometrial); (v) >5 adenomas to date in any individual (with 
fewer than 100 adenomas in total and excluding germline APC mutations); or (vi) three or 
more individuals affected by CRC in one generation (Umar, Boland et al. 2004). Families 
from whom archival tumour tissue specimens could not be retrieved were excluded, although 
families without a living affected person were not automatically excluded. Pedigree 
information was obtained from family members and the presence of cancer confirmed, 
wherever possible, from hospital records, pathology reports, cancer registry records or death 
certificates.
8.2.2 Family Variables
Each included family was given a score in each of the following binary categories: (i) the 
apparent mode of inheritance - dominant or recessive; (ii) one or more persons with two 
primary tumours (colorectal and/or endometrial cancer) in the family; (iii) presence or 
absence of a woman with endometrial cancer in the family; (iv) the mean age at diagnosis of 
CRC (<45 or >45 years); (v) the age at diagnosis of the youngest person with CRC or 
endometrial cancer (<45 or >45 years); (vi) predominance of right- or left-sided colorectal 
cancers in the family; and (vii) presence or absence of a patient with five or more adenomas 
in the family (Table 8.1). Binary coding was necessary for statistical analysis in this project. 
In addition, the number of persons affected by CRC in the family and the total number of 
other cancers (apart from colorectal or endometrial) developed by family members were 
noted.
8.2.3 Collection of Blood and Tumour Samples from Families
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Blood collection was performed by Mrs Carole Cummings, Dr Ella Barclay and me. 
Microdissection and DNA extraction were performed by Dr Halford for the cancers without 
known family history and by me for others. Living, affected family members were asked to 
give a 10ml blood sample and consent for access to archival tumour tissue. Where affected 
family members were deceased, their next-of-kin was asked to give consent for access to 
archival tumour and normal tissue specimens. This project was approved by the human ethics 
committees at Northwick Park Hospital, Harrow and Guy’s Hospital. All available colorectal 
carcinomas were obtained from affected family members. The histological features of the 
tumours, including size, grade, mucinous component and stage, were taken from pathology 
reports or assessed by Dr A.T. Eftekhar Sadat and me where no reports were provided. 
Microdissection of neoplastic and normal areas from paraffin-embedded archival tissue was 
guided by reference to haematoxylin and eosin-stained sections; tumour and normal DNAs 
were then extracted using a simple proteinase K digestion.
8.2.4 Germline Mutation Detection and Family Classification
Molecular and immunochemical diagnosis of tumours was performed by Miss Victoria 
Johnson and me. MYH  mutation testing was performed by Dr Oliver Sieber and me. APC 
mutation screening was performed by Dr Emma Jaeger and Miss Victoria Johnson. From the 
families ascertained from the Family Cancer Clinics of St Mark’s and Guy’s Hospitals, we 
sub-divided cases into those with germline mismatch repair mutations (HNPCC), bi-allelic 
MYH mutations (MAP), APC mutations (AFAP) or no mutation detectable in these genes. 
Molecular diagnosis of HNPCC was undertaken using the criteria in Chapter 7 which are 
based on a combination of mutation screening {MLHl, MSH2 and MSH6) and tumour 
analysis (MSI testing and immunohistochemistry for MLHl, MSH2 and MSH6) (Lipton, 
Johnson et al. 2004). MYH  screening was undertaken as described in Chapter 4 (Sieber, 
Lipton et al. 2003). APC screening used a fluorescence-SSCP method adapted from described 
protocols (Chapter 2), although no case was actually found to be ^ PC-mutant (Groden, 
Gelbert et al. 1993). The remaining families/cases were classed as ‘Multiple adenoma’ (five 
or more proven colorectal adenomas to date) or FCC families/cases (all others).
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8.2.5 Unselected Series of Colorectal Carcinomas
Analysis of this group was performed by Mr Andrew Rowan and Dr Sarah Halford. An 
unselected series of 100 fresh-frozen CRCs and paired normal bowel was obtained from St 
Mark’s Hospital, London; fixed tissue was obtained from the same tumours. All cancers 
contained more than 60% neoplastic cells, as assessed using routine histology. Clinico- 
pathological data were obtained from hospital records. DNA was extracted from each tumour 
sample and paired normal colon epithelium using standard methods. These samples were 
studied on an anonymous basis according to local research ethics guidelines and their 
features have previously been reported by Rowan et al (Rowan, Halford et al. 2005).
8.2.6 Immunohistochemistry for beta-catenin and p53
Available paraffin embedded colorectal cancers were tested by immunohistochemistry for 
over-expression of beta-catenin and p53. 5 pm tumour sections were analysed using the beta- 
catenin mouse monoclonal antibody (Sc 7963) from Santa Cruz Biotechnology and p53 
mouse antibody (M 7001) from Dako antibodies, respectively at 1/100 dilution after pressure 
cooking the sections for four minutes. After counterstaining with haematoxylin, the slides 
were examined by three independent observers, Dr A.T. Eftekhar Sadat, Miss Victoria 
Johnson and me. For beta-catenin, nuclear expression was scored as positive if more than 5% 
of cells had nuclear staining and negative otherwise. For tumours without normal tissue, 
sections containing some normal tissue were used to provide an internal control in the case of 
beta-catenin. For p53, a cancer was scored as positive if there was no staining of normal 
tissue and more than 20% of nuclei were stained. Tumours were reported as negative for p53 
if normal tissue showed no staining and <20% of neoplastic nuclei were stained. Tumours 
with other p53 staining patterns were excluded from analysis. For p53 controls, tumours 
known to be positive for nuclear staining were used.
8.2.7 Mutation Screening for K-ras and beta-catenin
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Mutations in K-ras (codons 12,13 and 61) and beta-catenin (exon 3) were detected in each 
cancer using direct sequencing in forward and reverse orientations as previously described 
(Chapters 5 and 7). This was performed by Victoria Johnson, Emmanuel Volikos and me.
8.2.8 Allelic Loss (LOH) Analysis
LOH was assessed at the APC and SMAD4 loci (the latter of these also referred to as 18q 
LOH). Microsatellites very close to each locus ((D5S346 and D5S421 for APC; D17S487,
D18S46, D18S474 and D18S35 for SMAD4) were typed in each cancer and in a sample of 
constitutional DNA. Constitutionally homozygous markers or markers showing MSI in 
tumours were scored as non-informative. Otherwise, at each marker, LOH was considered to 
be present if the area under one allelic peak in the tumour was less than 0.5x or greater than 
2x that of the other allele, after correcting for the relative allelic areas using the constitutional 
DNA. If there was any discordance among markers, the marker(s) closest to the gene of 
interest were given precedence in classifying the cancer.
8.2.9 Data Scoring
In order to make analysis practicable, we scored each of the molecular variables as a single 
binary data point for each family or isolated case. If it were only possible to analyse a single 
cancer for that family, those results were used. However, we reasoned that where multiple 
cancers were available, we should obtain as much data as possible in order to reduce the 
effects of chance variation in genetic pathways, and then assess each family/case on the basis 
of all available cancers. For families/cases in which more than one cancer was analysed, we 
therefore scored molecular changes according to the most frequent result; for example, if two 
of three cancers had a particular change, that family was scored as positive for that change 
but if one of three cancers had the change, the family was classed as negative. If the same 
number of cancers was with and without the change, we classed the family/case as positive.
8.2.10 Statistical Analysis
Single variable tests (Fisher’s exact, and Wilcoxon) and multi-variable analysis (logistic 
regression) were performed using STATA 7.0. We performed hierarchical cluster analysis
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using the cluster averagelinkage command of STATA. Occasional PCR failures or 
exhaustion of samples meant that not every data point was available for each of the tumours; 
missing data points for the cluster analysis were substituted by the mean across the whole 
patient set. The cluster generate command of STATA with two groups was used to partition 
out clustered groups of cases/families. Where testing specific hypotheses or confirming 
previously reported associations, or in the multivariable analysis, we used a threshold of 
p=0.05 to indicate statistical significance. Where searching for new associations in a single 
variable analysis we used the more restrictive threshold of p=0.01 in order to make allowance 
for multiple testing.
8.3 Results
I initially examined the frequency of each molecular change in the five series of 
patients/families (Table 8.2). K-ras mutations were found at similar frequencies (0.27-0.34) 
in each of the series, except for the MAP patients (0.64); the K-ras mutation frequency in the 
MAP carcinomas was significantly higher than in the other Multiple adenoma patients 
(p=0.009, Fisher’s exact test) and higher than in all the other patient groups combined 
(p=0.01, Fisher’s exact test). The frequency of LOH at APC ranged from zero in the MAP 
cancers to 0.36 in HNPCC and 0.58 in the multiple adenoma patients; with the exception of 
MAP, there were no significant differences in APC LOH frequency among the groups 
(p>0.14 in all cases, Fisher’s exact test). The frequencies of 18q LOH ranged from 0.36 in 
HNPCC to 0.55 in the FCC patient group ; the only significant difference between 18q LOH 
frequencies was when comparing these two groups (p=0.043, Fisher’s exact test). Q{i&To(r\£XS 
and MAP cancers also had 18q loss in around 50% of cases. As would be expected, MSI was 
present in all HNPCC cancers and none of the MAP cancers. The frequency of MSI+ was not 
statistically different in FCC patients (13%) to that in unselected patients (10%). All multiple 
adenoma cancers were MSI-. Beta-catenin mutations were almost exclusively found in the 
HNPCC cancers, as previously reported, although nuclear expression of beta-catenin protein 
was actually less frequent in these cancers than others (although not significantly so)
(Johnson, Volikos et al. 2005). p53 over-expression was fairly constant throughout all groups 
with over 50% of all tumour types showing staining.
I then focussed on the FCC patient series. I performed searches for pairwise associations 
between the molecular variables and for associations between the molecular and
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clinicopathological variables. The only association detected between the molecular variables 
was between LOH at APC and LOH on chromosome 18q (p=0.004, Fisher’s exact test; Table 
8.2). This observation may reflect the common co-occurrence of these changes in 
aneuploid/polyploid lesions (Jones, Douglas et al. 2005). Logistic regression analysis 
confirmed the association between APC LOH and 18q LOH, but did not reveal further 
associations between the molecular variables.
K-ras mutation, APC LOH, 18q LOH and nuclear beta-catenin expression were not 
associated with any of the clinico-pathological variables in the FCC patient series. Absence 
of p53 over-expression was, however, associated with a lower age of the youngest person 
with colorectal or endometrial cancer in the family (Fisher’s exact test, p=0.0012). For those 
families with p53 over-expression, mean age of the youngest affected individual was 37 
(median=39, interquartile range=29-43); for those without, mean age of the youngest affected 
individual was 47 (median=46, interquartile range=40-56). Multi-variable analysis did not 
reveal any additional associations between the molecular and clinico-pathological data.
Cluster analysis was then used in order to suggest groups of FCC patients who might have 
similar clinical features and hence arise from different genetic origins. The 149 FCC patients 
were divided into four groups of 37 or 38 at random. Hierarchical cluster analysis by 
clinicopathological features in each group revealed no consistent clusters (details not shown). 
Cluster analysis using the five molecular variables (K-ras mutation, APC and 18q LOH, beta- 
catenin expression and p53 expression) was also performed. Following clustering, for each of 
the four cluster replicates, the families/cases were partitioned into two dissimilar groups, with 
the aim of identifying molecular factors which consistently discriminated between different 
types of patient (Figure 8.1). In all of the four cluster replicates, presence or absence of K-ras 
mutation was a highly significant discriminant (p<0.002 in all cases, Fisher’s exact test, 
excluding missing data points). None of the other molecular variables was discriminatory in 
more than one of the four replicates. Only five families or patients failed to cluster correctly 
by K-ras status.
Cluster analysis was then performed on the multiple adenoma series of patients. Molecular 
data was generally similar to that in the FCC series. LOH at APC and chromosome 18q was 
more strongly associated overall (p=0.001, Fisher’s exact test). Cluster analysis on the entire 
multiple adenoma series using the five molecular variables showed no consistant
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discriminator when the families or cases were partitioned into two dissimilar groups. 
However, on partitioning into three groups, presence or absence of K-ras mutation was a 
perfect discriminant, all nine tumours with K-ras mutations being in groups 2 and 3 and all 
non-mutant tumours in group 1 (figure 8.2). None of the other molecular variables were 
discriminatory.
8.4 Discussion
Mutations in the germline which predispose to colorectal cancers such as APC in FAP, MMR 
genes in HNPCC and MYH  in MAP cause tumours to develop in different ways. The tumours 
in each condition have fairly uniform genetic profiles and in some cases, histology. The 
underlying genetic defect guides the pattern of somatic changes seen in the tumour. This has 
been demonstrated in FAP, HNPCC and more recently by me in MAP (Chapter 5). In this 
study I attempted to use molecular data from tumours as well as clinico-pathological 
variables to stratify FCC patients and families into strata for further investigation.
One obvious comparison is between cancers arising in the setting of MAP and those from 
patients with MA and no known genetic cause. In the groups studied, MAP cancers had 
molecular features which were different from those of the multiple adenoma patients. K-ras 
mutations were particularly frequent in MAP as previously documented and, specifically, 
more common than in the multiple adenoma cases (Lipton, Halford et al. 2003). APC LOH 
was infrequent in MAP compared with other cancers, including those from multiple adenoma 
patients. This may well be because the primary method of APC inactivation in MAP tumours 
is through G—>T transversion mutations which are known to occur commonly in MAP due to 
defective BER. MSI was absent in tumours from both MAP and Multiple adenoma patients. 
This result was not unexpected as BER and MMR deficiency are unlikely to be a viable 
combination in MAP cancers and the multiple adenoma phenotype is negatively correlated 
with HNPCC (Lipton, Johnson et al. 2004). My results suggest that multiple adenoma 
patients without germline mutations in MYH or APC do not result from a mutator phenotype 
at the base pair level which is comparable with that of MAP or from a defect in MMR.
I found that p53 over-expression was equally common in HNPCC, multiple adenoma and 
FCC cancers (68-72%). The level of expression found in HNPCC cancers was high given
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that there is frequent inactivation of the p53 pathway in such cancers due to mutations in BAX 
fulfilling a similar role (Percesepe, Pedroni et al. 2000)(Yagi, Akiyama et al. 1998). It would 
be an interesting further project to check for BAX mutations in the HNPCC subset of cancers 
in this study. As others have found, the frequencies of LOH at APC and on chromosome 18q 
were lower in HNPCC carcinomas than in the other series, although these differences did not 
reach statistical significance and could not reliably be used to distinguish HNPCC patients 
from the FCC cases or Unselected series (Johnson, Lipton et al. 2005)(Konishi, Kikuchi- 
Yanoshita et al. 1996). Generally lower frequencies of allelic loss are seen in MSI+ cancers, 
both sporadic and inherited possibly because of lack of viability of cells will chromosomal 
instability and MMR defects (MSI+CIN+).
In this series the frequency of MSI+ in FCC cases was approximately the same as for 
unselected and multiple adenoma cancers. These data suggest that the previously used 
strategies for detection of HNPCC - immunohistochemistry for MLH1, MSH2 and MSH6 as 
well as MSI on as many tumours as are available in a family, followed by mutation testing of 
MLH1, MSH2 and MSH6 as indicated - have been highly effective in ‘weeding out’ those 
with a germline mutation (Lipton, Johnson et al. 2004). It may have been expected that, if all 
HNPCC had been extracted from the FCC group, that the prevalence of MSI+ cancers would 
have been lower than that in the unselected group as the remainder should be associated with 
somatic epigenetic mutation which increases with age and the average age of sporadic cancer 
patients was 67 as compared to 51 in the FCC group. The reason that this was not the case 
may relate to only a phenocopy tumour being available in the family for testing or one family 
member’s tumour with loss of MLH1 and MSI+ who is not available for mutation testing 
with no other tumours available. The latter would have been classified as non-HNPCC if the 
person was >45. The hypothesis that more HNPCC remains to be detected in the FCC group 
is supported by the strong association of absent p53 over-expression in the FCC patients with 
a family member affected at a young age. Alternative, but less plausible, explanations for 
these data are germline mutations at unknown loci involved in mismatch repair and unknown 
germline variation which predisposes cancers in these patients to follow a mismatch repair- 
deficient pathway. Based on the 13% frequency of MSI in the FCC series compared with 
10% in the unselected CRCs, perhaps 3-5% of FCC patients were actually affected by 
HNPCC in this study.
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The similar frequencies of nuclear beta-catenin expression in the different CRC series and the 
absence of an association between nuclear beta-catenin and any clinico-pathological variable 
suggest that some form of Wnt pathway dysregulation may be common to all types of CRC, 
even if not all tumours achieve this in the same way. The cases without nuclear beta-catenin 
localisation may be developing along a different pathway or may represent tumours with 
more subtle Wnt dysregulation. Other explanations include production of a variant beta- 
catenin protein which does not react with the staining antibody or dimerisation or interaction 
with other proteins which abolishes an antibody binding site. Previous reports that not all 
FAP carcinomas show nuclear beta-catenin, despite obligate bi-allelic APC mutation, suggest 
that the latter is at least partly true (Kobayashi, Honma et al. 2000).
The fact that the FCC series was consistently divided into two groups by presence or absence 
of K-ras mutation suggests that this may be a true classifier of familial bowel cancers of 
different, but unknown genetic origins. Under-diagnosis of HNPCC cannot explain this 
classification, since K-ras mutation and MSI were not associated in the FCC cancers. There is 
precedence for a classification of CRCs based partly on K-ras status, given the relatively high 
K-ras mutation in MAP and the low frequencies in FAP and sporadic and hereditary, MSI+ 
CRCs, even though the functional basis of these observations is not well understood. It is 
interesting to note that in comparison to MAP cancers which are predominantly left sided, in 
a group of over 300 sporadic adenomas, those in the rectum contained more k-ras mutations 
(Barry, Baron et al. 2006). Variable reports are given for K-ras mutations in HNPCC tumours 
with most investigators finding low numbers of mutations compatible with our series (Losi, 
Ponz de Leon et al. 1997)(Young, Simms et al. 2001). Sporadic CRC and adenomas on the 
other hand tend to show high levels of K-ras mutation. K-ras is certainly central to cellular 
events in colorectal cancer, showing interactions with the Wnt pathway through GSK3B and 
TCF as well as effects on VEGF and interaction with the BRAF(Li, Mizukami et al. 2005).
In summary, there is considerable overlap between the genetic pathways followed by 
colorectal cancers in the known dominant and recessive inherited syndromes, in undiagnosed 
families and cases from the Family Cancer Clinic and in unselected CRC patients. Specific 
differences between these pathways are also well established, although they cannot currently 
be fully explained. I have identified a set of patients with multiple adenomas and no 
evidence of (attenuated) FAP or MAP, and these patients’ tumours resemble unselected 
CRCs and FAP CRC’s more than MAP CRCs. There is additional evidence to show that a
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minority of the remaining CRC kindreds from family cancer clinics may be true cases of 
HNPCC, with cryptic mutations and a family history which makes tumour-based diagnosis 
difficult. Nevertheless, it is possible that K-ras mutation status distinguishes two groups of 
non-HNPCC, FCC patients who currently have unknown genetic origins.
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Table 8.1 Clinical Features of the Cases and Families Studied
Group (No. 
of cancers
Dominant
inheritance
>1 primary 
cancer
Endometrial
cancer
present
Mean age 
<45 years
Youngest 
age <45 
years
R>L Any patient 
with >5 
adenomas
Mean no. of
persons
with
colorectal
cancer
(range)
No. of 
persons 
with cancer 
other than 
colorectal 
or
endometrial
HNPCC 34/43 20/42 18/42 20/42 29/42 27/40 3/42 2.5 (1 to 9) 1 (0 to 6)
(43) (82%) (48%) (43%) (48%) (69%) (68%) (7%)
MAP 8/17 3/17 0/17 2/17 2/17 12/17 17/17 1 (0 to 3) 0 (0 to 4)
(17) (47%) (18%) (0%) (12%) (12%) (71%) (100%)
Multiads 38/47 10/47 2/47 9/46 17/46 18/32 49/49 2 (1 to 6) 0 (0  to 4)
(49) (81%) (21%) (4%) (20%) (37%) (56%) (100%)
FCC 81/137 18/117 11/116 37/119 66/117 57/101 0/150 2 (1 to 6) 0.5 (0 to 6)
(150) (59%) (15%) (9%) (31%) (56%) (56%) (0%)
t o
■4^
Table 8.2 Numbers of Families/Cases Studied from Each of the Five Series and the Frequency of Each Molecular Change
Series (no. cancers) K-ras APC LOH 18q LOH MSI Beta-cat mutation Beta-cat IHC p53 IHC
HNPCC (43) 11/39 (28%) 10/28 (36%) 9/25 (36%) 43/43 (100%) 5/34 (15%) 17/37 (46%) 23/32 (72%)
MAP (17) 9/14 (64%) 0/13 (0%) 7/14 (50%) 0/17 (0%) 0/16 (0%) 12/17(71%) 8/15 (53%)
Multiads (44) 11/41(27%) 18/31 (58%) 15/28 (54%) 5/49 (10%) N/D 27/45 (60%) 28/39 (72%)
Familial CRC (149) 34/117(29%) 54/112(48%) 47/86 (55%) 18/139(13%) 0/54 (0%) 50/104 (48%) 50/73 (68%)
Unselected (100) 30/89 (34%) 38/69 (55%) 42/94 (45%) 10/100 (10%) 1/100 (1%) N/D N/D
Numbers of cancers with that molecular change as proportion of total cancers of that type studied (and percentages) are shown. Pairwise and overall comparisons of each 
molecular variable between Series showed no significantly different frequencies (at p=0.05), except as detailed in the text. N/D = not determined. IHC = 
immunohistochemistry.
Table 2. Association between APC LOH and 18q LOH in FCC CRC Series
The table shows numbers of FCC cancers with LOH at the APC locus and close to the 
SMAD4 locus on chromosome 18q21.1.
APC
TotalLOH No LOH
18q
LOH 24 12 36
No LOH 16 30 46
Total 40 42 82
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Figure 8.1 Results of Hierarchical Cluster Analysis on FCC Patients Split into Four Sets
Each branch of the dendrogram represents one family/patient. The Group (1 or 2) assigned by 
STATA cluster group command is shown below each branch of the dendrogram. For all four 
dendrograms, the cancers of those patients/families in Group 1 almost all had no K-ras 
mutation and those in group 2 almost all had a mutation. Five discordant families are shown 
marked by an asterisk.
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Chapter 9 Conclusions
Throughout the period of this thesis I have attempted to uncover information and explore 
themes relevant to familial colorectal cancer and polyposis. The project has spanned the 
genetics of FAP, HNPCC, MAP, and multiple colorectal adenomas of unknown cause. It has 
dealt with analysis of family history, case finding, associated cancer risks and mechanisms of 
tumourigenesis. I have been fortunate to be able to perform true transitional research in that 
the patients whom I saw and helped to manage in the familial cancer clinic contributed and in 
many cases ultimately derived some benefit from the research.
The first project undertaken was the classification of families with a strong history of 
colorectal cancers into strata, aiming to further analyse these groups, this was done by means 
of a cluster analysis. One of its novelties lay in the fact that families, individuals, cancer 
pathology and genetic information were analysed together, mimicking our true situation in 
the clinic. A broad range of information was collected about families including patterns of 
inheritance, cancer spectrum and ages at diagnosis as well as tumour pathology. As much 
molecular information s possible was also uncovered using techniques to detect gene 
mutations and losses and measure gene expression. The major problems encountered in this 
project were difficulties in fully verifying pedigrees as reported by probands, obtaining 
archival tumour samples from a range of hospitals from up to twenty years ago and working 
with DNA derived from paraffin-embedded tissue which may give poor results in mutation 
detection.
Despites this, 250 families were informative enough to be included in this analysis. The 
success in recruiting patients may largely be attributable to the existence of the Bobby Moore 
database at St Marks Hospital which is a comprehensive database of all patients seen and 
includes pathological and follow-up data. Many of the families with mutation positive 
HNPCC were diagnosed as such during this project after findings on tumours of MSI-H or 
MMR protein loss. Our methods of distinguishing such patients appeared to work well as 
very few families outside of these were likely to harbour mutations based on our cluster 
analysis. We saw little evidence for a discriminatory effect of TP53, beta-catenin, APC or 
SMAD changes between subgroups of colorectal cancers. There did appear to be two groups 
identifiable based on K-ras mutations. K-ras mutations are one of the most frequent events in 
colorectal adenoma and carcinoma development and this effect may be used as an initial
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stratification in future studies of this nature. Key limitations in this study include sample size, 
and perhaps number of genes assessed.
Closely allied to such efforts in stratification of familial colorectal cancers is the issue of 
deciding upon which families have HNPCC with a germline mutation in a MMR gene. It is 
not always possible to carry out mutation testing in an effected individual to inform the 
family of overall risk and allow predictive testing to be undertaken. It is important to make 
the diagnosis of HNPCC in the right families to allow frequent screening colonoscopy even 
in the absence of germline mutation. Equally we wish to avoid over-screening families 
unlikely to carry a mutation as colonoscopy is not without risk of morbidity and mortality. In 
a recent paper, Lindor et al showed that unaffected relatives in families who met the 
Amsterdam criteria but did not harbour MMR gene mutations were at much lower risk for 
colorectal and other HNPCC-associated cancers than were those from mutation positive 
families (Lindor, Rabe et al. 2005). This finding certainly provided evidence that familial 
clustering may occur due to shared environmental or lifestyle influences or because of 
multiple low to moderate disease causing alleles within families.
We did improve upon the Amsterdam Criteria in terms of specificity and the Bethesda 
Criteria in terms of specificity using a simple algorithm which relies on pedigree information. 
To verify this we used groups of families where HNPCC status was known and then 
validated this in a test set where results of mutation detection were known. We proposed a 
method of classifying families as HNPCC even if no live affected member is available for 
mutation testing. This involves assessment of as many tumours are available and performing 
IHC for MMR proteins as well as MSI. Using our methods we define families who should go 
forward for further testing with MSI and IHC, with potential mutation testing in some. All 
families classified as HNPCC by our criteria should undergo regular (two yearly) 
colonoscopy with gynaecological screening for women.
In parallel with the above projects was the work performed on the syndrome of multiple 
colorectal adenomas. It had been recognised for some time that the majority of individuals 
who developed 5 to 100 colorectal polyps during their lifetime did not have mutations in the 
main gene known to cause a polyposis syndrome -  APC nor were they part of the spectrum 
of HNPCC (Lamlum, Al Tassan et al. 2000). Many cases appear isolated or recessive and 
phenotypes vary widely. Our first effort in finding the genetic basis of such persons was a
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candidate gene search in Wnt and SMAD pathway genes. A highly representative group of 
multiple adenoma patients were assessed and no pathogenic mutations were found in Wnt 
pathway genes in particular. This resounding negative result was somewhat surprising to us 
but convinced us that APC changes and effects from outside the Wnt pathway on beta-catenin 
may well be the major mechanisms of tumourigenesis here.
After the first report emerged of a group of siblings with germline mutations in MYH causing 
multiple adenomas in a seemingly recessive pattern we explored this mechanism in two large 
groups of patients, the first will multiple adenomas and the second with classical polypsis; 
both groups without detectible mutations in APC. We looked for mutations in MYH and also 
in two other important BER genes, OGGI and MTH1. Although we found no mutations in 
the latter two genes we confirmed that in around 30% of APC mutation negative patients with 
over 15 adenomas, bi-allelic MYH  mutations were responsible for disease. We uncovered a 
number of new mutations some of which were likely to be pathogenic and confirmed that 
these patients have on average a higher number of adenomas than multiple adenoma patients 
without mutations. We also saw an excess of G—>T transversion mutations in APC in 
tumours from bi-allelic mutation carriers. This along with the occurrence of MAP patients 
with duodenal polyposis made us hypothesis that APC dysfunction was a crucial step in the 
carcinogenic effect of MYH  mutations.
Since our publication in 2003 a multitude of investigators have confirmed our findings in 
groups of multiple adenoma and polyposis patients from around the world (Feamhead 2003; 
Hes F. 2003; Sampson, Dolwani et al. 2003; Sieber, Lipton et al. 2003; Gismondi, Meta et al. 
2004; Kambara, Whitehall et al. 2004; Wang, Baudhuin et al. 2004; Miyaki, Iijima et al. 
2005; Nielsen, Franken et al. 2005). It has become apparent also that founder mutations exist 
in certain ethnic populations with many others still unstudied.
The magnitude of colorectal cancer risk to the MYH heterozygote remains open to debate 
although recent studies put the relative risk at somewhere between 1.5 and three (Tenesa, 
Farrington et al. 2005; Jenkins, Croitoru et al. 2006). The implication is that mono-allelic 
MYH  mutations may be low to moderate risk alleles for colorectal cancer. Several studies 
have looked for MYH  mutations in cohorts of colorectal cancer patients in groups of sporadic 
colorectal cancer patients and some have shown an increased number of mono-allelic MYH 
mutation carriers compared to their population (Enholm, Hienonen et al. 2003; Fleischmann,
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Peto et al. 2004; Kambara, Whitehall et al. 2004). Bi-allelic mutation carriers are also seen 
with few or no colorectal adenomas (Enholm, Hienonen et al. 2003; Wang, Baudhuin et al. 
2004; Zhou, Djureinovic et al. 2005). If single MYH  mutations do confer a degree of risk 
sufficient to warrant screening colonoscopy, the resource issues of such may be enormous 
depending entirely on the population frequency of MYH mutations. The population frequency 
of mutations has been estimated in a number of different populations with estimates between 
0% and 1.8% for the Y165C mutations and between 0% and 2.2% for G382D mutations (Al- 
Tassan, Chmiel et al. 2002; Enholm, Hienonen et al. 2003; Sieber, Lipton et al. 2003; 
Fleischmann, Peto et al. 2004; Isidro, Laranjeira et al. 2004; Kambara, Whitehall et al. 2004; 
Wang, Baudhuin et al. 2004; Leite, Isidro et al. 2005; Zhou, Djureinovic et al. 2005). The 
frequency of potential founder mutations in other ethnic groups is unknown. As time 
progresses increasing numbers of MYH missense mutations are being found to be pathogenic 
also (Bai, Jones et al. 2005). The potential for MYH mutations to cause disease outside the 
gastrointestinal tract has not yet adequately been explored and is a fertile area for further 
research.
Mutations in the BER pathway are a novel initiating event in tumourigenesis and might have 
been expected to cause cancer in a way analogous to defective DNA mismatch repair. I 
performed the first exploration of this hypothesis in as many cancers and adenomas from 
biallelic MYH mutation carriers as possible. Because this is a rare syndrome and many 
patients were diagnosed retrospectively such material was not easy to come by, nonetheless 
around 20 cancers and 150 adenomas were able to be included in the analysis. The findings 
were most interesting and established beyond doubt that these tumours do not show MSI and 
that they are highly enriched for one specific K-ras mutation (G12C) both of which findings 
have since been confirmed by other investigators (Jones, Lambert et al. 2004; Kambara, 
Whitehall et al. 2004). My findings pointed strongly towards these tumours showing little 
gain or loss of genetic material however a recent publication by Cardoso et al using 
comparative genomic hybridisation has suggested that these tumours do show chromosomal 
instability to the same extent as FAP cancers (Cardoso, Molenaar et al. 2006).
Thus, a small but significant part of the problem of multiple colorectal adenomas has been 
solved by the description o f MAP. Many other individuals and families exist at present for 
whom we cannot find a genetic explanation for disease. Methods worthy of consideration for 
further studies include the use of gene expression microarrays using tumour material, SNP
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analysis o f germline and tumour DNA and classical linkage analysis. Study of adenoma 
material is particularly important as ‘initiating’ events may be best appreciated at an early 
stage of tumourigenesis. Tumour and germline DNA banking is thus a crucial component of 
the ongoing progress towards explaining not only the genetic basis of colorectal cancer but 
how we can use this to prevent disease and better care for our patients.
Although we classically think of deleterious germline mutations in a small number of genes 
being responsible for inherited CRC, the truth is likely to be much more complex. It is 
probable that a range of mutations or polymorphisms in a range of genes may lead to a small 
increase in lifetime colorectal cancer risk (low to moderate penetrance alleles). Possibly if a 
number o f these changes are inherited together, an individual or family may mistakenly be 
assumed to be carrying a mutation in a high penetrance cancer causing allele. Such variants 
may be common, such as MYH missense mutations (1-2% of the population), or extremely 
rare. Missense mutations in genes such APC and the MMR genes which have been thought to 
be non-pathogenic may in fact confer a small increase in risk, such that disease ‘skipping’ 
generations is common. Common variants conferring a mild increase in CRC risk acting on 
their own or in concert with other low penetrance alleles will only be appreciated using large 
studies, both case or cohort control and based on linkage, using families with apparent 
increase in CRC incidence. The CORGI study is an international research effort which will 
recruit over one thousand colorectal cancer families without known genetic predisposition 
and use a linkage approach to uncover new alleles involved in colorectal cancer risk. Large 
studies which follow cohorts of thousands of persons for many years may be used as cohorts 
for case control studies. Until we characterise the range of variants that lead to inherited 
forms of colorectal cancer it will remain difficult to give appropriate advice to the majority of 
patients who seek our advice in the Familial Colorectal Cancer Clinic.
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